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Chapter 1 provides a brief introduction. Chapters 2 and 3 of this thesis describe 
the development new methods for the synthesis of nitrogen containing heterocycles via 
palladium catalyzed carboamination reactions. The development of conditions for the 
synthesis of functionalized pyrrolidines from N-protected γ−aminoalkenes and aryl 
bromides or triflates mediated by weak base and palladium catalysis is described in 
Chapter 2. These conditions, which use Cs2CO3 or K3PO4 in place of the strong base 
NaOtBu, tolerate the presence of a broad array of functio al groups and significantly 
expand the scope of the methodology. Chapter 3 describ  the development of a four-step 
synthesis of cis-3,5-disubstituted morpholines from enantiomerically pure amino 
alcohols. The key step in the synthesis is a Pd-catalyzed carboamination reaction between 
a substituted ethanolamine derivative and an aryl or alkenyl bromide. The morpholine 
products are generated in good diastereoselectivity with full retention of enantiopurity. 
This chapter also describes the synthesis of fused bicyclic morpholines, 2,3- and 2,5-
disubstituted morpholines, and 3,4-dihydro-2H 1,4-oxazine products. 
Chapter 4 describes the development of a simple step-wise procedure to achieve a 
room temperature Curtius rearrangement of benzylic and heteroarylmethyl carboxylic 
acids. The developed conditions provide an alternative to previously described one-pot 




the Curtius rearrangement to occur while preventing he formation of unwanted ester 
byproducts or other deleterious side reactions. 
The investigation of synthetic small molecule transcription activation domains 
(TADs) is described in Chapter 5. The synthesis of a small library of compounds 
intended to replicate key aspects of potent natural TADs is described. The compounds are 
functionally evaluated as either activators or inhibitors of transcription in cells. 
Chapter 6 describes efforts to expand the scope of tandem Wittig 
rearrangement/aldol reactions to allow the synthesis of anti-α-alkyl-α,β-dihydroxy esters 
and anti-α-alkyl-α,γ-dihydroxy esters. Strategies focusing on the use of dialkyl acetals or 
Lewis acid activated aldehydes as electrophiles are discussed. An alternative approach 
involving use of Ti, Al, or Sc enolates as nucleophiles is reported. Preliminary work on 
the utilization of pyridinium salt electrophiles for the preparation of substituted 







1.1 Importance of Alkaloids and Nitrogen-Containing Compounds 
Alkaloids and nitrogen-containing natural compounds have potent activity in many 
different biological systems. As a result of their b ological activity, these compounds 
have played a profound role in the course of human society. These compounds are found 
at the heart of some religious rituals, various healing therapies, and some recreational 
activities (Figure 1-1). For example mescaline (1), a natural product found in the peyote 
cactus, has been used for over 3000 years as an entheogen and supplement to various 
transcendence practices including meditation, psychonautics, and psychedelic 
psychotherapy.1 In a similar fashion, tetrahydroharmine (2) is an active ingredient in the 
drink ayahuasca, a brew used for divinatory and healing purposes by the native peoples 
of the Amazonian Colombia.2 Alternatively, penicillin (3) was discovered in 1928 and is 
the most widely used antibiotic in the world.3 Cocaine (4) is a highly addictive 
recreational drug with activity as a serotonine reuptake inhibitor.4 





The chemical methods for preparing alkaloids and nitrogen-containing natural 
compounds are diverse. A key aspect of any method for the preparation of these 
compounds is the need to form new carbon-nitrogen bonds. This chapter will highlight 
some of the most useful and widely used methods for the formation of this important 
linkage.  
1.2 Standard Methods for Forming New Carbon-Nitrogen Bonds 
Early chemical methods for the formation of carbon-nitrogen bonds include 
substitution reactions, chemical rearrangements, or pericyclic reactions (Figure 1-2).5 
Nucleophilic substitution reactions are one of the most basic and broadly used 
transformations in organic chemistry. Chemical rearrangements are a powerful alternative 
to substitution reactions, as many chemical rearrangements form new carbon-nitrogen 
bonds from structures not suitable for displacement chemistry. Pericyclic reactions are a 
type of chemical rearrangement that proceeds throug a cyclic transition state while 
simultaneously forming and breaking both σ- and π-bonds. 





Nucleophilic substitution reactions require substrates containing a carbon-bound 
leaving group, where nitrogen nucleophiles can attack he electrophilic carbon to form a 
new carbon-nitrogen bond. Bimolecular nucleophilic substitution reactions proceed with 
inversion of the carbon stereocenter, so the stereochemistry of the product is controlled 
by the stereochemistry of the substrate. 
Many different chemical rearrangements are known to pr duce new carbon-
nitrogen bonds. These rearrangements include the Beckmann rearrangement, Curtius 
rearrangement, the Lossen rearrangement, the Hofmann rearrangement, and the Schmidt 
rearrangement. These rearrangement reactions allow the migration of an alkyl group by 
the intermediate formation of a nitrogen bound leaving group. In contrast to the 
bimolecular nucleophilic substitution reactions, rear angement reactions typically 
proceed with retention of the relative stereochemistry at the migrating carbon center.  
Pericyclic reactions have been widely used in chemical syntheses because they can 
be used to generate multiple new stereocenters with excellent diastereoselectivity. While 
the Diels-Alder cycloaddition for the formation of two new carbon-carbon σ-bonds in 
cyclohexene is one of the most widely known and used pericyclic reactions, this class of 
reactions can be used to form new carbon-nitrogen σ-bonds as well. Example pericyclic 
reactions include: electrocyclic reactions, cycloadditions, sigmatropic reactions, group 
transfer reactions, cheletropic reactions, and dyotropic reactions.  
1.3 Metal-Catalyzed Methods for Forming New Carbon-Nitrogen Bonds 
Work with metal catalysts has led to the development of ew types of reactions for 




bond formation via insertion reactions and reductive elimination reactions. Key metals in 
this field include copper, nickel, palladium, gold, and rhodium. Focusing on palladium, 
this metal has been used effectively in alkene hydroaminations,7 carboaminations,8 
diaminations,9 oxidative aminations,10 chloroaminations,11 aminoacetoxylations,12 and 
hetero-Heck transformations13 (Figure 1-3). Further advancements in these 
methodologies are important for the development of useful and highly efficient chemical 
methodologies. 






While many methods are known for the efficient preparation of new carbon-
nitrogen bonds in biologically important molecules, challenges still remain in this area of 
research. Much of the work presented in this thesis is focused on the discovery and 
application of new or improved methods for addressing some challenges in the current 
field of chemistry. A unifying feature in the methods developed in Chapters 2, 3, and 4 of 
this thesis is the formation of new carbon-nitrogen bonds. Alternatively, Chapter 5 
investigates nitrogen-containing heterocyclic isoxazolidines and isoxazolines as small 
molecule compounds with potential activity as artificial transcriptional activation 
domains (TADs). The final chapter of this thesis (Chapter 6) focuses on the formation of 
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Mild Conditions for the Synthesis of Functionalized Pyrrolidines via Palladium 
Catalyzed Carboamination Reactions 
2.1 Introduction 
The development of synthetic methods for the construction of substituted 
pyrrolidines has been of longstanding importance in organic chemistry due to the 
prevalence of this moiety in biologically active molecules and natural products (Figure 
2-1).1 For example, the natural product preussin (1) has antifungal, antiviral, and 
antitumor activity.2 Anisomycin (2) is a pyrrolidine natural product that has antifungal 
and cytotoxic activity, while broussonetine C (3) is a potent glycosidase inhibitor.3,4 
Captopril (4) is an angiotensin converting enzyme (ACE) inhibitor that is marketed as a 
hypertension therapeutic and accounted for $1.1 billion in sales in 1996.5 Compound 5 
has been identified as a potent BACE-1 inhibitor and is a potential therapeutic for 
Alzheimer’s disease.6 
Over the past several years, the palladium-catalyzed carboamination of γ-
aminoalkenes with aryl bromides has emerged as an efficient and stereoselective method 
for the construction of substituted pyrrolidine derivatives.7,8 These transformations effect 
tandem cyclization and coupling in a process that generates a C–N bond, a C–C bond, 




with 4-bromoanisole in the presence of NaOtBu and catalytic amounts of Pd2( ba)3 and 
dppb afforded pyrrolidine 7 in 60% yield with >20:1 dr (Figure 2-2).7c 
Figure 2-1: Biologically Active Pyrrolidines 
 
Figure 2-2: Pyrrolidine Synthesis via Palladium-Catalyzed Carboamination 
 
Despite the synthetic utility of these transformations, the reactions are typically 
conducted in the presence of the strong base NaOtBu, which limits the scope of this 
method. For example, the use of NaOtBu restricts the functional group tolerance of these 
reactions, and transformations of aryl triflate electrophiles, which decompose in the 
presence of strong base, have not been reported. Aditionally, Cbz protecting groups, 
which are frequently employed in the synthesis of complex alkaloids, are incompatible 




conditions that replace NaOtBu with weaker bases (Cs2CO3 or K3PO4), which 
significantly expands the scope of the carboaminatio  method. 
The work for this chapter was conducted in collaborti n with another graduate 
student, Myra Bertrand.9 My contribution to the project consisted of optimization of 
reaction conditions and partial establishment of reaction scope. 
2.2 Development of Reaction Conditions Utilizing Weak Base 
The use of weak bases in Pd-catalyzed N-arylation reactions of amines with aryl 
halides had been previously established.10 Using the reported weak base N-arylation 
conditions in combination with our conditions for pyrrolidine synthesis, an initial screen 
of potential weak bases was conducted (Table 2-1). Both Cs2CO3 and K2CO3 generated 
the desired pyrrolidines (9) in moderate yield (Table 2-1, entries 1-2). The other 
inorganic bases (Na2CO3, K3PO4) and KOAc generated a complex mixture of products 
(Table 2-1, entries 3-5), while soluble nitrogen bases did not induce catalytic turnover 
and only led to recovery of starting material (Table 2-1, entries 6-8). While K2CO3 
provided the best crude yield of the desired pyrrolidine, inseperable impurities prevented 
the isolation of clean product. The Cs2 O3 reaction led to isolation of clean product and 




Table 2-1: Base Optimizationa 
 
Results from the solvent screen are shown in Table 2-2. Reaction temperature 
played an important role in reaction selectivity and yield. Temperature was initially 
varied to maintain reactions below the boiling point of the main solvent. Reducing the 
temperature to 65 °C for THF led to a greatly reduced reaction rate (Table 2-2, entry 8). 
The optimal result was obtained using dioxane as solvent at 85 °C, while 
dimethoxyethane provided a nearly comparable yield (Table 2-2, entries 5-6). After 
changing solvent, the weak base K2CO3 provided a significantly reduced yield of desired 




Table 2-2: Solvent Optimizationa 
 
2.3 Exploration of Scope 
With optimal reaction conditions established for an initial substrate and aryl 
halide combination, the full reaction scope was explored (Table 2-3). Reactions utilizing 
weak base are effective for the transformation of a number of different substrate 
combinations. Many functional groups are tolerated under these mild conditions, 
including aldehydes (Table 2-3, entry 3), enolizable ketones (Table 2-3, entry 4), nitro 
groups (Table 2-3, entries 6 and 11), methyl esters (Table 2-3, entries 8 and 14), and alkyl 
acetates (Table 2-3, entry 9). In addition, the carbo mination reactions of electron-rich 
(Table 2-3, entry 10), electron-neutral (Table 2-3, entries 1, 2, 5, 7, and 13), and 
heterocyclic (Table 2-3, entry 12) aryl bromides proceed with good chemical yield. The 




that are comparable to those observed in reactions that use NaOtBu as base. For example, 
transformations of starting materials 6 and 16, which bear a substituent adjacent to the 
nitrogen atom, provide cis-2,5-disubstituted products 28 and 29 with excellent (>20:1) 
diastereoselectivity (Table 2-3, entries 11–12). Similarly, substrates 14 and 15, which are 
substituted at the allylic position, are transformed to trans-2,3-disubstituted products 26 
and 27 with good stereocontrol (12 to 15:1). 
In addition to providing increased tolerance of base-sensitive functional groups, 
the new reaction conditions also allow for the efficient carboamination of substrates 
bearing Cbz-protecting groups. For example, the Pd-catalyzed coupling of 13 with 2-
bromonaphthalene using Cs2 O3 as base provided the desired product 24 in 88% isolated 
yield (Table 2-3, entry 7). In contrast, cleavage of the Cbz-group from the substrate was 
problematic when reactions were conducted with NaOtBu as base; these conditions 
provided only a 17% yield of 24. More complex γ-aminoalkene substrates are also 
efficiently transformed using the new reaction conditions. As shown in Table 2-3 (entries 
13–14), Pd-catalyzed reactions of 17 with bromobenzene or methyl-4-bromobenzoate 
proceeded smoothly to provide 30 and 31 with excellent stereoselectivity. Trisubstituted 
pyrrolidine 30 has been previously employed as an intermediate in he synthesis of the 




Table 2-3: Palladium-Catalyzed Carboamination of N-Protected γ-Aminoalkenes 





The main limitations of these new reaction conditions involve transformations of 
sterically encumbered substrate combinations. For example, attempts to convert 
substrates bearing internal alkenes to pyrrolidines were unsuccessful under these 
conditions. In addition, the reaction of methyl 2-bromobenzoate with 6, which bears a 
substituent on C-1 (adjacent to the nitrogen atom), was not effective. However, Myra 
Bertrand demonstrated that this o-substituted aryl bromide was effectively coupled with 
the less hindered carbamate 15.9 This limitation was later overcome in subsequent studies 
in the lab.12 
In addition to greatly expanding the scope of Pd-catalyzed carboamination 
reactions involving aryl bromide substrates, the usof mildly basic reaction conditions 
also allows for the first Pd-catalyzed carboamination reactions with aryl triflates, as 
demonstrated by Myra Bertrand.9 
2.4 Conclusions 
In conclusion, we have developed new conditions for palladium-catalyzed 
carboamination reactions of N-protected γ−aminoalkenes with aryl bromides and triflates. 
These conditions, which use Cs2 O3 (or K3PO4 for aryl triflates) in place of the strong 
base NaOtBu, tolerate the presence of a broad array of functio al groups, and 
significantly expand the scope of this method. 
2.5 Experimental Section 
General:  All reactions were carried out under an argon or itrogen atmosphere in 




anhydrous DME were obtained from commercial sources and were used without further 
purification. Pent-4-enyl-carbamic acid tert-butyl ester (11),13 N-pent-4-enylacetamide 
(12),13 (3-methylpent-4-enyl)carbamic acid tert-butyl ester (15),13 (1-phenylpent-4-
enyl)carbamic acid tert-butyl ester (6),13 4-pentenylamine,13 and (±)–(1R,3S)-3-(tert-
butyldimethylsiloxy)-1-nonylpent-4-enylcarbamic acid tert-butyl ester (17)14 were 
prepared according to published procedures. Ratios of regioisomers and/or diastereomers 
were determined by 1H NMR and/or capillary GC analysis of crude reaction mixtures. 
Yields refer to isolated yields of compounds estimaed to be ≥95% pure as determined by 
1H NMR, GC, and/or combustion analysis. The yields reported in the experimental 
section describe the result of a single experiment, whereas the yields reported in Table 2-
3 are average yields of two or more experiments. Thus, the yields reported in the 
experimental section may differ from those shown in Table 2-3. 
Synthesis of Substrates: 
 4-Bromobenzyl acetate.15 A flame-dried flask equipped with a 
magnetic stirbar was cooled under a stream of nitrogen and charged with 4-bromobenzyl 
alcohol (4.0 g, 21.4 mmol), acetic anhydride (20 mL), pyridine (20 mL), and DMAP (268 
mg, 2.14 mmol, 10 mol %). The tube was purged with n rogen, and the mixture was 
stirred at rt for 22 h until the starting material h d been consumed as determined by TLC 
analysis. Water (10 mL) and ethyl acetate (10 mL) were added, and the layers were 
separated. The organic layer was washed with 1 M aqueous HCl (10 mL) and brine (10 
mL). The organic layer was then dried over Na2SO4, filtered, and concentrated in vacuo. 




as the eluent to afford 4.4 g (90%) of the title comp und as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.45 (d, J = 8.4 Hz, 2 H), 7.21 (d, J = 8.2 Hz, 2 H), 5.03 (s, 2 H), 2.08 (s, 
3 H). 
 Pent-4-enylcarbamic acid benzyl ester (13).16 A flame-dried flask 
was cooled under a stream of nitrogen and charged with a solution of 4-pentenylamine 
(175 mL, 17.5 mmol, 0.1 M in diethyl ether). Triethylamine (7.4 mL, 52.5 mmol) and 
benzyl chloroformate (3.8 mL, 26.3 mmol) were added, and the resulting mixture was 
stirred at rt until the starting material was consumed as judged by TLC analysis (ca. 2 h). 
A solution of aqueous HCl (100 mL, 1.0 M) was added, the mixture was transferred to a 
separatory funnel, and was extracted with diethyl ether (100 mL). The layers were 
separated and the organic layer was washed with a solution of saturated aqueous Na2CO3 
(100 mL) and brine (100 mL). The organic layer was then dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography using 10%  15% ethyl acetate/hexanes as the eluent to afford 1.9 g 
(50%) of the title compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.42–7.27 
(m, 5 H), 5.86–5.70 (m, 1 H), 5.19–4.93 (m, 4 H), 4.92–4.62 (m, 1 H), 3.26–3.08 (m, 2 
H), 2.16–2.00 (m, 2 H), 1.67–1.52 (m, 2 H). 
 
 3-Methylpent-4-enylcarbamic acid benzyl ester (14). A flame-
dried flask was cooled under a stream of nitrogen and charged with 3-methylpent-4-enoic 




added and the resulting solution was cooled to ca. 10 °C using an ice water bath. Oxalyl 
chloride (14 mL, 160 mmol) was added dropwise via syringe to the solution and the 
resulting mixture was warmed to rt, stirred for 1 h, and then concentrated in vacuo. The 
crude 3-methylpentenoyl chloride product of this reaction was dissolved in THF (100 
mL), and slowly added to a separate flask containing aqueous ammonium hydroxide (100 
mL) at 0 °C. The resulting mixture was stirred for 6 h and then concentrated in vacuo. 
The mixture was diluted with H2O (50 mL) and ethyl acetate (100 mL), the layers were 
separated and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The 
combined organic extracts were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The resulting crude 3-methylpent-4-enylcarboxamide was 
dissolved in THF (100 mL) and cooled to 0 °C. A soluti n of LiAlH4 in THF (200 mL, 
200 mmol, 1.0 M) was added dropwise via syringe. The reaction mixture was warmed to 
rt and stirred for 36 h, then was cooled to 0 °C, quenched with H2O (16 mL), and diluted 
with ether (200 mL). An aqueous solution of NaOH (30 mL, 10 M) was added and an 
insoluble white material precipitated. The organic supernatant was decanted to a clean 
Erlenmeyer flask and the precipitate was washed with ether (100 mL). The combined 
organic extracts were dried over anhydrous sodium slfate and filtered to afford a 
solution of 3-methylpentenylamine in diethyl ether (ca. 0.1 M). The solution of 3-
methylpentenylamine (300 mL, 30 mmol, 0.1 M) was cooled to 0 °C, triethylamine (11.5 
mL, 90 mmol) and benzyl chloroformate (6.6 mL, 45 mmol) were added, and the 
resulting mixture was stirred at rt until the starting material was consumed as judged by 
TLC analysis (ca. 16 h). A solution of 1.0 M aqueous HCl (200 mL) was added, the 




mL). The combined organic extracts were washed withsaturated aqueous NaHCO3 (200 
mL) and brine (100 mL). The organic layer was then dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography using 5%  10% ethyl acetate/hexanes as the eluent to afford 1.2 g 
(17% over the five steps) of the title compound as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.39–7.26 (m, 5 H), 5.73–5.60 (m, 1 H), 5.16–5.05 (m, 2 H), 5.02–4.90 (m, 2 
H), 4.87–4.58 (m, 1 H), 3.27–3.08 (m, 2 H), 2.25–2.11 (m, 1 H), 1.58–1.40 (m, 2 H), 1.00 
(d, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 156.3, 143.6, 136.6, 128.4, 128.1, 
128.0, 113.4, 66.5, 39.2, 36.4, 35.6, 20.2; IR (film) 1706 cm–1. Anal calcd for C14H19NO2: 
C, 72.07; H, 8.21; N, 6.00. Found: C, 72.28; H, 8.29; N, 6.08. 
 
 1-Phenylpent-4-enylcarbamic acid benzyl ester (16). Treatment 
of a solution of 1-phenylpent-4-enyl-amine1 in diethyl ether (250 mL, 25 mmol, 0.1 M) 
with triethylamine (9.6 mL, 75 mmol) and benzyl chloroformate (5.5 mL, 37.5 mmol) 
using a procedure analogous to that described above for the synthesis of 6 afford 3.86 g 
(52%) of the title compound as a waxy white solid, m.p. 51–53 °C. 1H NMR (400 MHz, 
CDCl3) δ 7.54–6.97 (m, 10 H), 5.86–5.65 (m, 1 H), 5.43–5.21 (m, 1 H), 5.14–4.90 (m, 4 
H), 4.79–4.47 (m, 1 H), 2.12–1.94 (m, 2 H), 1.92–1.64 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 155.6, 142.3, 137.4, 136.4, 128.5, 128.4, 128.0, 127.2, 126.3, 115.2, 66.6, 54.9, 
35.6, 30.2 (two aromatic carbons are incidentally equivalent); IR (film) 1710 cm–1. Anal 




Synthesis of Functionalized Pyrrolidines via Coupling with Aryl Bromides (Table 3) 
General Procedure for Pd-Catalyzed Carboamination Reactions of Aryl Bromides. 
A flame-dried Schlenk tube equipped with a magnetic stirbar was cooled under a stream 
of nitrogen and charged with the aryl bromide (1.2 equiv), Pd(OAc)2 (2 mol %), dpe-phos 
(4 mol %) and Cs2CO3 (2.3 equiv). The tube was purged with nitrogen and solution of 
the N-protected amine substrate (1.0 equiv) in dioxane (5 mL/mmol substrate) was then 
added via syringe. The resulting mixture was heated to 100 °C with stirring until the 
starting material had been consumed as determined by GC analysis. The reaction mixture 
was cooled to room temperature and saturated aqueous NH4Cl (1 mL) and ethyl acetate 
(1 mL) were added. The layers were separated, the aqu ous layer was extracted with 
ethyl acetate (3 x 5 mL), and the combined organic layers were dried over Na2SO4, 
filtered, and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel. 
 2-Napthalen-2-ylmethylpyrrolidine-1-carboxylic acid tert-butyl 
ester (18).1 The general procedure was employed for the reaction of 2-bromonapthalene 
(62 mg, 0.30 mmol) with pent-4-enyl-carbamic acid tert-butyl ester (47 mg, 0.25 mmol). 
This procedure afforded 58 mg (75%) of the title comp und as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ 7.85–7.74 (m, 3 H), 7.66–7.60 (m, 1 H), 7.51–7.40 (m, 2 H), 7.40–
7.33 (m, 1 H), 4.16– 4.02 (m, 1 H), 3.43–3.21 (m, 3 H), 2.77–2.65 (m, 1 H), 1.83–1.70 





 2-(4-tert-Butylbenzyl)pyrrolidine-1-carboxylic acid tert-butyl 
ester (19). The general procedure was employed for the reaction of 4-tert-butyl 
bromobenzene (52 µL, 0.30 mmol) with pent-4-enyl-carbamic acid tert-butyl ester (47 
mg, 0.25 mmol). This procedure afforded 66 mg (83%) of the title compound as a pale 
yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.38–7.26 (m, 2 H), 7.22–7.07 (m, 2 H), 4.12–
3.84 (m, 1 H), 3.49–3.23 (m, 2 H), 3.23–2.96 (m, 1 H), 2.60–2.42 (m, 1 H), 1.92–1.67 
(m, 4 H), 1.55–1.48 (s, 9 H), 1.36–1.28 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 154.5, 
148.9, 136.1, 129.1, 125.2, 79.0, 58.8, 46.4, 40.0, 34.3, 31.4, 29.7, 28.6, 22.7; IR (film) 
1695 cm–1. Anal calcd for C20H31NO2: C, 75.67; H, 9.84; N, 4.41. Found: C, 75.46; H, 
9.88; N, 4.38. 
 
 2-(4-Formylbenzyl)pyrrolidine-1-carboxylic acid tert-butyl ester 
(20). The general procedure was employed for the reaction of 4-bromobenzaldehyde (89 
mg, 0.48 mmol) with pent-4-enyl-carbamic acid tert-butyl ester (74 mg, 0.40 mmol) 
except DME was used in place of dioxane and the reaction was conducted at 85 °C. This 
procedure afforded 94 mg (81%) of the title compound as a colorless oil. This compound 




for the mixture. 1H NMR (400 MHz, CDCl3) δ 9.97 (s, 1 H), 7.80 (d, J = 8.0 Hz, 2 H), 
7.41–7.29 (m, 2 H), 4.13–3.92 (m, 1 H), 3.46–3.01 (m, 3 H), 2.74–2.58 (m, 1 H), 1.85-
1.60 (m, 4 H), 1.52–1.45 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 191.9, 154.4, 146.6, 
134.7, 130.1, 129.8, 79.3, 58.4, 46.3, 40.8, 39.9, 29.6, 28.5, 28.3, 23.4, 22.6; IR (film) 
1693, 1606 cm–1. Anal calcd for C17H23NO3: C, 70.56; H, 8.01; N, 4.84. Found: C, 70.45; 
H, 8.14; N, 4.72. 
 
 2-(4-Acetylbenzyl)pyrrolidine-1-carboxylic acid tert-butyl ester 
(21). The general procedure was employed for the reaction of 4-bromoacetophenone (120 
mg, 0.60 mmol) with pent-4-enyl-carbamic acid tert-butyl ester (93 mg, 0.50 mmol) 
except DME was used in place of dioxane and the reaction was conducted at 85 °C. This 
procedure afforded 118 mg (78%) of the title compound as a white solid, m.p. 63–65 °C. 
This compound was found to exist as a 1:1 mixture of rotamers as judged by 1H NMR 
analysis; data are for the mixture. 1H NMR (500 MHz, CDCl3) δ 7.94–7.85 (m, 2 H), 
7.35–7.22 (m, 2 H), 4.11–3.94 (m, 1 H), 3.46–3.04 (m, 3 H), 2.74–2.55 (m, 4 H), 1.85–
1.60 (m, 4 H), 1.51 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 197.9, 197.7, 154.5, 154.4, 
145.0, 144.9, 135.3, 135.2, 129.7, 129.5, 128.5, 128.3, 79.4, 79.1, 58.5, 58.3, 46.7, 46.2, 
40.6, 39.6, 29.7, 28.9, 28.5, 26.5, 23.4, 22.6; IR (film) 1686, 1607 cm–1. Anal calcd for 





 1-(2-(Naphthalen-2-ylmethyl)pyrrolidin-1-yl)ethanone (22).1 
The general procedure was employed for the reaction of 2-bromonapthalene (125 mg, 
0.60 mmol) with N-pent-4-enyl-acetamide (64 mg, 0.50 mmol). This procedure afforded 
101 mg (80%) of the title compound as a pale yellow oil. This compound was found to 
exist as a ~ 3:1 mixture of rotamers as judged by 1H NMR analysis; data are for the 
mixture. 1H NMR (400 MHz, CDCl3) δ 7.84–7.74 (m, 3 H), 7.66–7.58 (m, 1 H), 7.51–
7.37 (m, 2.3 H), 7.32–7.27 (m, 0.7 H), 4.45–4.37 (m, 0.7 H), 4.17–4.09 (m, 0.3 H), 3.63–
3.49 (m, 0.7 H), 3.45–3.32 (m, 2 H), 3.09–3.02 (m, 0.3 H), 2.86–2.69 (m, 1 H), 2.11 (s, 2 
H), 2.06 (s, 1 H), 1.96–1.72 (m, 4 H). 
 
 1-(2-(4-Nitrobenzyl)pyrrolidin-1-yl)ethanone (23). The general 
procedure was employed for the reaction of 1-bromo-4-nitrobenzene (97 mg, 0.48 mmol) 
with N-pent-4-enyl-acetamide (51 mg, 0.4 mmol) except dppe was used in place of Dpe-
phos as ligand, DME was used in place of dioxane and the reaction was conducted at 85 
°C. This procedure afforded 77 mg (77%) of the title compound as a white solid, m.p. 
139–140 °C. This compound was found to exist as a ~ 7:1 mixture of rotamers as judged 
by 1H NMR analysis; data are for the mixture. 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 




Hz, 0.3 H), 4.34–4.24 (m, 0.85 H), 4.11–4.03 (m, 0.15 H), 3.64–3.51 (m, 0.3 H), 3.50–
3.35 (m, 1.7 H), 3.28 (dd, J = 3.4, 13.2 Hz, 0.85 H), 2.97 (dd, J = 5.2, 13.2 Hz, 0.15 H), 
2.80 (dd, J = 8.8, 13.6 Hz, 0.15 H), 2.68 (dd, J = 9.2, 13.2 Hz, 0.85 H), 2.07 (s, 2.55 H), 
1.99 (s, 0.45 H), 1.94–1.73 (m, 3.15 H), 1.71–1.60 (m, 0.85 H); 13C NMR (100 MHz, 
CDCl3) δ 169.4, 168.9, 147.0, 146.5, 145.5, 130.2, 130.0, 123.8, 123.5, 59.4, 57.9, 47.8, 
45.4, 40.6, 38.8, 30.1, 28.5, 23.7, 22.9 22.0, 21.7; IR (film) 1640, 1516 cm–1. Anal calcd 
for C13H16N2O3: C, 62.89; H, 6.50; N, 11.28. Found: C, 62.85; H, 6.44; N, 11.08. 
 
 2-(Naphthalen-2-ylmethyl)pyrrolidine-1-carboxylic acid benzyl 
ester (24). The general procedure was employed for the reaction of 2-bromonaphthalene 
(125 mg, 0.6 mmol) with pent-4-enylcarbamic acid benzyl ester (110 mg, 0.5 mmol). 
This procedure afforded 151 mg (88%) of the title compound as a colorless oil. This 
compound was found to exist as a 1:1 mixture of rotamers as judged by 1H NMR 
analysis; data are for the mixture. 1H NMR (500 MHz, CDCl3) δ 7.85–7.63 (m, 3.5 H), 
7.56–7.32 (m, 7.5 H), 7.25–7.19 (m, 1 H), 5.27–5.16 (m, 2 H), 4.28–4.12 (m, 1 H), 3.54–
3.35 (m, 2.5 H), 3.25–3.16 (m, 0.5 H), 2.82–2.69 (m, 1 H), 1.87–1.72 (m, 4 H); 13C NMR 
(125 MHz, CDCl3) δ 154.9, 154.8, 137.1, 136.8, 136.5, 136.4, 133.4, 132.1, 128.4, 128.1, 
128.0, 127.9, 127.85, 127.79, 127.74, 127.65, 127.6, 127.4, 125.93, 125.86, 125.34, 
125.26, 67.0, 66.5, 59.3, 58.8, 46.8, 46.6, 40.8, 39.6, 29.7, 28.9, 23.5, 22.7; IR (film) 
1698 cm–1. Anal calcd for C23H23NO2: C, 79.97; H, 6.71; N, 4.05. Found: C, 80.01; H, 





 2-(4-(Methoxycarbonyl)benzyl)pyrrolidine-1-carboxylic acid 
benzyl ester (25). The general procedure was employed for the reaction of 4-
bromobenzoate (129 mg, 0.6 mmol) with pent-4-enylcarbamic acid benzyl ester (110 mg, 
0.5 mmol) except DME was used in place of dioxane ad the reaction was conducted at 
85 °C. This procedure afforded 152 mg (86%) of the titl  compound as a pale yellow oil. 
This compound was found to exist as a 1:1 mixture of rotamers as judged by 1H NMR 
analysis; data are for the mixture. 1H NMR (400 MHz, CDCl3) δ 7.98–7.86 (m, 2 H), 
7.44–7.23 (m, 6 H), 7.16–7.08 (m, 1 H), 5.22–5.11 (m, 2 H), 4.18–4.02 (m, 1 H), 3.90 (s, 
3 H), 3.51–3.31 (m, 2 H), 3.28–3.17 (m, 0.5 H), 3.11–3.00 (m, 0.5 H), 2.76–2.58 (m, 1 
H), 1.88–1.61 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 167.1, 167.0, 154.8, 144.4, 144.3, 
137.0, 136.7, 129.64, 129.56, 129.3, 128.5, 128.2, 128.1, 127.9, 127.8, 67.0, 66.5, 58.9, 
58.5, 52.0, 46.8, 46.6, 40.7, 39.5, 29.8, 28.9, 23.5, 22.7; IR (film) 1721, 1700 cm–1. Anal 





carboxylic acid benzyl ester (26). The general procedure was employed for the reaction 




benzyl ester (117 mg, 0.5 mmol). The diastereoselectivity of the transformation was 
assessed by LAH reduction of the crude product obtained in a duplicate reaction, and was 
found to be 12:1 dr as judged by 1H NMR analysis. The minor diastereomer was 
separated upon chromatographic purification to afford 143 mg (82%) of the title 
compound as a colorless oil with >20:1 dr. Data are fo  the major diastereomer, which 
was found to exist as a 1:1 mixture of rotamers as judged by 1H NMR analysis; data are 
for the mixture. 1H NMR (500 MHz, CDCl3) δ 7.42–7.29 (m, 5 H), 7.28–7.13 (m, 3 H), 
7.09–7.02 (m, 1 H), 5.23–5.10 (m, 2 H), 5.09–5.02 (m, 2 H), 3.73–3.48 (m, 2 H), 3.34–
3.18 (m, 1 H), 3.15–3.07 (m, 0.5 H), 3.01–2.92 (m, 0.5 H), 2.82–2.73 (m, 0.5 H), 2.70–
2.61 (m, 0.5 H), 2.12–1.99 (m, 4 H), 1.94–1.80 (m, 1 H), 1.50–1.37 (m, 1 H), 0.87 (d, J = 
6.6 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 170.9, 155.1, 154.9, 138.8, 137.1, 136.8, 
133.9, 133.7, 129.8, 129.6, 128.5, 128.4, 128.3, 128.0, 127.9, 127.8, 67.0, 66.5, 66.15, 
66.09, 65.9, 65.7, 45.4, 45.2, 39.9, 38.3, 36.8, 35.8, 31.1, 30.2, 21.0, 19.3, 19.1. IR (film) 
1740, 1698 cm–1. MS (ESI): 404.1839 (404.1838 calculated for C20H27NO4, M + Na
+). 
The stereochemistry of the above compound was assigned based on comparison of 1H
and 13C NMR spectra to those obtained for the related product (±)–(2R,3S)-2-(4-
Acetylbenzyl)-3-methylpyrrolidine-1-carboxylic acid benzyl ester, the stereochemistry of 
which was elucidated through 1H NMR nOe experiments.9 
 
 (±)–(2R,3S)-2-(4-Methoxybenzyl)-3-methylpyrrolidine-1-




reaction of 4-bromoanisole (38 µL, 0.3 mmol) with 3-methylpent-4-enylcarbamic acid 
benzyl ester (50 mg, 0.25 mmol). The diastereoselectivity of the transformation was 
assessed by TFA-mediated deprotection of the crude product obtained in a duplicate 
reaction, and was found to be 15:1 dr as judged by 1H NMR analysis. The minor 
diastereomer was separated upon chromatographic purification to afford 58 mg (78%) of 
the title compound as a pale yellow oil with >20:1 dr. Data are for the major 
diastereomer, which was found to exist as a 1:1 mixture of rotamers as judged by 1H 
NMR analysis; data are for the rotamers mixture. 1H NMR (400 MHz, CDCl3) δ 7.14–
7.03 (m, 2 H), 6.86–6.78 (m, 2 H), 3.79 (s, 3 H), 3.63–3.34 (m, 2 H), 3.26–3.06 (m, 1 H), 
3.05–2.89 (m, 1 H), 2.75–2.52 (m, 1 H), 2.09–1.95 (m, 1 H), 1.91–1.75 (m, 1 H), 1.51 (s, 
9 H), 1.45–1.30 (m, 1 H), 0.85 (d, J = 6.8 Hz, 3 H); 13C NMR (125 MHz, CDCl3) 
δ 158.1, 154.7, 131.0, 130.6, 130.3, 113.8, 113.6, 79.2, 78.9, 65.9, 65.5, 55.2, 45.5, 44.9, 
39.1, 37.7, 36.7, 35.8, 31.1, 30.3, 28.6, 19.4, 19.2; IR (film) 1692 cm–1. Anal calcd for 
C18H27NO3: C, 70.79; H, 8.91; N, 4.59. Found: C, 70.56; H, 8.87; N, 4.60. 
The stereochemistry of the above compound was determin d by 1H NMR nOe analysis of 
the product obtained through treatment of 27 with TFA to afford 27a as shown below. 
 
(±)–(2R,3S)-2-(4-Methoxybenzyl)-3-methylpyrrolidinium-2,2,2-trifluoroacetate 
(27a). A flame-dried flask was cooled under a stream of nitrogen and charged with 27 (42 




°C. Trifluoroacetic acid (1 mL) was then added slowly and the resulting mixture was 
stirred at rt for 25 min. The crude mixture was concentrated in vacuo to afford 41 mg 
(96%) of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 9.41 (s, br, 1 
H), 8.74 (s, br, 1 H), 7.10 (d, J = 8.5 Hz, 2 H), 6.80 (d, J = 8.5 Hz, 2 H), 6.72 (s, br, 1 H), 
3.74 (s, 3 H), 3.28–3.18 (m, 1 H), 3.15–3.07 (m, 2 H), 3.00–2.86 (m, 2 H), 2.23–2.15 (m, 
1 H), 2.14–2.05 (m, 1 H), 1.66–1.57 (m, 1 H), 0.99 (d, J = 6.6 Hz, 3 H); 13C NMR (125 
MHz, CDCl3) δ 161.5 (q, J = 36.8 Hz), 158.8, 129.9, 127.6, 116.1 (q, J = 290.4 Hz), 
114.2, 66.8, 55.1, 43.4, 38.3, 36.0, 32.2, 16.8; IR (film) 3502, 1690 cm-1; MS (ESI): 




acid tert-butyl ester (28). The general procedure was employed for the reaction of 1-
bromo-3-nitrobenzene (122 mg, 0.6 mmol) with (1-phenylpent-4-enyl)carbamic acid tert-
butyl ester (131 mg, 0.5 mmol). The diastereoselectivity of the transformation was 
assessed by TFA-mediated deprotection of the crude product obtained in a duplicate 
reaction, and was found to be >20:1 dr as judged by 1H NMR analysis. Chromatographic 
purification afforded 151 mg (79%) of the title compound as a colorless oil with >20:1 dr. 
1H NMR (500 MHz, CDCl3) δ 8.16–8.05 (m, 2 H), 7.72–7.52 (m, 1 H), 7.50–7.44 (m, 1 
H), 7.36–7.16 (m, 5 H), 5.08–4.68 (m, 1 H), 4.28–4.09 (m, 1 H), 3.69–3.43 (m, 1 H), 




1.66 (m, 1 H), 1.65–1.05 (m, 9 H); 13C NMR (100 MHz, CDCl3) δ 154.8, 148.2, 144.3, 
141.1, 135.7, 129.3, 128.2, 126.6, 125.5, 124.1, 12.4, 79.7, 63.0, 60.4, 40.6, 34.3, 28.1 
(two aliphatic carbons are accidentally equivalent); IR (film) 1687, 1530 cm–1. Anal calcd 
for C22H26N2O4: C, 69.09; H, 6.85; N, 7.32. Found: C, 68.97; H, 6.98; N, 7.19. 
The stereochemistry of the above compound was determin d by 1H NMR nOe analysis of 
the product obtained through treatment of 28 with TFA, followed by aqueous NaOH, to 
afford 28a as shown below. 
 
 (±)–(2R,5S)-2-(3-Nitrobenzyl)-5-phenylpyrrolidine (28a). Treatment of 28 (100 mg, 
0.26 mmol) with TFA/CH2Cl2 was effected using a procedure analogous to that described 
above for the preparation of compound 27a, with the following modification. The crude 
residue obtained upon removal of TFA/CH2Cl2 was dissolved in CH2Cl2 (10 mL), and 
washed with 1.0 M NaOH (10 mL). The organic layer was dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo. This procedure afforded 65 mg (88%) of the title 
compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.17–8.12 (m, 1 H), 8.09–8.02 
(m, 1 H), 7.63–7.57 (m, 1 H), 7.44 (t, J = 8.0 Hz, 1 H), 7.40–7.35 (m, 2 H), 7.31 (t, J = 
7.2 Hz, 2 H), 7.25–7.18 (m, 1 H), 4.15 (t, J = 7.4 Hz, 1 H), 3.55–3.44 (m, 1 H), 2.99–2.86 
(m, 2 H), 2.20–2.09 (m, 1 H), 2.00–1.91 (m, 1 H), 1.85 (s, 1 H), 1.75–1.55 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 148.2, 144.9, 142.3, 135.5, 129.1, 128.2, 126.8, 126.5, 123.9, 
121.2, 62.2, 59.6, 42.9, 33.9, 30.9; IR (film) 1526 cm-1; MS (ESI): 283.1435 (283.1447 







carboxylic acid benzyl ester (29). The general procedure was employed for the reaction 
of 3-bromopyridine (60 µL, 0.6 mmol) with 1-phenylpent-4-enylcarbamate benzyl ester 
(148 mg, 0.5 mmol). The diastereoselectivity of the transformation was assessed by HCl-
mediated deprotection of the crude product obtained i  a duplicate reaction, and was 
found to be >20:1 dr as judged by 1H NMR analysis. Chromatographic purification 
afforded 144 mg (78%) of the title compound as a colorless oil with >20:1 dr. 1H NMR 
(400 MHz, CDCl3) δ 8.59–8.31 (m, 2 H), 7.77–6.76 (m, 12 H), 5.29–4.85 (m, 3 H), 4.30–
4.09 (m, 1 H), 3.67–3.27 (m, 1 H), 2.77–2.64 (m, 1 H), 2.35–2.24 (m, 1 H), 2.04–1.80 
(m, 2 H), 1.76–1.65 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 155.5, 150.5, 147.9, 143.6, 
136.7, 136.5, 134.3, 128.4, 128.3, 127.5, 127.3, 126.8, 125.6, 123.4, 66.7, 63.0, 61.1, 
38.1, 34.3, 28.6; IR (film) 1698 cm–1; MS (ESI): 395.1736 (395.1735 calculated for 
C24H24N2O2, M + Na
+). 
The stereochemistry of the above compound was determin d by 1H NMR nOe analysis of 
the product obtained through treatment of 29 with 6N HCl, followed by aqueous NaOH, 





 (±)–(2R,5S)-3-(5-Phenylpyrrolidin-2-ylmethyl)pyridine (29a). A flask was charged 
with 29 (40 mg, 0.11 mmol) and 6 N HCl (5 mL). The mixture was heated to reflux for 5 
h, and then was cooled to rt. Distilled water was then added (2 mL), the crude mixture 
was washed with ether (3 x 10 mL), and the ether layers were discarded. The aqueous 
layer was then basified with 1M NaOH to pH 11 and extracted twice with ether (10 mL).  
The combined ether layers were washed with brine, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography using 5%  10% methanol/dichloromethane as the eluent to afford 22 
mg (87%) of the title compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.55–
8.42 (m, 2 H), 7.61–7.55 (m, 1 H), 7.43–7.36 (m, 2 H), 7.34–7.25 (m, 2 H), 7.24–7.17 
(m, 2 H), 4.19 (t, J = 8.0 Hz, 1 H), 3.56–3.43 (m, 1 H), 3.25–2.89 (m, 1 H), 2.82 (d, J = 
6.6 Hz, 2 H), 2.23–2.11 (m, 1 H), 2.02–1.90 (m, 1 H), 1.85–1.73 (m, 1 H), 1.72–1.60 (m, 
1 H); 13C NMR (100 MHz, CDCl3) δ 150.4, 147.7, 136.6, 135.1, 128.3, 127.1, 126.7, 
123.3, 62.3, 60.0, 39.7, 33.3, 30.6 (two aromatic carbons are incidentally equivalent); IR 




nonylpyrrolidine-1-carboxylic acid tert-butyl ester (30).2 The general procedure was 
employed for the reaction of bromobenzene (26 µL, 0.24 mmol) with (±)–(1R,3S)-3-(tert-
butyldimethylsiloxy)-1-nonylpent-4-enylcarbamic acid tert-butyl ester (89 mg, 0.20 




formation of the desired product as a >20:1 mixture of diastereomers. This procedure 
afforded 74 mg (71%) of the title compound as a colorless oil with >20:1 dr. The 
stereochemistry was assigned by comparison of the 1H NMR spectrum to data previously 
reported in the literature.14 This compound was found to exist as a 3:1 mixture of 
rotamers as judged by 1H NMR analysis; data are for the mixture. 1H NMR (400 MHz, 
CDCl3) δ 7.35–7.06 (m, 5 H), 4.32– 4.15 (m, 1.25 H), 4.08–3.95 (m, 0.75 H), 3.83–3.44 
(m, 1 H), 3.06–2.96 (m, 1 H), 2.82–2.68 (m, 0.25 H), 2.61–2.47 (m, 0.75 H), 2.32–2.12 
(m, 1.75 H), 2.05–1.93 (m, 0.25 H), 1.67–1.54 (m, 1 H), 1.51–1.03 (m, 24 H), 0.97–0.84 
(m, 12 H), 0.13– -0.08 (m, 6 H). 
 
 (±)–(2S,3S,5R)-3-(tert-Butyldimethylsiloxy)-2-(4-
methoxycarbonylbenzyl)-5-nonylpyrrolidine-1-carboxylic acid tert-butyl ester (31). 
The general procedure was employed for the reaction of methyl 4-bromobenzoate (52 
mg, 0.24 mmol) with (±)–(1R,3S)-3-(tert-butyldimethylsiloxy)-1-nonylpent-4-
enylcarbamic acid tert-butyl ester (89 mg, 0.20 mmol). The diastereoselectivity of the 
transformation was assessed by LAH reduction of the crude product obtained in a 
duplicate reaction, and was found to be >20:1 dr as judged by 1H NMR analysis. 
Chromatographic purification afforded 83 mg (72%) of the title compound as a colorless 
oil with >20:1 dr. This compound was found to exist a  a 3:1 mixture of rotamers as 




δ 7.99–7.88 (m, 2 H), 7.39–7.22 (m, 2 H), 4.32–4.19 (m, 1.3 H), 4.07–3.98 (m, 0.7 H), 
3.90 (s, 3 H), 3.72–3.51 (m, 1 H), 3.11–3.01 (m, 1 H), 2.87–2.75 (m, 0.3 H), 2.67–2.53 
(m, 0.7 H), 2.33–2.12 (m, 1.7 H), 2.07–1.93 (m, 0.3 H), 1.65–1.55 (m, 1 H), 1.46–1.05 
(m, 24 H), 0.96–0.81 (m, 12 H), 0.12– -0.12 (m, 6 H); 13C NMR (100 MHz, CDCl3) 
δ 167.3, 154.8, 145.9, 129.9, 129.4, 127.6, 79.2, 71.4, 62.1, 55.7, 51.9, 38.0, 37.2, 36.3, 
31.9, 29.7, 29.6, 29.3, 28.1, 26.5, 25.8, 22.7, 18.1, 14.1, -4.7, -5.0; IR (film) 1726, 1694 
cm–1. Anal calcd for C33H57NO5Si: C, 68.82; H, 9.98; N, 2.43. Found: C, 68.43; H, 9.98; 
N, 2.42. 
The stereochemistry of the above compound was determin d through LiAlH4 reduction 
of 31 to afford 31a as shown below. The stereochemistry of 31a was assigned by 
comparison of the 1H NMR spectrum of 31 to that previously obtained for the related 
molecule 32.14  
 
(±)–(2S,3S,5R)-2-(4-Hydroxymethylbenzyl)-1-methyl-5-nonylpyrrolidin-3-ol (31a). A 
flame-dried flask was cooled under a steam of nitrogen and charged with 31 (70 mg, 0.12 
mmol) and tetrahydrofuran (3 mL). The resulting soluti n was cooled to 0 °C and LiAlH4 
(1.2 mL, 1.2 mmol, 1 M in tetrahydrofuran) was adde dropwise via syringe. The 
resulting mixture was heated to reflux until the starting material was consumed as judged 
by TLC analysis (ca. 21 h). The reaction mixture was cooled to 0 °C, slowly quenched 




M) and water (0.3 mL) were added sequentially and a insoluble white precipitate 
formed. The organic supernatant was decanted to a clean Erlenmeyer flask and the 
precipitate was washed with diethyl ether. The combined organic extracts were dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude oil obtained was 
purified by flash chromatography using 10%  20% methanol/dichloromethane as the 
eluent to afford 38 mg (91%) of the title compound as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.32–7.28 (m, 4 H), 4.66 (s, 2 H), 3.83–3.75 (m, 1 H), 2.94–2.80 (m, 2 
H), 2.33 (s, 3 H), 2.30–2.03 (m, 5 H), 1.77–1.66 (m, 1 H), 1.46–1.38 (m, 1 H), 1.37–1.15 
(m, 15 H), 0.88 (t, J = 6.6 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 138.8, 129.5, 127.1, 
73.7, 70.2, 65.9, 64.9, 39.5, 38.6, 34.7, 33.1, 31.9, 29.9, 29.6, 29.5, 29.3, 26.4, 22.6, 14.1 
(two aromatic carbons are incidentally equivalent); IR (film) 3384 cm-1; MS (ESI): 
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Synthesis of Substituted Morpholines via Palladium Catalyzed Carboamination 
Reactions 
3.1 Background 
In recent years drug discovery efforts have revealed several interesting biologically 
active compounds that contain C-substituted morpholine units (Figure 3-1).1,2 
Specifically, Polygonapholine (1), the first reported 2,6-disubstituted morpholine natural 
product was collected from the marine sponge  Chelonaplysilla sp. from a marine lake in 
the nation of Palau. Compound 1 exhibits antimicrobial activity against Bacillus subtilis 
and shows in vivo anti-inflammatory activity.3 Compound 2 was found to be the most 
potent compound in a screen for new centrally acting α1 agonists and has potential 
therapeutic value in the treatment of dementia and other central nervous system disorders 
characterized by symptoms of noradrenergic insufficien y.4 Phendimetrazine (3) is a 
widely prescribed appetite suppressant with annual sales of 3.1 million dollars for one of 
the generic varieties in 2007.5 The remaining compounds in Figure  (4, 5) contain cis-3,5-
disubstituted morpholines. Compound 4 acts as a selective cholecystokinin-2 receptor 
antagonists, with potential for treatment of gastroin estinal  adenocarcinomas, such as 
Barrett’s metaplasia and pancreatic cancer, as well as gastroesophageal reflux disease and 
peptic ulcers.2b The meso-cis-3,5-dimethyl morpholine subunit was obtained by 




cyclization. Compound 5 has shown nanomolar activity as a caspase-1 inhibitor and is a 
potential therapeutic for inflammatory diseases such as rheumatoid arthritis or 
osteoarthritis.2a 
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Despite the medicinal importance of these molecules, the development of new 
approaches for their synthesis remains relatively unexplored.1,6 For example, few 
methods allow the preparation of 3,5-disubstituted morpholines,7 and only two 
approaches for the stereoselective synthesis of cis-3,5-disubstituted derivatives have been 
described (Figure 3-2).2a,8 Both of these strategies are limited in scope, as one affords 
symmetrically disubstituted (meso) products (6),8 and the other was used only for the 
generation of a single monocyclic morpholine (7) in route to biologically active 
compound 5.2a Development of a new, efficient, method for the diastereoselective 





Figure 3-2: Known Methods for Synthesizing cis-3,5-Disubstituted Morpholines 
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Previous work in the Wolfe lab established a concise a ymmetric synthesis of cis-
2,6-disubstituted piperazines that involves Pd-catalyzed carboamination reactions of N-
allyl ethylenediamine derivatives.9,10 It was hypothesized that a similar strategy may be 
applied to the construction of 3,5-disubstituted morph lines. As shown in Scheme 3-1, 
enantiopure N-Boc amino alcohols (8) could be converted to O-allyl ethanolamines 9 
using standard methods. These compounds could then be transformed to the desired 
heterocycles 10 through Pd-catalyzed coupling with an aryl or alkenyl halide.11 This 
strategy should provide access to a broad array of enantiopure cis-3,5-disubstituted 
morpholines that are difficult to generate using existing methods. 
Scheme 3-1: Synthetic strategy 
 
The substrates for the Pd-catalyzed carboamination reactions were synthesized in 
three steps from commercially available starting materi ls 8a–e (Scheme 2). Treatment of 




Cleavage of the Boc-group followed by Pd-catalyzed N-arylation of the resulting amine 
trifluoroacetate salts provided 9a–f in moderate to good yield. For a representative 
reaction sequence, chiral HPLC analysis indicated complete retention of enantiomeric 
purity (99% ee) during the preparation of substrate 9  from 8a. 
Scheme 3-2: Synthesis of Substrates 
 
3.3 Exploration of Reaction Conditions 
Initial studies examined the coupling of a simple substrate and aryl bromide under 
reaction conditions similar to those used in the related piperazine-forming 
carboamination reactions.9 A preliminary ligand screen revealed the formation of three 
main products (Table 3-1, Entry 1-5). The desired 3,5-disubstituted morpholine (10) 
formed in most cases, but an unsaturated morpholine (12) and Heck-type alkene arylation 
product (13) were also generated. Small amounts of several other unidentified side 
products were detected. The ratio of ligand to palladium played an important role in 
reaction selectivity (Table 3-1, Entries 4,5). Increasing the amount of base and aryl 




ligands surveyed did not provide improved results for the desired morpholine product 
(Table 3-1, Entries 7-17). The initial choice of ligand based on the related piperazine 
system proved to be the optimal catalyst. 
Table 3-1: Ligand Screena 
 
With a preferred catalytic system established, the remaining reaction conditions 
were investigated. Testing alternative bases known to facilitate similar palladium 
catalyzed reactions confirmed that NaOtBu was the best choice (Table 3-2). Similarly, 





Table 3-2: Base Screena 
 
Table 3-3: Solvent Screena 
 
3.4 Synthesis of cis-3,5-Disubstituted Morpholines 
The results of studies on the scope of 3,5-disubstituted morpholine-forming 
carboamination reactions are illustrated in Table 3-4. Several different 2-subsituted O-




heteroatom-containing substrates derived from methionine (Table 3-4, Entry 7), serine 
(Table 3-4, Entry 8), and tryptophan (Table 3-4, Entry 9). Although the yields in these 
reactions were modest (46–66%), the diastereoselectivities were uniformly high (> 20:1 
dr). As a representative example, the Pd-catalyzed carboamination reaction of 9a to 10b 
proceeded with no erosion of enantiopurity. Side products of general structure 12 were 
observed in crude reaction mixtures, accounting for reduced yield of the desired 
morpholines. Spectroscopic analysis (1H-NMR) of crude reaction mixtures indicated 
these side products were formed as 10–35% of the mixture (Table 3-5). The presence of 
electron-neutral or slightly electron-deficient N-aryl groups on the substrates was 
tolerated. However, efforts to employ a morpholine precursor bearing an N-(p-
methoxyphenyl) moiety led to a poor yield of 10d due to competing N-arylation or Heck 
arylation of the substrate (Table 3-4, Entry 3). In some instances side products resulting 
from sequential N-arylation and Heck arylation of the substrate were also isolated. Low 
yields were also obtained when starting materials with N-(p-cyanophenyl) groups were 
used, as competing Heck arylation of the substrate alk ne group was again problematic. 
Similarly, efforts to couple N-Boc-protected substrate 11a with 1-bromo-4-tert-










2 mol % Pd(OAc)2
8 mol % P(2-furyl)3







































































































a Conditions: 1.0 equiv substrate, 2.0 equiv R1Br, 2.0 equiv NaOtBu, 2 mol % Pd(OAc)2, 8 mol % P(2-furyl)3,
toluene (0.4 M), 105 °C. b Isolated yield (average of two experiments). All products were formed with >20:1
dr as judged by 1H NMR analysis of crude products prior to purif ication. c The reaction was conducted using




Table 3-5: Reaction Product Ratios 
 
3.5 Expansion to Bicyclic Morpholines and Other Substitution Patterns. 
In order to further explore the utility of this method for the synthesis of other 
substituted morpholines, reactions of several N-aryl ethanolamine derivatives with 
different substitution patterns were examined. The synthetic work for the bicyclic 
morpholine examples was conducted by Brandon Rosen, an undergraduate co-worker on 
this project. Substrates 14a–d were prepared by O-allylation of 2-(N-
phenylamino)cyclohexanol or –cyclopentanol. The know  trans-2-(N-
phenylamino)cycloalkanols were prepared in one step from aniline and cyclohexene 
oxide or cyclopentene oxide. As shown in Table 3-6, the substrates were coupled with 
aryl bromides using the optimized reaction conditions. These transformations afforded 
the desired bicyclic morpholines 15a–e in moderate to good yields with excellent 




2,3-disubstituted morpholine 17 and 2,5-disubstituted morpholine 19 (Scheme 3-3). 
However, both 17 and 19 were produced with only modest (2:1) diastereoselectivity.  
The nature of the aryl halide coupling partner had a significant effect on the yield 
of the morpholine-forming reactions. Use of electron- ich or electron-neutral derivatives 
provided acceptable yields of the desired heterocycles. In addition, the coupling of 9a 
with an alkenyl halide (Table 3-4, entry 2) was also successful. However, most attempts 
to employ electron-poor aryl bromides led to complex mixtures of products, although the 
carboamination reactions of 14c–d with 4-bromobenzophenone (Table 3-6, entries 4–5) 
and of 16 with 3-bromobenzonitrile (Scheme 3-3) gave useful q antities of desired 
products. The coupling of 9c with the sterically hindered 2-bromotoluene provided a 66% 
yield of 10a (Table 3-4, entry 5), but 1-bromo-2-methylnaphthalene failed to react with 

















2 mol % Pd (OAc)2
8 mol % P(2-furyl)3















































a Conditions: 1.0 equiv substrate, 2.0 equiv R1Br, 2.0-2.7 equiv NaOtBu, 2 mol % Pd(OAc)2, 8 mol %
P(2-furyl)3, toluene (0.3 M), 105 °C.
b Isolated yield (average of two or more experiments). All products
were formed with >20:1 dr as judged by 1H NMR analysis of crude products prior to purif ication.  





The mechanism of the morpholine-forming carboaminatio  reactions is likely 
similar to that of related transformations that generate piperazines, pyrrolidines, and other 
nitrogen heterocycles.9-11 As shown in Scheme 3-4, the key intermediate in the
conversion of 9 to 10 is palladium(aryl)(amido) complex 20, which is produced by 
oxidative addition of the aryl bromide to Pd(0) followed by Pd–N bond formation.12 The 
relative stereochemistry of the substituted morpholine products is most consistent with a 
pathway involving syn-aminopalladation of 20 through a boat-like transition state (21) to 
afford 22. Chair-like transition states for intramolecular syn-aminopalladation reactions 
that generate six-membered rings appear to be less favorable than boat-like transition 
states due to poor overlap between the alkene π-system and the Pd–N bond.9b Reductive 
elimination from 22 would provide the cis-3,5-disubstituted morpholine products 10. This 
mechanism also accounts for the conversion of 16 to cis-2,3-disubstituted morpholine 17, 
and 18 to trans-2,5-disubstituted morpholine 19 (Scheme 3-5). The modest 
diastereoselectivities observed in the reactions of 16 and 18 are presumably due to 
relatively small differences in the energies of transition states in which the substrate R-
group is oriented in a psueduoaxial vs. pseudoequatorial position.9b 





Scheme 3-5: Stereochemical Rational for 2,3- and 2,5-Disubstituted Morpholines 
 
As noted above in Table 3-1, we observed the formation of 3,4-dihydro-2H-1,4-
oxazine 5a as a side product in the Pd/P(2-furyl)3 catalyzed coupling of 9c with 2-
bromotoluene. This compound is presumably generated via β-hydride elimination from 
intermediate 22 to provide 23 (Scheme 3-6). This complex could then be transformed into 
unsaturated heterocycle 12a by alkene dissociation and subsequent Heck arylation13 of 
the resulting product 24. 
Scheme 3-6: Formation of 3,4-dihydro-2H-1,4-oxazine 12a 
 
We felt that it may be possible to optimize conditions so that unsaturated 
compounds such as 12a would be generated as the major products in coupling reactions 
between 9 and aryl bromides. The mechanism outlined in Scheme 3-6 suggests that 
catalysts or ligands that either slow C–C bond-forming reductive elimination, facilitate 
β−hydride elimination, or both, may favor the conversion of 22 to 23, which in turn leads 
to generation of 12. Thus, we examined the use of catalysts supported by relatively 




decreases as ligand basicity increases and ligand size decreases. However, steric effects 
can outweigh electronic effects, as electron-rich ligands that are sterically bulky are 
known to promote reductive elimination.13 While a phosphite ligand showed improved 
selectivity for 12, the best result was obtained after switching to an N-heterocyclic 
carbene based system (Table 3-1, Entries 15-16). Reaction conditions that generated the 
catalytic system in situ led to poor reproducibility. Utilization of the premade catalyst 
(IPr)Pd(acac)Cl14 provided consistent results for the coupling of bromobenzene with 9c, 
providing clean selectivity for the unsaturated product 12b with a 57% isolated yield 
(Scheme 3-7). The scope of this reaction is currently limited, as use of 2-bromotoluene as 
the electrophile afforded only 21% yield of 12a. Increased sterics bulk on the aryl 
coupling partner appears to promote C—C bond forming reductive elimination leading to 
the substituted morpholine products. Purification of the unsaturated morpholine products 
is also difficult due to their hydrolytic lability. Preliminary efforts to further manipulate 
the 3,4-dihydro-2H-1,4-oxazines proved unsuccessful. Further optimization of conditions 
or use of this transformation in tandem/sequenced reactions may improve synthetic 
utility. A catalytic hydrogenation reduced 12a with no selectivity, providing a roughly 
equal mixture of both product diastereomers (Scheme 3-8). An ionic hydrogenation has 
been accomplished by the Zhou group, but the reaction was likely facilitated by 
protection of the ring nitrogen with the strong electron withdrawing tosyl group (26, 
Scheme 3-9).15 While good diastereoselectivity was attained with a sterically demanding 





Scheme 3-7: Steric Influence on 3,4-Dihydro-2H-1,4-oxazine Synthesis 
 
Scheme 3-8: Hydrogenation of 3,4-Dihydro-2H-1a,4-oxazine 
 
Scheme 3-9: Ionic Hydrogenation of 3,4-Dihydro-2H-1a,4-oxazine 
 
3.6 Conclusions 
In conclusion, a new method has been developed for the concise asymmetric 
synthesis of cis-3,5-disubstituted morpholines from readily available enantiopure amino 
alcohol precursors. The modular nature of this approach permits variation of the 
morpholine substituents, and also provides access to fused-ring morpholine derivatives. 
In addition, modification of catalyst structure can lead to potentially useful 3,4-dihydro-
2H-1,4-oxazine products. The strategies described in this chapter significantly expand the 





3.7 Experimental Section 
General:  All reactions were carried out under a nitrogen atmosphere in oven or 
flame dried glassware. Tris(dibenzylideneacetone)dipalladium (0) and all phosphine 
ligands were purchased from Strem Chemical Co. and use  without further purification. 
All aryl bromides were obtained from commercial sources (Aldrich Chemical CO or 




ylcarbamate,20 (S)-tert-butyl 1-hydroxy-4-(methylthio)butan-2-ylcarbamate,21 and 1-
(phenylamino)butan-2-ol,22 were prepared according to published procedures. (±)-trans-
2-(phenylamino)cyclohexanol23 and (±)-trans-2-(phenylamino)cyclopentanol24 were 
synthesized via ring-opening of cyclohexene oxide or cyclopentene oxide with aniline.23 
Toluene and THF were purified using a GlassContour s lvent purification system. Yields 
refer to isolated yields of compounds estimated to be ≥95% pure as determined by 1H 
NMR, and either capillary GC (known compounds) or ESI Mass Spectrometry (new 
compounds). The yields reported in the Supporting Information describe the result of a 
single experiment, whereas the yields reported in Table 3-4, Table 3-5, and Table 6 are 
average yields of two or more experiments. Thus, the yields reported in the supporting 
information may differ from those shown in Table 3-4, Table 3-5, and Table 6. 
 









S1 (±)-N-Phenyl-2-(but-3-en-2-yloxy)acetamide (S1). A flame-dried 
flask was cooled under a stream of nitrogen and charged with 3-butene-2-ol (0.73 mL, 
8.41 mmol) and THF (3.5 mL). The resulting solution was cooled to 0 °C in an ice/H2O 
bath and sodium hydride (60% dispersion in mineral oil, 336 mg, 8.41 mmol) was added. 
The resulting mixture was stirred at 0 °C for 30 min, then a solution of phenyl 
bromoacetamide16 (1.50 g, 7.0 mmol) in THF (13.5 mL) was added dropwise. The 
reaction mixture was warmed to rt and stirred until the starting material was consumed as 
judged by TLC analysis (ca. 1 h). The reaction mixture was then quenched with saturated 
aqueous NH4Cl (10 mL), diluted with EtOAc (10 mL), filtered by suction filtration to 
remove insoluble material, and the layers were separated. The aqueous layer was 
extracted with EtOAc (3 x 10 mL), and the combined organic layers were washed with 
saturated aqueous NaHCO3, dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude product was purified by flash chromatography on silica gel using 10% 
EtOAc/hexanes as the eluent to afford the title comp und (220 mg, 15%) as colorless 
crystals, m.p. 48−50 °C. 1H NMR (400 MHz, CDCl3) δ 8.35 (s, br, 1 H), 7.57 (d, J = 7.8 
Hz, 2 H), 7.31 (t, J = 7.8 Hz, 2 H), 7.10 (t, J = 7.4 Hz, 1 H), 5.74 (ddd, J = 7.5, 10.1, 17.2 
Hz, 1 H), 5.28−5.18 (m, 2 H), 4.05 (d, J = 15.7 Hz, 1 H), 3.98−3.89 (m, 2 H), 1.34 (d, J =
6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 167.8, 138.4, 137.0, 128.8, 124.2, 119.6, 
117.2, 78.0, 67.5, 20.9; IR (film) 3386, 1682 cm–1; MS (ESI) 228.0996 (228.1000 calcd 








 (±)-N-[2-(But-3-en-2-yloxy)ethyl]aniline (16). A flame-dried flask was cooled 
under a stream of nitrogen and charged with S1 (450 mg, 2.2 mmol) and THF (4.4 mL). 
The resulting solution was cooled to 0 °C in an ice/H2O bath, and LiAlH4 (1M in THF, 
4.4 mL, 4.4 mmol) was added. The reaction mixture was armed to rt and stirred until 
the starting material was consumed as judged by TLCanalysis (ca. 23 h). The mixture 
was then cooled to 0 °C, quenched with H2O (0.2 mL) and diluted with diethyl ether (10 
mL). An aqueous solution of NaOH (0.2 mL, 10 M) was added followed by H2O (0.6 
mL), and an insoluble white solid precipitated. The organic supernatant was decanted to a 
clean Erlenmeyer flask and the precipitate was washed with diethyl ether (10 mL). The 
combined organic layers were concentrated in vacuo to afford an amber oil. The crude 
material was purified by flash chromatography using 10% EtOAc/hexanes as the eluent 
to afford the title compound (263 mg, 63%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.14 (t, J = 7.7 Hz, 2 H), 6.68 (t, J = 7.4 Hz, 1 H), 6.59 (t, J = 8.1 Hz, 2 H), 5.71 
(ddd, J = 7.1, 10.2, 17.2 Hz, 1 H), 5.19−5.07 (m, 2 H), 4.00 (s, br, 1 H), 3.86−3.77 (m, 1 
H), 3.66−3.59 (m, 1 H), 3.52−3.44 (m, 1 H), 3.29−3.16 (m, 2 H), 1.24 (d, J = 6.7 Hz, 3 
H); 13C NMR (100 MHz, CDCl3) δ 148.1, 140.0, 129.0, 117.3, 115.8, 112.9, 77.0, 66.4, 
43.6, 21.1; IR (film) 3403, 1604 cm–1; MS (ESI) 192.1382 (192.1388 calcd for 












butoxycarbonylamino)propanoate (S2). A flame-dried flask was cooled under a stream 
of nitrogen and charged with Nα-Boc-L-tryptophan
18 (1.00 g, 3.29 mmol, 1.0 equiv) and 
DMF (3.3 mL). The resulting solution was cooled to 0 °C in an ice/H2O bath, and sodium 
hydride (60% dispersion in mineral oil, 389 mg, 9.73 mmol) was added. The resulting 
mixture was allowed to stir at 0 °C for 30 min, then benzyl bromide (1.4 mL, 11.8 mmol) 
was added dropwise. The reaction mixture was warmed to rt and stirred until the starting 
material was consumed as judged by TLC analysis (ca. 36 h). The reaction was quenched 
with saturated aqueous NH4Cl (10 mL), diluted with EtOAc (10 mL), and the layers were 
separated. The aqueous layer was extracted with EtOAc (3 x 10 mL), and the combined 
organic layers were washed with brine (3 x 15 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo. The crude yellow oil was purified by flash 
chromatography on silica gel using 15% EtOAc/hexanes as the eluent to afford the title 
compound (1.25 g, 78%) as a white solid, m.p. 98−99 °C. [α]23D − 3.2 (c = 2.88, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 7.8 Hz, 1 H), 7.20−6.89 (m, 13 H), 6.61 (s, 1 
H), 5.05 (s, 2 H), 5.00−4.87 (m, 3 H), 4.63−4.51 (m, 1 H), 3.25−3.09 (m, 2 H), 1.30 (s, 9 
H); 13C NMR (100 MHz, CDCl3) δ 172.0, 155.1, 137.4, 136.4, 135.3, 128.7, 128.5, 
128.4, 128.3, 127.5, 126.9, 126.6, 121.9, 119.3, 119.0, 109.6, 109.2, 79.7, 66.9, 54.4, 
49.8, 28.3, 27.9 (two aromatic carbon signals are incidentally equivalent); IR (film) 3427, 










ylcarbamate (8e). The reduction of S2 (10.82 g, 22.3 mmol) was conducted for 18 h 
using a procedure analogous to that described above for the preparation of 16. This 
procedure afforded the title compound (7.22 g, 85%) as a colorless solid, m.p. 94−96 °C. 
[α]23D − 7.0 (c = 1.43, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 7.9 Hz, 1 H), 
7.31–7.21 (m, 4 H), 7.20–7.07 (m, 4 H), 6.98 (s, 1 H), 5.26 (s, 2 H), 4.84 (d, J = 7.7 Hz, 1 
H), 4.03–3.91 (m, 1 H), 3.73–3.53 (m, 2 H), 2.98 (d, J = 6.8 Hz, 2 H), 2.60 (s, br, 1 H), 
1.41 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 156.3, 137.5, 136.6, 128.7, 128.3, 127.6, 
126.8, 126.7, 121.9, 119.3, 119.1, 111.0, 109.7, 79.6, 64.9, 53.0, 49.9, 28.3, 26.9; IR 







S3 (±)-(1S*,2S*)-N-(2-hydroxycyclohexyl)-N-phenylbenzamide (S3). A 
solution of trans-2-(phenylamino)cyclohexanol23 (956 mg, 5.0 mmol) and triethylamine 
(2.1 mL, 15 mmol), in dichloromethane (10 mL), was cooled to 0 °C and benzoyl 
chloride (0.6 mL, 4.9 mmol) was added dropwise. Thereaction mixture was warmed to 
room temperature and stirred for 48 h, then was transferred to a separatory funnel. The 
mixture was washed with 2 M HCl (2 x 10 mL) and extrac ed with dichloromethane (3 x 




concentrated in vacuo. The crude material was purified by flash chromatography on silica 
gel using 2.5% MeOH/dichloromethane as the eluant to afford 1.13 g (77%) of the title 
compound as a white solid, m.p. 182–184 °C. 1H NMR (400 MHz, CDCl3) δ 7.30–7.24 
(m, 2 H), 7.24–7.06 (m, 8 H), 4.77–4.61 (m, 1 H), 3.53–3.37 (m, 1 H), 2.76 (s, br, 1 H), 
2.12 (d, J = 12.0 Hz, 1 H), 2.01–1.89 (m, 1 H), 1.78–1.63 (m, 2 H), 1.52–1.29 (m, 2 H), 
1.29–1.00 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 173.2, 139.5, 136.8, 130.8, 129.1, 
128.7, 128.3, 127.63, 127.56, 71.7, 61.5, 35.7, 30.2, 25.2, 24.3; IR (film) 3319, 1622, cm-







S4 (±)-cis-2-(phenylamino)cyclohexanol (S4). A solution of S3 (3.0 g, 10.2 
mmol) in dichloromethane (50 mL) under nitrogen was cooled to 0 °C and thionyl 
chloride (4.4 mL, 61 mmol) was added. The reaction mixture was warmed to room 
temperature and stirred overnight. The reaction mixture was then concentrated in vacuo, 
and 6 N HCl (50 mL) was added. The resulting mixture was heated to reflux with 
vigorous stirring for 6 h, then was cooled to rt, filtered, and the aqueous phase was 
extracted with EtOAc (3 x 50 mL). The combined ethyl acetate layers were discarded, 
and the aqueous layer was basified to pH > 9 using 5 M NaOH. The aqueous layer was 
then extracted with ether (3 x 50 mL), and the combined ether layers were dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was purified 
by flash chromatography on silica gel using 15% EtOAc/hexanes as the eluant to afford 




1H NMR (400 MHz, CDCl3) δ 7.24–7.17 (m, 2 H), 6.79–6.72 (m, 1 H), 6.68 (dd, J = 1.0, 
7.8 Hz, 2 H), 4.09–4.02 (m, 1 H), 3.73 (s, br, 1 H), 3.44–3.37 (m, 1 H), 2.31 (s, br, 1 H), 
1.90–1.80 (m, 1 H), 1.76–1.56 (m, 5 H), 1.52–1.28 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 147.2, 129.2, 117.6, 113.7, 67.6, 54.8, 31.3, 27.0, 23.5, 20.0; IR (film) 3397, 







(±)-(1S*,2S*)-N-(2-hydroxycyclopentyl)-N-phenylbenzamide (S5). A 
solution of trans-2-(phenylamino)cyclopentanol24 (1.78 g, 10 mmol) and triethylamine 
(8.4 mL, 60 mmol) in dichloromethane (20 mL), was cooled to 0 °C with stirring and 
benzoyl chloride (3.5 mL, 30 mmol) was added dropwise.  The reaction mixture was then 
warmed to room temperature and stirred overnight. Te mixture was transferred to a 
separatory funnel then washed with 2 M HCl (2 x 10 mL) and extracted with 
dichloromethane (3 x 20 mL). The combined organic layers were then dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The resulting oil was dissolved in 
methanol (25 mL) and potassium carbonate (6.9 g, 50 mmol) was added slowly at room 
temperature. The reaction mixture was stirred at rt for 48 h, then was quenched with 
saturated ammonium chloride (25 mL). The mixture was transferred to a separatory 
funnel and extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo to give a red-orange oil. The 
crude material was dissolved in a minimal amount of hot ethyl acetate and then cooled in 




compound as a white solid, mp 109–113 °C.  1H NMR (400 MHz, CDCl3) δ 7.30–7.03 
(m, 10 H), 4.79–4.69 (m, 1 H), 4.28–4.18 (m, 1 H), 4.02 (s, br, 1 H), 1.97–1.86 (m, 2 H), 
1.82–1.63 (m, 2 H), 1.61–1.50 (m, 1 H), 1.47–1.34 (m, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 173.1, 140.1, 136.4, 130.3, 129.3, 128.8, 128.3, 127.64, 127.57, 76.8, 67.5, 
32.5, 28.4, 21.0; IR (film) 3401, 1633 cm–1; MS (ESI) 304.1312 (304.1313 calcd for 








(±)-cis-2-(phenylamino)cyclopentanol (S6).  The conversion of S5 (1.41 g, 
5.0 mmol) to the title compound was accomplished using a procedure analogous to that 
described above for the synthesis of S4. This procedure afforded 880 mg (99%) of the 
title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.23–7.14 (m, 2 H), 6.81–
6.61 (m, 3 H), 4.33–4.23 (m, 1 H), 3.69–3.53 (m, 1 H), 3.05 (s, br, 1 H), 2.17–2.01 (m, 1 
H), 2.00–1.75 (m, 3 H), 1.69–1.49 (m, 2 H) (the OH signal was not observed due to 
broadening); 13C NMR (100 MHz, CDCl3) δ 147.7, 129.3, 118.1, 113.5, 71.3, 59.4, 32.5 
30.1, 20.3; IR (film) 3398, 1504 cm–1; MS (ESI) 178.1225 (178.1232 calcd for C11H15NO 















General Procedure 1: Conversion of N-Boc-2-aminoethanols to N-Boc-1-allyloxy-2-
aminoethanes. A flame-dried flask was cooled under a stream of nitrogen and charged 
with N-Boc-2-aminoethanol (1 equiv) and a sufficient volume of DMF to provide a 0.5 M 
solution. The resulting solution was cooled to 0 °C in an ice/H2O bath, and sodium 
hydride (1.1 equiv, 60% dispersion in mineral oil) was added. The resulting mixture was 
allowed to stir 5–10 min, then allyl bromide (1.1 equiv) was added. The mixture was 
stirred at rt until the starting material was consumed as judged by TLC analysis (ca. 2 h). 
The reaction mixture was then quenched with saturated queous NH4Cl and the layers 
were separated. The aqueous layer was extracted thre imes with EtOAc, and the 
combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, 






 (–)-(S)-tert-Butyl (2-allyloxy-1-methylethyl)carbamate (11a). General 
Procedure 1 was conducted on (S)-2-(Boc-amino)-1-propanol17 8a (3.00 g, 17.1 mmol), 
and gave the title compound (2.71 g, 73%) as a colorless oil after purification by 





1H NMR (400 MHz, CDCl3) δ 5.94−5.83 (m, 1 H), 5.30−5.23 (m, 1 H), 
5.20−5.15 (m, 1 H), 4.71 (s, br, 1 H), 4.04−3.92 (m, 2 H), 3.82 (s, br, 1 H), 3.44−3.33 (m, 
2 H), 1.44 (s, 9 H), 1.17 (d, J = 6.6 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 154.9, 
134.3, 116.3, 78.3, 72.9, 71.5, 45.6, 28.0, 17.5; IR (film) 3345, 1715 cm−1; MS (ESI) 
238.1415 (238.1419 calcd for C11H21NO3, M + Na
+). 
 
 (–)-(S)-tert-Butyl 1-(allyloxy)-3-phenylpropan-2-ylcarbamate (11b). 
General Procedure 1 was conducted on (S)-tert-butyl 1-hydroxy-3-phenylpropan-2-
ylcarbamate20 8a (10.30 g, 41.0 mmol), and gave the title compound (10.21 g, 86%) as a 
colorless oil after purification by chromatography with 10% EtOAc/hexanes as the 
eluant. [α]23D − 21.8 (c = 2.85, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.31−7.18 (m, 5 
H), 5.97−5.85 (m, 1 H), 5.31−5.24 (m, 1 H), 5.21−5.16 (m, 1 H), 4.85 (s, br, 1 H), 
4.02−3.88 (m, 3 H), 3.39−3.30 (m, 2 H), 2.95−2.80 (m, 2 H), 1.42 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 155.1, 138.0, 134.3, 129.2, 128.1, 126.0, 116.7, 78.7, 71.8, 69.8, 
51.4, 37.6, 28.1; IR (film) 3348, 1714 cm–1; MS (ESI) 314.1735 (314.1732 calcd for 
C17H25NO3, M + Na
+). 
 
 (–)-(S)-tert-Butyl 1-(allyloxy)-4-(methylthio)butan-2-ylcarbamate 
(11c). General Procedure 1 was conducted on (S)-tert-butyl 1-hydroxy-4-




2.0 equiv of sodium hydride. This modified procedure gave the title compound (353.7 
mg, 59%) as a yellow oil after purification by chromatography with 10% EtOAc/hexanes 
as the eluant. [α]23D − 17.6 (c = 0.59, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 5.94−5.82 
(m, 1 H), 5.30−5.22 (m, 1 H), 5.21−5.15 (m, 1 H), 4.86−4.73 (m, 1 H), 4.04−3.91 (m, 2 
H), 3.82 (s, br, 1 H), 3.49−3.40 (m, 2 H), 2.61−2.46 (m, 2 H), 2.11 (s, 3 H), 1.95−1.72 
(m, 2 H), 1.44 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.5, 134.5, 117.0, 79.2, 72.1, 
71.7, 49.7, 31.9, 30.7, 28.3, 15.5; IR (film) 3342, 1714 cm–1; MS (ESI) 298.1445 
(298.1453 calcd for C13H25NO3S, M + Na
+). 
 
 (+)-(R)-tert-Butyl 1-(allyloxy)-3-(benzyloxy)propan-2-ylcarbamate 
(11d). General Procedure 1 was conducted on (R)-tert-butyl 1-(benzyloxy)-3-
hydroxypropan-2-ylcarbamate19 8d (2.00 g, 7.11 mmol) using NaOtBu (1.1 equiv) in 
place of sodium hydride. This modified procedure gave the title compound (1.66 g, 73%) 
as a colorless oil after purification by chromatography with 5% EtOAc/hexanes as the 
eluant. [α]23D + 2.6 (c = 2.93, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.37−7.24 (m, 5 
H), 5.92−5.81 (m, 1 H), 5.28−5.21 (m, 1 H), 5.19−5.13 (m, 1 H), 4.92 (s, br, 1 H), 4.52 
(s, 2 H), 4.03−3.84 (m, 3 H), 3.64−3.45 (m, 4 H), 1.44 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 155.4, 138.2, 134.6, 128.3, 127.6, 127.5, 116.9, 79.3, 73.1, 72.0, 68.9, 68.8, 
49.7, 28.3; IR (film) 3345, 1714 cm–1; MS (ESI) 344.1833 (344.1838 calcd for 






yl)propan-2-ylcarbamate (11e). General Procedure 1 was conducted on 8e (3.00 g, 7.88 
mmol), and gave the title compound (2.37 g, 71%) as a colorless oil after purification by 
chromatography using 10% EtOAc/hexanes as the eluant. [α]23D − 10.4 (c = 0.96, 
CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 7.8 Hz, 1 H), 7.28−7.18 (m, 4 H), 
7.18−7.02 (m, 4 H), 6.94 (s, 1 H), 5.93−5.82 (m, 1 H), 5.28−5.19 (m, 3 H), 5.16−5.11 (m, 
1 H), 4.99−4.89 (m, 1 H), 4.04 (s, br, 1 H), 3.96−3.84 (m, 2 H), 3.39−3.29 (m, 2 H), 
3.10−2.95 (m, 2 H), 1.42 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.4, 137.5, 136.4, 
134.6, 128.6, 128.5, 127.4, 126.7, 126.6, 121.6, 119.2, 119.0, 116.8, 111.4, 109.4, 78.9, 
71.9, 70.2, 50.8, 49.7, 28.3, 27.0; IR (film) 3425, 1709 cm–1; MS (ESI) 443.2314 





Et  (±)-N-[2-(Allyloxy)butyl]aniline (18).  General Procedure 1 was conducted 
on 1-(phenylamino)butan-2-ol22 (1.00 g, 6.05 mmol) using THF as solvent. This modifie  
procedure gave the title compound (0.639 g, 51%) as a yellow oil after purification by 
chromatography with 5% EtOAc/hexanes as the eluant. 1H NMR (400 MHz, CDCl3) δ 
7.21−7.14 (m, 2 H), 6.74−6.67 (m, 1 H), 6.66−6.59 (m, 2 H), 5.99−5.87 (m, 1 H), 
5.32−5.24 (m, 1 H), 5.20−5.14 (m, 1 H), 4.10−3.94 (m, 3 H), 3.57−3.48 (m, 1 H), 
3.33−3.23 (m, 1 H), 3.13−3.04 (m, 1 H), 1.74−1.52 (m, 2 H), 0.96 (t, J = 7.4 Hz, 3 H); 




25.0, 9.8; IR (film) 3402, 1604 cm–1; MS (ESI) 206.1535 (206.1545 calcd for C13H19NO, 
M + H+). 
1) TFA, CH2Cl2





4 mol % (o-biphenyl)PtBu2 OR 2 mol % (±)–BINAP OR 






General Procedure 2: Conversion of N-Boc-2-(allyloxy)ethylamines to N-aryl-2-
(allyloxy)ethylamines. A flame-dried flask was cooled under a stream of nitrogen and 
charged with the N-Boc-2-(allyloxy)ethylamine (1.0 equiv) and a sufficient volume of 
CH2Cl2 to provide a 2 M solution. The resulting solution was cooled to 0 °C in an 
ice/H2O bath and an equal volume of trifluoroacetic acid was added dropwise. The 
solution was warmed to rt and stirred until the starting material was consumed as judged 
by TLC analysis (ca. 1 h). The reaction was concentrated in vacuo, then azeotroped twice 
with toluene to remove any remaining trifluoroaceti acid. The crude 2-
(allyloxy)ethylammonium trifluoroacetate was immediately carried on without further 
purification.  
 
A Schlenk tube was evacuated, flame dried, and backfilled with nitrogen. The tube was 
charged with NaOtBu (2.4 equiv), Pd2(dba)3 (1 mol % complex, 2 mol % Pd), and either 
(o-biphenyl)P(t-Bu)2 (4 mol %), (±)-BINAP (2 mol %), or P(tBu)3•HBF4 (8 mol %). The 
tube was then evacuated and backfilled with nitrogen, and the aryl bromide (1.0 equiv) 
and a 0.5 M solution of the 2-(allyloxy)ethylammonium trifluoroacetate (1.0 equiv) in 




solids following the addition of NaOtBu). The mixture was heated to 50–80 °C with 
stirring until the amine was consumed as judged by GC analysis (12–18 h). The mixture 
was cooled to rt, diluted with ether (5 mL), filtered through Celite, and concentrated in 




 (–)-(S)-N-[1-(Allyloxy)propan-2-yl]aniline (9a). General Procedure 2 was 
employed for the coupling of 11a (278 mg, 1.29 mmol), and bromobenzene using (o-
biphenyl)P(t-Bu)2 as ligand and a reaction temperature of 50 °C. This procedure gave the 
title compound (180 mg, 73%) as a light yellow oil after purification by chromatography 
with 7.5% EtOAc/hexanes as the eluant. The enantiopurity was judged to be 99% ee by 
chiral hplc analysis (chiralcel OD column, 0.5% isopropanol/hexanes, 2.0 mL/min, RT = 
5.71 min and 8.39 min), [α]23D – 9.0 (c = 0.30, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 
7.18−7.11 (m, 2 H), 6.70−6.65 (m, 1 H), 6.63−6.58 (m, 2 H), 5.96−5.84 (m, 1 H), 
5.30−5.22 (m, 1 H), 5.20−5.14 (m, 1 H), 4.01−3.96 (m, 2 H), 3.78 (s, br, 1 H), 3.71−3.61 
(m, 1 H), 3.48 (dd, J = 4.4, 9.3 Hz, 1 H), 3.40 (dd, J = 5.3, 9.3 Hz, 1 H), 1.23 (d, J = 6.4 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 147.4, 134.7, 129.3, 117.3, 117.0, 113.4, 73.5, 
72.2, 48.3, 18.1; IR (film) 3401, 1603 cm–1; MS (ESI) 214.1204 (214.1208 calcd for 
C12H17NO, M + Na
+). 
 (±)-N-[1-(Allyloxy)-3-phenylpropan-2-yl]-4-methoxyaniline (9b). 
General Procedure 2 was employed for the coupling of 11b (1.00 g, 3.43 mmol) with 4-




temperature of 40 °C. This procedure gave the title compound (581 mg, 57%) as a yellow 
oil after purification by chromatography with 5% EtOAc/hexanes as the eluant. 1H NMR 
(400 MHz, CDCl3) δ 7.32−7.26 (m, 2 H), 7.24−7.18 (m, 3 H), 6.82−6.76 (m, 2 H), 
6.65−6.60 (m, 2 H), 5.98−5.87 (m, 1 H), 5.31−5.24 (m, 1 H), 5.21−5.16 (m, 1 H), 3.98 
(d, J = 5.6 Hz, 2 H), 3.75 (s, 3 H), 3.72−3.63 (m, 1 H), 3.39 (d, J = 4.0 Hz, 2 H), 
2.98−2.85 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 152.1, 141.1, 138.6, 134.6, 129.3, 
128.2, 126.1, 116.7, 115.0, 114.8, 71.9, 70.0, 55.5, 55.0, 37.0; IR (film) 3386, 2932, 1513 
cm–1; MS (ESI) 298.1794 (298.1807 calcd for C19H23NO2, M + H
+). 
 (–)-(S)-N-[1-(Allyloxy)-3-phenylpropan-2-yl]aniline (9c). General 
Procedure 2 was employed for the coupling of 11b (1.50 g, 5.15 mmol) with 
bromobenzene using (±)-BINAP as ligand and a reaction emperature of 80 °C. This 
procedure gave the title compound (806 mg, 59%) as a yellow oil after purification by 
chromatography with 5% EtOAc/hexanes as the eluant. [α]23D − 42.9 (c = 0.92, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.33−7.28 (m, 2 H), 7.23 (d, J = 7.5 Hz, 3 H), 7.21−7.16 
(m, 2 H), 6.73−6.68 (m, 1 H), 6.68−6.63 (m, 2 H), 5.98−5.88 (m, 1 H), 5.31−5.25 (m, 1 
H), 5.21−5.17 (m, 1 H), 4.04−3.91 (m, 3 H), 3.81−3.73 (m, 1 H), 3.45−3.37 (m, 2 H), 
3.00−2.88 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 147.1, 138.5, 134.6, 129.4, 129.3, 
128.4, 126.3, 117.4, 117.0, 113.5, 72.2, 70.0, 53.9, 37.1; IR (film) 3406, 1602 cm–1; MS 





 (–)-(S)-N-[1-(Allyloxy)-4-(methylthio)butan-2-yl]aniline (9d ). 
General Procedure 2 was employed for the coupling of 11c (165 mg, 0.60 mmol), with 
bromobenzene using (o-biphenyl)P(t-Bu)2 as ligand and a reaction temperature of 50 °C. 
This procedure gave the title compound (107 mg, 71%) as a light amber oil after 
purification by chromatography using 5% EtOAc/hexanes as the eluant. [α]23D − 31.8 (c = 
0.76, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.19 (t, J = 7.9 Hz, 2 H), 6.75−6.69 (m, 1 
H), 6.69−6.65 (m, 2 H), 5.98−5.86 (m, 1 H), 5.33−5.25 (m, 1 H), 5.23−5.18 (m, 1 H), 
4.01 (d, J = 5.3 Hz, 2 H), 3.85 (s, br, 1 H), 3.77−3.70 (m, 1 H), 3.56 (dd, J = 3.6, 9.4 Hz, 
1 H), 3.49 (dd, J = 5.1, 9.4 Hz, 1 H), 2.71−2.58 (m, 2 H), 2.12 (s, 3 H), 2.09−1.96 (m, 1 
H), 1.93−1.82 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 147.3, 134.5, 129.1, 117.2, 
116.8, 113.2, 72.0, 71.1, 51.6, 31.4, 30.9, 15.4; IR (film) 3391, 1602 cm–1; MS (ESI) 
252.1419 (252.1422 calcd for C14H21NOS, M + H
+). 
 (+)-(R)-N-[1-(Allyloxy)-3-(benzyloxy)propan-2-yl]-4-chloroaniline 
(9e). General Procedure 2 was employed for the coupling of 11d (1.50 g, 4.67 mmol) 
with 4-chlorobromobenzene using (±)-BINAP as ligand and a reaction temperature of 80 
°C. This procedure gave the title compound (910 mg, 59%) as a yellow oil after 
purification by chromatography with 5% EtOAc/hexanes as the eluant. [α]23D + 2.8 (c = 
0.95, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.38−7.27 (m, 5 H), 7.11−7.06 (m, 2 H), 
6.56−6.50 (m, 2 H), 5.94−5.82 (m, 1 H), 5.26 (dq, J = 1.6, 17.2 Hz, 1 H), 5.20−5.16 (m, 1 




13C NMR (100 MHz, CDCl3) δ 145.7, 138.1, 134.5, 129.1, 128.4, 127.7, 127.6, 121.9, 
117.1, 114.3, 73.3, 72.2, 68.8, 68.7, 52.8; IR (film) 3414, 1600 cm–1; MS (ESI) 332.1403 




ylamino]benzonitrile (9f). General Procedure 2 was employed for the coupling of 11e 
(249.6 mg, 0.593 mmol), with 3-bromobenzonitrile using (±)-BINAP as ligand and a 
reaction temperature of 80 °C. This procedure gave the title compound (151.0 mg, 60%) 
as a yellow oil after purification by chromatography with 7.5% EtOAc/hexanes as the 
eluant followed by heating under vacuum in a Kugelrohr apparatus (185 °C, 0.3 Torr) to 
remove hydrocarbon impurities. [α]23D – 45.4 (c = 0.53, CH2Cl2). 
1H NMR (400 MHz, 
CDCl3) δ 7.62 (d, J = 7.8 Hz, 1 H), 7.32−7.24 (m, 4 H), 7.23−7.11 (m, 3 H), 7.10−7.06 
(m, 2 H), 6.95−6.90 (m, 2 H), 6.81−6.73 (m, 2 H), 5.97−5.85 (m, 1 H), 5.32−5.23 (m, 3 
H), 5.21−5.16 (m, 1 H), 4.18 (d, J = 8.5 Hz, 1 H), 3.99−3.95 (m, 2 H), 3.88−3.79 (m, 1 
H), 3.49−3.39 (m, 2 H), 3.16−3.03 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 147.6, 
137.4, 136.5, 134.4, 129.9, 128.7, 128.5, 127.6, 12.8, 126.7, 121.9, 120.4, 119.4, 119.3, 
118.8, 117.4, 117.2, 115.4, 112.8, 110.8, 109.7, 72.1, 70.3, 53.0, 49.8, 26.5; IR (film) 





cis-2-(allyloxy)cyclohexylaniline  (14a). A solution of S4 (764 mg, 4.0 
mmol) in THF (16 mL) cooled to 0 °C under nitrogen with stirring. Solid NaH (216 mg, 
5.6 mmol, 60% suspension in mineral oil) was added slowly and the resulting mixture 
was stirred for 30 minutes at 0 °C. Allyl bromide (0.4 mL, 4.4 mmol) was added, and the 
mixture was warmed to rt. After the starting material had been completely consumed as 
judged by TLC analysis, the reaction mixture was quenched with saturated aqueous 
NH4Cl and transferred to a separatory funnel. The mixture was extracted with EtOAc (3 x 
15 mL), and the combined organic layers were washed with brine, dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography on silica gel using 2% EtOAc/hexanes as the eluant to afford 610 mg 
(66%) of the title compound as an amber oil.  1H NMR (400 MHz, CDCl3) δ 7.20–7.13 
(m, 2 H), 6.70–6.60 (m, 3 H), 5.98–5.86 (m, 1 H), 5.31–5.24 (m, 1 H), 5.17–5.12 (m, 1 
H), 4.16–4.03 (m, 2 H), 3.93–3.86 (m, 1 H), 3.71–3.66 (m, 1 H), 3.45–3.37 (m, 1 H), 
2.05–1.97 (m, 1 H), 1.81–1.68 (m, 2 H), 1.67–1.50 (m, 2 H), 1.48–1.26 (m, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 147.4, 135.4, 129.2, 117.0, 116.2, 113.6, 75.5, 69.6, 53.7, 
28.3, 27.4, 24.2, 20.2; IR (film) 3402, 1505 cm–1; MS (ESI) 232.1707 (232.1701 calcd for 





trans-2-(allyloxy)cyclohexylaniline (14b).26 The conversion of trans-2-
(phenylamino)cyclohexanol23 (500 mg, 2.62 mmol) to the title compound was 




14a. This procedure afforded 578 mg (95%) of the title compound as an amber oil. 
Spectroscopic properties were consistent with those reported in the literature.26  
trans-2-(allyloxy)cyclopentylaniline (14c). The conversion of trans-2-
(phenylamino)cyclopentanol24 (500 mg, 2.82 mmol) to the title compound was 
accomplished using a procedure analogous to that describ d above for the synthesis of 
14a. This procedure afforded 535 mg (87%) of the title compound as an amber oil. 1H 
NMR (400 MHz, CDCl3) δ 7.19–7.10 (m, 2 H), 6.71–6.57 (m, 3 H), 5.98–5.83 (m, 1 H), 
5.26 (dd, J = 1.6, 17.2 Hz, 1 H), 5.13 (d, J = 10.0 Hz, 1 H), 4.04–3.89 (m, 2 H), 3.74–
3.65 (m, 2 H), 3.48 (s, br, 1 H), 2.25–2.10 (m, 1 H), 1.87–1.59 (m, 4 H), 1.43–1.30 (m, 1 
H); 13C NMR (100 MHz, CDCl3) δ 147.6, 135.0, 129.0, 117.0, 116.4, 113.0, 84.9, 69.9, 
59.8, 31.5, 30.0, 21.7; IR (film) 3404 cm–1; MS (ESI) 218.1543 (218.1545 calcd for 
C14H19NO, M + H
+). 
cis-2-(allyloxy)cyclopentylaniline (14d). The conversion of S6 (532 mg, 3 
mmol) was accomplished using a procedure analogous to that described above for the 
synthesis of 14a. This procedure afforded 601 mg (92%) of the title compound as an 
amber oil. 1H NMR (400 MHz, CDCl3) δ 7.19–7.13 (m, 2 H), 6.70–6.59 (m, 3 H), 5.95–
5.82 (m, 1 H), 5.26 (dq, J = 1.6, 15.3 Hz, 1 H), 5.15 (dq, J = 1.5, 9.0 Hz, 1 H), 4.34 (s, br, 
1 H), 4.05–3.98 (m, 1 H), 3.96–3.89 (m, 2 H), 3.75–3.65 (m, 1 H), 2.07–1.94 (m, 1 H), 




129.2, 116.9, 116.7, 113.3, 79.9, 70.3, 56.1, 29.8, 29.4, 20.3; IR (film) 3401, 1602, 1505 
cm–1; MS (ESI) 240.1366 (240.1364 calcd for C14H19NO, M + Na
+). 
 
General Procedure 4: Synthesis of Morpholines via Pd-Catalyzed Carboamination. 
A Schlenk tube was evacuated, flame dried, and backfilled with nitrogen. The tube was 
charged with Pd(OAc)2 (2.3 mg, 0.01 mmol), P(2-furyl)3 (9.3 mg, 0.04 mmol), and 
NaOtBu (96.1 mg, 1.0 mmol). The tube was evacuated and b ckfilled with nitrogen, then 
the aryl bromide (1.0 mmol) and a solution of the amine substrate (0.50 mmol) in toluene 
(1.25 mL) were added to the schlenk tube (aryl bromides that were solids at room 
temperature were added as solids following the addition of NaOtBu). The mixture was 
heated to 105 °C with stirring until the substrate was consumed as judged by GC analysis 
(12–18 h). The reaction mixture was cooled to rt, quenched with saturated aqueous 
NH4Cl (3 mL), and extracted with EtOAc (3 x 3 mL). The combined organic layers were 
concentrated in vacuo and the crude product was purified by flash chromatography on 
silica gel. 
 (–)-(3S,5R)-3-Benzyl-5-(2-methylbenzyl)-4-phenylmorpholine 
(10a). General Procedure 4 was employed for the coupling of 2-bromotoluene with 9c. 
This procedure gave the title compound (121 mg, 68%) as a yellow oil after purification 
by chromatography with 5% EtOAc/hexanes as the eluant. This material was judged to be 
of >20:1 dr by 1H NMR analysis before and after purification. [α]23D − 3.1 (c = 1.20, 
CH2Cl2). 




7.14−7.07 (m, 4 H), 7.07−7.00 (m, 1 H), 3.71 (dd, J = 5.4, 11.5 Hz, 1 H), 3.66−3.46 (m, 5 
H), 2.81−2.66 (m, 4 H), 2.23 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 147.5, 138.9, 
137.0, 136.5, 130.4, 129.6, 129.5, 129.1, 128.5, 126.3, 126.3, 125.9, 121.7, 119.6, 69.6, 
69.6, 57.9, 56.9, 37.0, 33.6, 19.6; IR (film) 1598 cm–1; MS (ESI) 358.2174 (358.2171 
calcd for C25H27NO, M + H
+). 
 (+)-(3R,5S)-3-(4-tert-Butylbenzyl)-5-methyl-4-
phenylmorpholine (10b). General Procedure 4 was employed for the coupling of 1-
bromo-4-tert-butylbenzene with 9a. This procedure gave the title compound (88.7 mg, 
55%) as a yellow oil after purification by chromatography with 5% EtOAc/hexanes as the 
eluant. This material was judged to be of >20:1 dr by 1H NMR analysis before and after 
purification. The enantiopurity was judged to be 99% ee by chiral hplc analysis (chiralcel 
OD column, 0.05% isopropanol/hexanes as the eluant, 0.25 mL/min, RT = 51.29 min and 
63.38 min), [α]23D + 112.1 (c = 0.90, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.37−7.32 
(m, 2 H), 7.29−7.25 (m, 2 H), 7.15−7.11 (m, 2 H), 7.06−7.01 (m, 3 H), 3.79 (dd, J = 3.4, 
11.1 Hz, 1 H), 3.68−3.59 (m, 2 H), 3.56 (dd, J = 6.4, 11.1 Hz, 1 H), 3.47−3.40 (m, 1 H), 
3.40−3.32 (m, 1 H), 2.62 (dd, J = 3.0, 13.6 Hz, 1 H), 2.47 (dd, J = 10.8, 13.6 Hz, 1 H), 
1.29 (s, 9 H), 0.96 (d, J = 6.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 149.0, 148.0, 
135.9, 129.2, 128.7, 125.3, 122.5, 121.6, 73.0, 70.1, 58.7, 52.7, 36.3, 34.3, 31.3, 16.4; IR 





 (+)-(3R,5S)-3-Cinnamyl-5-methyl-4-phenylmorpholine (10c). 
General Procedure 4 was employed for the coupling of β-bromostyrene (2.0 mmol, 4 
equiv) with 9a using 4 equiv of NaOtBu and a catalyst composed of Pd(OAc)2 (4.5 mg, 
0.02 mmol, 4 mol %), and P(2-furyl)3 (18.6 mg, 0.08 mmol, 16 mol %). This modified 
procedure gave the title compound (70 mg, 47%) as a dark amber oil after purification by 
chromatography with 5% EtOAc/hexanes as the eluant. This material was judged to be of 
>20:1 dr by 1H NMR analysis before and after purification. [α]23D + 48.3 (c = 1.50, 
CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.35−7.30 (m, 2 H), 7.30−7.24 (m, 4 H), 
7.22−7.15 (m, 1 H), 7.12−7.03 (m, 3 H) 6.29 (d, J = 15.8 Hz, 1 H), 6.05 (dt, J = 7.3, 15.8 
Hz, 1 H), 3.86 (dd, J = 7.3, 15.8 Hz, 1 H), 3.80 (dd, J = 7.3, 15.8 Hz, 1 H), 3.64 (dd, J = 
7.3, 11.4 Hz, 1 H), 3.50 (dd, J = 7.3, 11.2 Hz, 1 H), 3.34−3.26 (m, 2 H), 2.18 (t, J = 6.8 
Hz, 2 H), 0.86 (d, J = 6.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 148.1, 137.3, 132.1, 
129.1, 128.4, 127.1, 126.7, 125.9, 123.2, 122.7, 73.1, 70.7, 57.3, 53.4, 34.2, 16.2; IR 
(film) 1598 cm–1; MS (ESI) 294.1858 (294.1858 calcd for C20H23NO, M + H
+). 
 (±)-(3S*,5R*)-3-Benzyl-4-(4-methoxyphenyl)-5-(4-
methylbenzyl)morpholine (10d). General Procedure 4 was employed for the coupling of 
4-bromotoluene with 9b on a 0.30 mmol scale. This procedure gave the title compound 
(27 mg, 23%) as a yellow oil after purification by chromatography with 5% 
EtOAc/hexanes as the eluant. This material was judged to be of >20:1 dr by 1H NMR 




7.17−7.12 (m, 1 H), 7.05−7.00 (m, 4 H), 6.99−6.94 (m, 2 H), 6.93−6.89 (m, 2 H), 3.83 (s, 
3 H), 3.67 (dt, J = 2.8, 11.3 Hz, 2 H), 3.49−3.43 (m, 2 H), 3.32−3.21 (m, 2 H), 2.67−2.57 
(m, 2 H), 2.37−2.26 (m, 5 H); 13C NMR (100 MHz, CDCl3) δ 156.7, 141.3, 138.7, 135.6, 
135.6, 129.0, 129.0, 128.8, 128.3, 126.1, 125.9, 114.6, 71.1, 71.1, 61.4, 61.3, 55.5, 37.2, 
36.8, 21.0; IR (film) 3436, 2924, 1509 cm–1; MS (ESI) 388.2280 (388.2277 calcd for 
C26H29NO2, M + H
+). 
 (+)-(3S,5R)-3-Benzyl-5-(3-methoxybenzyl)-4-
phenylmorpholine (10e). General Procedure 4 was employed for the coupling of  3-
bromoanisole with 9c. This procedure gave the title compound (96.4 mg, 52%) as a 
yellow oil after purification by chromatography with 5% EtOAc/hexanes as the eluant. 
This material was judged to be of >20:1 dr by 1H NMR analysis before and after 
purification. [α]23D + 3.5 (c = 1.28, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.41 (t, J = 
7.5 Hz, 2 H), 7.30 (t, J = 7.5 Hz, 2 H), 7.25−7.18 (m, 4 H), 7.15 (d, J = 7.8 Hz, 2 H), 6.97 
(t, J = 7.3 Hz, 1 H), 6.82 (d, J = 7.5 Hz, 1 H), 6.79−6.74 (m, 2 H), 3.84−3.76 (m, 5 H), 
3.62−3.53 (m, 4 H), 2.83−2.76 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 159.7, 147.1, 
140.7, 139.1, 129.6, 129.5, 129.2, 128.6, 126.3, 121.5, 120.1, 116.9, 115.1, 111.4, 68.8, 
68.7, 56.3, 56.2, 55.1, 36.6, 36.6; IR (film) 1598 cm–1; MS (ESI) 374.2117 (374.2120 
calcd for C25H27NO2, M + H
+). 
 (+)-(3S,5R)-3-Benzyl-5-(4-methoxybenzyl)-4-




bromoanisole with 9c. This procedure gave the title compound (96 mg, 51%) as a yellow 
oil after purification by chromatography with 5% EtOAc/hexanes as the eluant. This 
material was judged to be of >20:1 dr by 1H NMR analysis before and after purification. 
[α]23D + 11.9 (c = 0.71, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.46−7.39 (m, 2 H), 
7.35−7.29 (m, 2 H), 7.27−7.21 (m, 3 H), 7.18−7.12 (m, 4 H), 6.98 (t, J = 7.3 Hz, 1 H), 
6.89−6.84 (m, 2 H), 3.86−3.76 (m, 5 H), 3.63−3.50 (m, 4 H), 2.87−2.73 (m, 4 H); 13C 
NMR (100 MHz, CDCl3) δ 158.1, 147.2, 139.1, 131.1, 130.1, 129.6, 129.2, 128.6, 126.3, 
120.0, 116.9, 114.0, 68.7, 56.5, 56.3, 55.2, 36.6, 35.7. (two aliphatic carbon signals are 
incidentally equivalent); IR (film) 1597 cm–1; MS (ESI) 374.2113 (374.2120 calcd for 
C25H27NO2, M + H
+). 
 (+)-(3R,5S)-3-Benzyl-5-[2-(methylthio)ethyl]-4-
phenylmorpholine (10g). General Procedure 4 was employed for the coupling of 
bromobenzene with 9d. This procedure gave the title compound (100 mg, 61%) as a 
yellow oil after purification by chromatography with 10% EtOAc/hexanes as the eluant. 
This material was judged to be of >20:1 dr by 1H NMR analysis before and after 
purification. [α]23D + 122.9 (c = 0.88, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.37−7.31 
(m, 2 H), 7.28 (t, J = 7.5 Hz, 2 H), 7.22−7.15 (m, 3 H), 7.10 (d, J = 7.9 Hz, 2 H), 6.94 (t, 
J = 7.3 Hz, 1 H), 3.84−3.70 (m, 3 H), 3.58−3.49 (m, 3 H), 2.75−2.63 (m, 2 H), 2.58−2.51 
(m, 1 H), 2.43−2.36 (m, 1 H), 2.02 (s, 3 H), 1.97−1.87 (m, 1 H), 1.76−1.67 (m, 1 H); 13C 




68.9, 56.8, 53.9, 36.6, 31.3, 29.1, 15.5; IR (film) 1598 cm–1; MS (ESI) 328.1725 
(328.1735 calcd for C20H25NOS, M + Na
+). 
 (+)-(3S,5R)-3-(Benzyloxymethyl)-4-(4-chlorophenyl)-5-(4-
methylbenzyl)morpholine (10h). General Procedure 4 was employed for the coupling of 
4-bromotoluene with 9e. This procedure gave the title compound (108 mg, 51%) as an 
amber oil after purification by chromatography with 7.5% EtOAc/hexanes as the eluant. 
This material was judged to be of >20:1 dr by 1H NMR analysis before and after 
purification. [α]23D + 136.8 (c = 0.93, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.38−7.22 
(m, 7 H), 7.14−7.06 (m, 4 H), 6.87−6.83 (m, 2 H), 4.56 (d, J = 11.9 Hz, 1 H), 4.49 (d, J = 
11.9 Hz, 1 H), 4.15−4.09 (m, 1 H), 3.84−3.79 (m, 1 H), 3.76−3.66 (m, 2 H), 3.61−3.55 
(m, 1 H), 3.52−3.46 (m, 2 H), 3.42−3.37 (m, 1 H), 2.59 (d, J = 7.6 Hz, 2 H), 2.32 (s, 3 H); 
13C NMR (100 MHz, CDCl3) δ 145.5, 138.0, 136.0, 135.4, 129.4, 129.4, 129.0, 128.4, 
127.8, 127.6, 123.7, 115.8, 73.4, 68.3, 67.8, 67.7, 54.9, 53.2, 35.7, 21.0; IR (film) 1595 
cm–1; MS (ESI) 422.1873 (422.1887 calcd for C26H28ClNO2, M + H
+). 
 (+)-(3S,5R)-3-{3-[(1-Benzyl-1H-indol-3-yl)methyl]-5-
(naphthalen-2-ylmethyl)morpholino}benzonitrile (10i). General Procedure 4 was 
employed for the coupling of 2-bromonaphthalene with 9f. This procedure gave the title 
compound (159 mg, 58%) as a yellow solid after purification by chromatography with 




apparatus (195 °C, 0.3 Torr) to remove hydrocarbon impurities. This material was judged 
to be of >20:1 dr by 1H NMR analysis before and after purification. m.p. 83−87 °C; 
[α]23D + 55.5 (c = 1.18, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.85−7.79 (m, 3 H), 
7.77−7.72 (m, 2 H), 7.50−7.40 (m, 4 H), 7.33−7.19 (m, 8 H), 7.13−7.08 (m, 3 H), 7.05 (s, 
1 H), 5.26 (s, 2 H), 4.09 (d, J = 11.5 Hz, 1 H), 3.99 (d, J = 11.5 Hz, 1 H), 3.69 (d, J = 
11.2 Hz, 2 H), 3.51 (ddd, J = 2.2, 11.7, 26.1 Hz, 2 H), 3.33− .21 (m, 2 H), 3.00−2.89 (m, 
2 H); 13C NMR (100 MHz, CDCl3) δ 147.3, 137.3, 136.6, 135.9, 133.5, 132.2, 130.4, 
128.7, 128.6, 128.0, 127.9, 127.6, 127.5, 127.5, 127.2, 126.7, 126.5, 126.3, 125.6, 122.1, 
121.2, 119.6, 119.4, 118.7, 117.8, 116.9, 113.5, 111.8, 109.9, 68.4, 67.6, 54.4, 54.0, 49.9, 
36.6, 25.8; IR (film) 2228, 1596 cm–1; MS (ESI) 570.2519 (570.2521 calcd for 
C38H33N3O, M + Na
+). 
 (+)-(S)-3-Benzyl-5-(2-methylbenzyl)-4-phenyl-3,4-dihydro-2H-
1,4-oxazine (12a). The title compound was isolated as a side product in the above 
reaction of 9b with 2-bromotoluene (yellow oil,14.6 mg, 8%). [α]23D + 74.9 (c = 1.02, 
CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.38–7.02 (m, 8 H), 7.01–6.91 (m, 2 H), 6.80–
6.74 (m, 2 H), 6.65–6.60 (m, 2 H), 6.23 (s, 1 H), 3.89 (dd, J = 1.1, 10.4 Hz, 1 H), 3.72 
(dd, J = 2.3, 10.4 Hz, 1 H), 3.47–3.39 (m, 2 H), 3.23 (d, J = 15.2 Hz, 1 H), 2.78 (dd, J = 
9.6, 13.6 Hz, 1 H), 2.61–2.54 (m, 1 H), 2.15 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
149.0, 139.6, 137.5, 136.6, 130.7, 130.2, 129.7, 129.5, 128.9, 128.2, 126.3, 126.0, 125.7, 
123.7, 122.7, 118.2, 64.1, 63.3, 36.2, 33.4, 19.3; IR (film) 1658, 1596 cm–1; MS (ESI) 





 (S)-3,5-Dibenzyl-4-phenyl-3,4-dihydro-2H-1,4-oxazine (12b). A 
Schlenk tube was evacuated, flame dried, and backfilled with nitrogen. The tube was 
charged with [(IPr)Pd(acac)Cl]27 (15.7 mg, 0.025 mmol, 5 mol %), KOtBu (112 mg, 1.0 
mmol), and phenanthrene (89.1 mg, 0.50 mmol, 1.0 equiv) and evacuated and backfilled 
with nitrogen. Bromobenzene (105 µL, 1.0 mmol) and a solution of 9b (133.7 mg, 0.50 
mmol) in toluene (1.25 mL, 0.4 M) were added to theSchlenk tube. The mixture was 
heated to 105 °C with stirring until the amine substrate was consumed as judged by GC 
analysis (15 h). The mixture was cooled to rt, quench d with saturated aqueous NH4Cl (3 
mL), and extracted with EtOAc (3 x 3 mL). The combined organic layers were 
concentrated in vacuo. A crude yield of 79% was calcul ted as judged by 1H-NMR 
analysis with phenanthrene as an internal standard  The crude product was purified by 
flash chromatography on silica gel with 1.5% EtOAc/hexanes as the eluant to afford the 
title compound (97 mg, 57%) as a colorless oil. This material contained ca. 10% of an 
unknown impurity as judged by 1H NMR analysis. This material readily decomposes on a 
TLC plate or in a chloroform solution open to air. 1H NMR (400 MHz, CDCl3) δ 7.35–
7.16 (m, 8 H), 7.12–7.05 (m, 2 H), 7.04–6.98 (m, 1 H), 6.81–6.73 (m, 2 H), 6.69–6.62 
(m, 2 H), 6.42 (s, 1 H), 3.93 (dd, J = 1.3, 10.3 Hz, 1 H), 3.75 (dd, J = 2.4, 10.2 Hz, 1 H), 
3.51-3.41 (m, 2 H), 3.22 (d, J = 14.8 Hz, 1 H), 2.76 (dd, J = 9.4, 13.3 Hz, 1 H), 2.58 (dd, 
J = 5.1, 13.3 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 148.6, 140.0, 139.6, 129.9, 129.5, 




(film) 1658, 1596, 1492 cm–1; MS (ESI) 342.1861 (342.1858 calcd for C24H23NO, M + 
H+).  
 (±)-(3R*,4aS*,8aR*)-3-Benzyl-4-phenyloctahydro-2H-
benzo[b][1,4]oxazine (15a). General Procedure 4 was employed for the coupling of 
bromobenzene with 14a (174 mg, 0.75 mmol). This procedure gave the title compound 
(150 mg, 65%) as white solid after purification by chromatography with 2% 
EtOAc/hexanes as the eluant. This material was judged to be of >20:1 dr by 1H NMR 
analysis before and after purification. m.p. 96–98 °C; 1H NMR (400 MHz, CDCl3) δ 
7.38–7.28 (m, 6 H), 7.26–7.20 (m, 1 H), 6.93–6.83 (m, 2 H), 6.79–6.71 (m, 1 H), 4.04 (d, 
J = 12.0 Hz, 1 H), 3.73–3.53 (m, 4 H), 3.05 (t, J = 12.0 Hz, 1 H), 2.80 (d, J = 13.0 Hz, 1 
H), 2.08 (d, J = 14.0 Hz, 1 H), 1.95 (d, J = 12.0 Hz, 1 H), 1.86–1.49 (m, 5 H), 1.34–1.20 
(m, 1 H); 13C NMR (100 MHz, CDCl3) δ 146.5, 139.9, 129.6, 129.3, 128.7, 126.3, 116.6, 
111.8, 75.6, 67.8, 53.0, 37.2, 31.7, 25.4, 25.0, 20.9 (one aliphatic carbon signal is absent 
due to incidental equivalence); IR(film) 1598, 1503 cm–1; MS (ESI) 308.2011 (308.2014 
calcd for C21H15NO + H
+). 
 (±)-(3R*,4aS*,8aS*)-3-Benzyl-4-phenyloctahydro-2H-
benzo[b][1,4]oxazine (15b). General Procedure 4 was employed for the coupling of 
bromobenzene with 14b (174 mg, 0.75 mmol). This procedure gave the title compound 
(126 mg, 55%) as a white crystalline solid, after pu ification by chromatography with 2% 




analysis before and after purification. m.p. 128–130 °C;1H NMR (400 MHz, CDCl3) δ 
7.40–7.08 (m, 8 H), 6.99–6.91 (m, 2 H), 3.78 (d, J = 11.3 Hz, 1 H), 3.48 (t, J = 10.3 Hz, 1 
H), 3.37–3.24 (m, 2 H), 2.56 (d, J = 13.0 Hz, 2 H), 2.21–2.09 (t, J = 11.7 Hz, 1 H), 1.92 
(d, J = 10.3 Hz, 1 H), 1.68 (d, J = 10.3 Hz, 1 H), 1.54 (d, J = 11.7 Hz, 1 H), 1.42–1.20 
(m, 3 H), 1.16–0.94 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 148.7, 138.5, 129.1, 128.9, 
128.2, 128.0, 126.3, 126.1, 80.8, 71.7, 66.6, 62.5, 37.5, 31.3, 29.7, 24.6, 24.5; IR (film) 
1488, 1448 cm–1; MS (ESI) 308.2018 (308.2014 calcd for C21H25NO, M + H
+). 
 (±)-(3R*,4aS*,7aS*)-3-benzyl-4-
phenyloctahydrocyclopenta[b][1,4]oxazine (15c). General Procedure 4 was employed 
for the coupling of bromobenzene with 14c (54 mg, 0.25 mmol). This procedure gave the 
title compound (52 mg, 71%) as yellow solid after pu ification by chromatography with 
15% EtOAc/hexanes as the eluant. This material was judged to be of >20:1 dr by 1H 
NMR analysis before and after purification. m.p. 84–86 °C; 1H NMR (400 MHz, CDCl3) 
δ 7.39–7.33 (m, 2 H), 7.30–7.26 (m, 2 H), 7.24–7.28 (m, 3 H), 7.17–7.12 (m, 1 H), 7.04–
7.00 (m, 2 H), 3.87 (dd, J = 3.1, 8.2 Hz, 1 H), 3.59–3.47 (m, 2 H), 3.30 (tt, J = 3.6, 10.1 
Hz, 1 H), 2.75–2.63 (m, 2 H), 2.23 (dd, J = 3.8, 10.2 Hz, 1 H), 1.98–1.89 (m, 1 H), 1.69–
1.52 (m, 3 H), 1.37–1.29 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 149.2, 138.6, 129.0, 
128.9, 128.3, 126.5, 126.2, 126.0, 82.9, 72.8, 68.7, 61.8, 36.6, 26.7, 26.2, 17.4; IR (film) 







phenyloctahydrocyclopenta[b][1,4]oxazin-3-ylmethyl)phenyl ketone (15d). General 
Procedure 4 was employed for the coupling of 4-bromobenzophenone with 14c (163 mg, 
0.75 mmol). This procedure gave the title compound (151 mg, 51%) as yellow solid after 
purification by chromatography with 15% EtOAc/hexanes as the eluant followed by 
heating under vacuum in a Kugelrohr apparatus (180 °C, 0.3 Torr) to remove 
hydrocarbon impurities. This material was judged to be of >20:1 dr by 1H NMR analysis 
before and after purification. m.p. 84–86 °C;1H NMR (400 MHz, CDCl3) δ 7.78–7.74 (m, 
2 H), 7.69–7.65 (m, 2 H), 7.60–7.54 (m, 1 H), 7.49–7.44 (m, 2 H), 7.40–7.34 (m, 2 H), 
7.30–7.25 (m, 2 H), 7.24–7.19 (m, 1 H), 7.15–7.10 (m, 2 H), 3.88 (dd, J = 3.3, 8.0 Hz, 1 
H), 3.61–3.48 (m, 2 H), 3.40–3.31 (m, 1 H), 2.81–2.65 (m, 2 H), 2.37 (dd, J = 4.0, 10.0 
Hz, 1 H), 2.00–1.89 (m, 1 H), 1.70–1.56 (m, 3 H), 1.38–1.29 (m, 2 H); 13C NMR (100 
MHz, CDCl3) δ 196.3, 149.1, 143.8, 137.7, 135.6, 132.3, 130.3, 129.9, 129.1, 128.8, 
128.2, 126.5, 126.1, 82.9, 72.7, 68.6, 61.6, 36.7, 26.6, 26.2, 17.4; IR (film) 1658, 1606 
cm–1; MS (ESI) 398.2119 (398.2120 calcd for C27H27NO2, M + H
+). 
 (±)-(3R*,4aS*,7aR*)-Phenyl 4-(4-
phenyloctahydrocyclopenta[b][1,4]oxazin-3-ylmethyl)phenyl ketone (15e). General 
Procedure 4 was employed for the coupling of 4-bromobenzophenone with 14d (109 mg, 




purification by chromatography with 10% EtOAc/hexanes as the eluant followed by 
heating under vacuum in a Kugelrohr apparatus (160 °C, 0.3 Torr) to remove 
hydrocarbon impurities. This material was judged to be of >20:1 dr by 1H NMR analysis 
before and after purification. 1H NMR (400 MHz, CDCl3) δ 7.83–7.77 (m, 4 H), 7.63–
7.56 (m, 1 H), 7.52–7.45 (m, 2 H), 7.44–7.40 (m, 2 H), 7.37–7.30 (m, 2 H), 6.91 (d, J = 
8.3 Hz, 2 H), 6.79 (t, J = 7.0 Hz, 1 H), 4.01–3.96 (m, 1 H), 3.89 (d, J = 11.6 Hz, 1 H), 
3.83–3.68 (m, 2 H), 3.58–3.50 (m, 1 H), 3.11 (dd, J = 1.2, 13.0, 1 H), 2.95 (d, J = 13.0, 1 
H), 2.38–2.25 (m, 1 H), 2.12–1.86 (m, 3 H), 1.74–1.50 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 196.3, 147.1, 144.7, 137.7, 135.8, 132.3, 130.6, 130.0, 129.6, 129.3, 128.3, 
116.9, 111.9, 78.2, 66.0, 56.3, 52.7, 35.6, 31.3, 28.1, 21.6; IR (film) 1658, 1597 cm–1; MS 
(ESI) 420.1925 (420.1939 calcd for C27H27NO2, M + Na
+). 
 (±)-3-[(2-Methyl-4-phenylmorphlin-3-yl)methyl]benzonitrile 
(17). General Procedure 4 was employed for the coupling of 3-bromobenzonitrile with 
16. This procedure gave the title compound as an inseparable mixture of diastereomers. 
The crude material was judged to be of 1.3:1 dr by 1H NMR analysis. Purification by 
chromatography with 15% EtOAc/hexanes as the eluant g ve the title compound (65 mg, 
45%) as a yellow oil. The pure material was judged to be of 2:1 dr by 1H NMR analysis.  
Major (cis) diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.37−7.28 (m, 3 H), 7.24−7.13 
(m, 3 H), 6.78–6.69 (m, 3 H), 4.07−3.89 (m, 3 H), 3.80 (dt, J = 3.3, 11.5 Hz, 1 H), 3.34 
(dt, J = 3.8, 12.3 Hz,  1 H), 3.14 (dd, J = 3.3, 12.3 Hz, 1 H), 3.00 (dd, J = 6.2, 14.5 Hz, 1 




CDCl3) δ 149.7, 141.6,  133.6, 132.7, 129.4, 129.3, 129.0, 119.2, 118.8, 116.1, 111.9,  
75.2, 66.8,  62.0, 41.6, 29.8, 18.8. Minor (trans) diastereomer: 1H NMR (400 MHz, 
CDCl3) δ 7.49−7.29 (m, 6 H), 6.96−6.87 (m, 3 H), 4.02 (dt, J = 3.9, 11.3 Hz, 1 H), 3.84–
3.74 (m, 2 H), 3.56–3.50 (m, 1 H), 3.31–3.23 (m, 1 H), 3.18–3.10 (m, 2 H), 2.71 (dd, J = 
3.8, 13.6 Hz, 1 H), 1.38 (d, J = 6.6 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 150.2,  
140.8, 133.9, 132.7, 129.8, 129.1, 128.7, 120.0, 118.7, 116.8, 112.3, 68.7, 67.9, 59.7, 
43.9, 32.4, 16.9. IR (film) 2229, 1598 cm–1; MS (ESI) 293.1656 (293.1654 calcd for 





(19). General Procedure 4 was employed for the coupling of 4-bromobiphenyl with 18. 
This procedure gave the title compound as a separable mixture of diastereomers. The 
crude material was judged to be of 2:1 dr by 1H NMR analysis. Purification by 
chromatography with 2→5% EtOAc/hexanes as the eluant gave the major diastereomer 
trans-19 (57.2 mg, 32%) and minor diastereomer cis-19 (30.1 mg, 17%) for a combined 
total mass of 87.3 mg (49%, 2:1 dr). The separated diastereomers were each judged to be 
of >20:1 dr by 1H NMR analysis after purification.  
Major diastereomer: trans-5-(Biphenyl-4-ylmethyl)-2-ethyl-




7.6 Hz, 2 H), 7.47 (d, J = 8.1 Hz, 2 H), 7.44−7.28 (m, 5 H), 7.23−7.13 (m, 4 H), 7.08 (t, J 
= 7.4 Hz, 1 H), 3.89 (dd, J = 2.6, 11.2 Hz, 1 H), 3.71–3.62 (m, 1H), 3.49 (dd, J = 7.8, 
11.3 Hz, 1 H), 3.45−3.37 (m, 1 H), 3.19 (dd, J = 2.7, 11.7 Hz, 1 H), 2.83 (dd, J = 2.9,13.8 
Hz, 1 H), 2.75 (dd, J = 8.2, 11.9 Hz, 1 H), 2.52 (dd, J = 9.8, 13.8 Hz, 1 H), 1.71−1.57 (m, 
1 H), 1.52−1.37 (m, 1 H), 0.93 (t, J = 7.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 151.1, 
140.9, 139.1, 137.6, 129.5, 129.3, 128.7, 127.1, 127.0, 126.9, 123.3, 122.5, 76.8, 68.5, 
58.5, 57.4, 34.8, 25.5, 9.9; IR (film) 1598 cm–1;MS (ESI) 358.2164 (358.2171 calcd for 
C25H27NO, M + H
+). 
Minor diastereomer: cis-5-(Biphenyl-4-ylmethyl)-2-ethyl-4-
phenylmorpholine (cis-19), yellow solid, m.p. 125−127 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.56 (d, J = 7.5 Hz, 2 H), 7.51 (d, J = 7.9 Hz, 2 H), 7.42 (t, J = 7.5 Hz, 2 H), 
7.37−7.29 (m, 3 H), 7.28−7.22 (m, 2 H), 6.97 (d, J = 8.3 Hz, 2 H), 6.87 (t, J = 7.2 Hz, 1 
H), 3.93 (d, J = 11.4 Hz, 1 H), 3.84−3.77 (m, 1 H), 3.71−3.65 (m,1 H), 3.56−3.48 (m, 1 
H), 3.28 (dd, J = 2.8, 11.8 Hz, 1 H), 3.09 (dd, J = 11.3, 12.8 Hz, 1 H), 2.88 (t, J = 11.3 
Hz, 1 H), 2.62 (d, J = 12.8 Hz, 1 H), 1.78−1.67 (m, 1 H), 1.67−1.57 (m,1 H), 1.06 (t, J = 
7.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 149.4, 140.9, 139.0, 138.6, 129.8, 129.4, 
128.7, 127.2, 127.1, 127.0, 118.9, 115.1, 77.2, 67.1, 57.2, 47.1, 30.7, 26.8, 9.9; IR (film) 
1598 cm–1; MS (ESI) 358.2171 (358.2171 calcd for C25H27NO M + H
+). 
 
Ligand Screen for the Synthesis of Morpholines via Pd-Catalyzed Carboamination. 




charged with the appropriate palladium catalyst or precatalyst, ligand (where 
appropriate), phenanthrene (1.0 equiv) as an internal standard, and NaOtBu or KOtBu 
(2.0 equiv). The tube was evacuated and backfilled with nitrogen, then the aryl bromide 
(2.0 equiv) and a solution of the amine substrate (1.0 equiv) in toluene (0.4 M) were 
added to the Schlenk tube. The mixture was heated to 105 °C with stirring for 15 h. The 
reaction mixture was cooled to rt, quenched with saturated aqueous NH4Cl (3 mL), and 
extracted with EtOAc (3 x 3 mL). The combined organic layers were concentrated in 
vacuo and the crude product mixture was analyzed by 1H NMR spectroscopy. Results are 
shown Table 3-1. 
 (–)-(E)-(2S)-N-(1-Phenyl-3-(3-o-tolylallyloxy)propan-2-
yl)aniline (13). Isolation of 13 from the mixtures described in Table 3-1 proved to be 
difficult. As such, a sample of 13 was prepared by a modification of General Procedure 4. 
A Schlenk tube was evacuated, flame dried, and backfilled with nitrogen. The tube was 
charged with Pd(OAc)2 (2.3 mg, 0.01 mmol), dppf (4.4 mg, 0.04 mmol), and K3PO4 (212 
mg, 1.0 mmol). The tube was evacuated and backfilled with nitrogen, then 2-
bromotoluene (120 µL, 1.0 mmol) and a solution of 9b (78 mg, 0.29 mmol) in toluene 
(1.25 mL) were added to the Schlenk tube. The mixture was heated to 105 °C with 
stirring until the substrate was consumed as judged by GC analysis (16 h). The reaction 
mixture was cooled to rt, quenched with saturated aqueous NH4Cl (3 mL), and extracted 
with EtOAc (3 x 3 mL). The combined organic layers were concentrated in vacuo. The 




the eluant to afford the title compound (8 mg, 7%) as a colorless oil. [α]23D – 21.7 (c = 
0.69, CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 7.46–7.40 (m, 1 H), 7.32–7.12 (m, 10 H), 
6.85–6.77 (m, 1 H), 6.73–6.69 (m, 1 H), 6.69–6.63 (m, 2 H), 6.17 (dt, J =6.2, 15.9 Hz, 1 
H), 4.22–4.12 (m, 2 H), 3.96 (s, br, 1 H), 3.80 (s, br, 1 H), 3.51–3.44 (m, 2 H), 3.03–2.90 
(m, 2 H), 2.33 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 147.1, 138.5, 135.7, 135.5, 130.4, 
130.3, 129.4, 129.4, 128.4, 127.6, 127.2, 126.3, 126.1, 125.8, 117.5, 113.5, 72.0, 69.8, 
54.0, 37.2, 19.8; IR (film) 3404, 1601, cm−1; MS (ESI) 380.1986 (380.1990 calcd for 
C25H27NO, M + Na
+). 
 
Assignment of Stereochemistry 
cis-3,5-Disubstituted morpholines derived from alanine, methionine, and serine. The 
stereochemistry of 5-methylmorpholine 10b was assigned on the basis of 2D NOESY 
experiments. The key nOe signals are shown below. The stereochemistry of morpholines 
10c, and 10g–h were assigned based on analogy to 10b. 
 
 
cis-3,5-Disubstituted morpholines derived from phenylalanine, and tryptophan. Due 
to overlap of key signals in the 1H NMR spectra of cis-3,5-disubstituted morpholines 
derived from phenylalanine, the stereochemistry of these compounds was established 
through preparation of a 1:1.4 mixture of cis-isomer 10a and trans-isomer 25 via 




disubstituted 3-benzylmorpholine 25 was assigned on the basis of 2D NOESY and 1D 
NOESY experiments. The key nOe signals are shown below. The stereochemistry of cis-
disubstituted morpholine 10a was assigned by comparison to 25. The stereochemistry of 
morpholines 10e–f, and 10i were assigned based on analogy to 10a. 
 
 (3S,5S)-3-Benzyl-5-(2-methylbenzyl)-4-phenylmorpholine (25). A Schlenk tube was 
evacuated, flame dried, and backfilled with hydrogen. The tube was charged with 
platinum (2 mg, 10 wt. % on activated carbon), then evacuated and backfilled with 
hydrogen four times. A solution of 12a (14.6 mg, 0.04 mmol) in MeOH:CH2Cl2 (2:1, 0.9 
mL, 0.05 M) was added to the Schlenk tube. The mixture was stirred until the oxazine 
was consumed as judged by GC analysis (15 h). The mixture was diluted with CH2Cl2 (2 
mL) and filtered through celite. The celite was washed with CH2Cl2 (2 x 2 mL) and the 
combined organic solutions were concentrated in vacuo to provide a yellow oil. This 
material was judged to be of 1.6:1 dr by 1H NMR analysis. The crude product was 
purified by flash chromatography on silica gel with 5% EtOAc/hexanes as the eluant to 
yield the title compound 25 (2.2 mg, 15%) as a yellow oil along with 10a (1.6 mg, 11%) 
as a yellow oil for a combined isolated yield (3.8 mg, 26%, 1.4:1 dr). The diastereomers 
were judged to be of >20:1 dr by 1H NMR analysis after purification. The (3S,5S)-
stereoisomer was characterized by 1H NMR and MS for purposes of comparison to 
compound 10a as described above. 1H NMR (400 MHz, CDCl3) δ 7.45–7.38 (m, 2 H), 




H), 3.63 (dd, J = 3.9, 11.2 Hz, 1 H), 3.54–3.46 (m, 2 H), 3.02 (dd, J = 2.9, 13.7 Hz, 1 H), 
2.84 (dd, J = 10.6, 13.2 Hz, 1 H), 2.77 (dd, J = 3.5, 13.2 Hz, 1 H), 2.45 (dd, J = 11.1, 13.8 
Hz, 1 H), 2.00 (s, 3 H); MS (ESI) 358.2163 (358.2171 calcd for C25H27NO, M + H
+). 
 
(±)-cis-3-[(2-methyl-4-phenylmorphlin-3-yl)methylbenzonitrile (cis-17). The 
stereochemistry of cis-2,3-disubstituted morpholine cis-17 was assigned on the basis of 





(±)-trans-5-(Biphenyl-4-ylmethyl)-2-ethyl-4-phenylmorpholine (trans-19) and (±)-
[cis]-5-(Biphenyl-4-ylmethyl)-2-ethyl-4-phenylmorpholine (cis-19).  
The stereochemistry of trans- and cis-2,5-disubstituted morpholines 19 were assigned on 





trans-Fused bicyclic morpholines 15b–d. The stereochemistry of 15d was assigned on 
the basis of 2D NOESY experiments. The key nOe signals are shown below. The 
stereochemistry of 15b and 15c was assigned based on analogy to 15d. 
 
 
cis-Fused bicyclic morpholines 15a and 15e. The stereochemistry of 15e was assigned 
on the basis of 2D NOESY experiments. The key nOe signals are shown below. The 
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Development of a Mild Curtius Rearrangement for the Synthesis of Benzylic and 
Heteroarylmethyl Amines 
4.1 Introduction 
The Curtius rearrangement was first reported in 1890 when Thomas Curtius 
described the conversion of benzoylhydrazine (1) to diphenylurea (3) (Scheme 4-1).1 
Scheme 4-1: Discovery of the Curtius Rearrangement 
 
 The defining step of the Curtius rearrangement is the conversion of an acyl azide (5) to 
an isocyanate (6) via a 1,2-carbon-to-nitrogen migration with extrusion of dinitrogen 
(Scheme 4-2).2  Subsequent hydrolysis of the isocyanate generates primary amines, or 
trapping of the isocyanate with a nucleophile leads to ureas, carbamates, or amides.  
Converting a carboxylic acid to an amine functionality is fundamentally useful in organic 
synthesis, and as such, the Curtius rearrangement has been widely utilized and has been 
carefully investigated. Useful reviews summarizing the development and application of 
this rearrangement are available.3 A key feature of the Curtius rearrangement is thatit 
proceeds with retention of stereopurity.4 Mechanistic studies indicate that the 





Scheme 4-2: The Curtius Rearrangement 
 
4.2 Modern Developments and Current Challenges 
The Curtius rearrangement was quickly recognized as a highly useful 
transformation, but the potential for acyl azides to decompose explosively introduced a 
safety hazard and methodological challenge for some substrates. This limitation led to the 
development of reagents and methods that facilitate acyl azide generation, Curtius 
rearrangement, and isocyanate trapping in a single flask. The most commonly used 
reagent for this transformation is diphenylphosphorylazide (DPPA), which allows the 
direct transformation of carboxylic acids into carbmates.6 Use of this reagent is 
potentially complicated by the high temperatures required to achieve conversion to the 
desired carbamate, which could compromise the stability of sensitive functionalities. 
Furthermore, substrates that contain acidic protons adjacent to the carboxylic acid 
undergoing rearrangement, such as benzylic or malonic acids (7), are problematic for the 
Curtius rearrangement using DPPA, often leading to ester byproducts (9) as judged by 
LC-MS characterization.7 This could potentially occur through elimination of hydrazoic 
acid, formation of the ketene (8) and subsequent trapping with the alcohol nucleophile 
(Scheme 4-3, eq 1).8 
For example, selective ester formation was observed by LC-MS when attempting to 




(Scheme 4-3, eq 2). To avoid this side reaction, it was found that sequential formation of 
the acyl azide 13 and treatment with BCl3 at room temperature in CH2Cl2 followed by 
addition of t-BuOH led to the desired product in moderate yield (Scheme 4-3, eq 3).  
Scheme 4-3: Formation of undesired ester byproducts 
 
Benzylic amines are found in many important biologically active molecules.9 For 
example, three highly profitable pharmaceutical products have chrial benzylic amines in 
their structures. Zoloft (14) helps treat depression and obsessive compulsive disorder 
(OCD); Cialis (15) is an erectile dysfunction therapeutic, and Sensipar  (16) helps to treat 
hyperparathyroidism. Furthermore, benzylic amines baring stereogenic centers have 
been used as ligands in asymmetric synthesis.10  Optimization of this room temperature 




Figure 4-1: Example Chiral Benzylic Amines Found in Bilogically Active Molecules 
 A general method for the formation of benzylic amines from readily available 
carboxylic acids would prove particularly useful, esp cially when considering the 
powerful asymmetric hydrogenation methods that have be n developed for accessing α-
chiral benzylic acids.11 This chapter describes the development of a step-wise procedure 
for conversion of benzylic and heteroarylmethyl acids to carbamate protected amines via 
a room temperature Curtius rearrangement. 
4.3 Initial Optimization 
The first task in optimization was to screen a variety of Lewis acids and solvents 
with the aim of determining the optimal conditions for Curtius rearrangement of benzylic 
acyl azides. For this initial study, the acyl azide 17, derived from 4-methoxybenzoic acid, 
was employed as a standard substrate, with MeOH as the nucleophile to trap the 
isocyanate. As a control, alternate Curtius conditions were tested (refluxing 4-
methoxybenzoic acid, DPPA, Et3N and MeOH or tBuOH), but they led to numerous side 
products instead of rearrangement product 18a. A wide variety of Lewis acids and 
solvents were tested, with no improvement over the initial result. A key observation was 
made during these studies that in some instances, ayl azide 17 was not undergoing 




us to the discovery that in the presence of MeOH, 17 was cleanly converted to the desired 
methyl carbamate 18a after 18 h at room temperature, in the absence of any additive 
(Figure 4-2). Attempts to increase the rate of conversion to 18a by addition of catalytic 
HCl, and other more acidic alchohol solvents such as hexafluoroisopropanol and 
trifluoroethanol led in all cases to ester byproducts in addition to product 18a. 
Figure 4-2: Room temperature Curtius rearrangement in MeOH 
 
There are few reports of low temperature Curtius rearrangements; one notable 
exception is the work by Lebel and coworkers where they report a useful one-pot Curtius 
rearrangement using TMSN3, Boc2O and Zn(OTf)2 at 40 °C.
12 The authors reveal that a 
benzylic acid substrate was problematic, leading to a mixture of desired product and the 
anticipated ester byproduct, thus highlighting the utility of this discovery. This simple 
solution to the problematic Curtius rearrangement of benzylic and heteroarylmethyl acyl 
azides is complementary to existing methods and provides an alternative procedure for 
more sensitive compounds that are unstable to heat or Lewis Acids. For example, the acyl 
azide derived from 2-(benzofuran-3-yl)acetic acid forms extensive side products in the 
presence of Lewis acids at room temperature or when heated with DPPA, but converts 









1. Cl2(CO)2, 0 ºC, CH2Cl2
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4.4 Synthesis of Methyl Carbamates 
To determine the generality of the step-wise acyl azide formation and room 
temperature Curtius rearrangement in methanol, the scope of the transformation was 
investigated (Table 4-1). A wide variety of benzylic and heterocyclic acids convert to the 
corresponding methyl carbamates in good yield (Table 4-1). Chiral, non-racemic acids 
can also be converted to the corresponding protected amines without racemization of the 
adjacent stereogenic center (Table 4-1, entries 6 and 7). The reaction can be run under an 
air atmosphere without strict moisture exclusion, ad purification of the resulting 
products is simplified by the absence of additives. In many applications, simply 
concentrating the reaction mixture provides product of sufficient purity for subsequent 
chemical transformations. Aromatic acids also undergo rearrangement cleanly in high 
yield (Table 4-1, entry 12), however aliphatic acids provide the corresponding carbamate 
in poor yields due to competetive hydrolysis of the acyl chloride during acyl azide 
formation. Substrates bearing a quarternary carbon center adjacent to the acyl azide 
undergo the rearrangement at a slower rate, achieving 86% yield after 12 days. (Table 
4-1, entry 11).  This limitation is not especially troubling, since substrates bearing 
quaternary carbons will not be susceptible to ester byp oduct formation using established 
procedures.13 It should also be noted that increasing the reaction temperature (40–60 °C) 
can shorten the reaction time considerably for substrates listed in Table 1, but often leads 




4.5 Synthesis of Various Carbamates 
The procedure described above provides a convenient and mild method for 
accessing benzylic and heteroarylmethyl amines without forming ester byproducts, 
however, removal of methyl carbamates can often requi  harsh basic conditions. Thus, 
conditions were sought to further expand this protoc l so that alternative alcohol 
nucleophiles could be utilized to form more readily deprotected carbamates. A simple 
solution would be to perform the rearrangement in t-BuOH to form the Boc carbamate, 
however, it was found that both i-PrOH and t-BuOH provided slow conversion to 
products 18m and 18n, revealing that the steric nature of the alcohol nucleophile greatly 
effects the rate of product formation (Table 4-2, entri s 9-11). 





An important consideration was to determine whether  rearrangement would 
take place without using the desired alcohol as the solvent. This would allow preparation 
of alternative carbamates that could be deprotected under more mild conditions without 
using excessive amounts of potentially expensive alchohol nucleophiles. A variety of 
solvents were screened using 5 equivalents of MeOH as an additive. Chloroform was 
effective in providing the fastest rearrangement. Although it is possible that 
rearrangement could be promoted by trace amounts of HCl present in CHCl3, we found 
that the product was formed with equal efficiency in base-washed CHCl3.  The hydrogen-
bonding capability of CHCl3 could also be responsible.
14 Comparison of entries 6–8 
(Table 4-2) reveals that 5 equivalents of the alcohol nucleophile was the optimal 
condition to achieve a reasonable yield in 24 hours. 
Using the optimal conditions from Table 4-2 (entry 6) a variety of substrates and 
different alcohol nucleophiles were tested (Table 4-3). Again, the transformation appears 
to be general for both benzylic and heteroaryl substrates with less sterically hindered 
nucleophiles. Note that the majority of commerically purchased chloroform is stabilized 
with added ethanol, even if unspecified. Ethanol can compete with other alcohol 
nucleophiles to trap the isocyanate intermediate. I is possible to use anhydrous 
chloroform stabilized with amylenes to avoid this complication. Carbamate derivatives 









1. Cl2(CO)2, 0 ºC, CH2Cl2
2. NaN3, 0 ºC, H2O, acetone
3. CHCl3, R
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In conclusion, a simple step-wise procedure to achieve a room temperature 
Curtius rearrangement of benzylic and heteroarylmethyl carboxylic acids is reported. The 




procedures that require heating or the use of Lewis ac ds. Hopefully this simple result 
will enable others to easily prepare benzylic and heteroarylmethyl carbamates without the 
formation of unwanted ester byproducts or other deleterious side reactions. The mild 
nature of these conditions and the ease of purification will hopefully encourage their use 
in more complicated synthetic applications.  
4.7 Experimental Section 
General: Unless otherwise noted, all material were obtained from commercial 
suppliers and used without further purification. Anhydrous solvents were purchased from 
Aldrich packaged under nitrogen in Sure/Seal™ bottles and used directly. Reactions were 
monitored using Agilent 1100 Series LCMS with UV detection at 254 nm and 215 nm 
and a low resonance electrospray mode (ESI). Medium pressure liquid chromatography 
(MPLC) was performed on a Combiflash® Companion® (Teledyne Isco) with Redisep® 
normal-phase silica gel (35 – 60 micron) columns and UV detection at 254 nM. 1H and 
13C NMR spectra were recorded on a Bruker AV-400 (400 mHz) spectrometer at ambient 
temperature. Chemical shifts are recorded in ppm from the solvent resonance. Mass 
spectra were obtained on a high resonance Electrospray Time-of-Flight mass 
spectrometer. Enantiomeric excess was measured by chiral SFC. 
 
General Procedure A (Acyl Azide Formation and Curtius Rearrangements in 
MeOH):  To a flask under nitrogen atmosphere containing acetic acid (1.0 mmol) was 
added CH2Cl2 (5 mL, 0.2 M). The resulting solution was cooled to 0 °C and oxalyl 




solution was allowed to warm to rt and maintained until gas evolution ceased (~1 h). The 
solution was concentrated in vacuo and the resulting residue was taken up in acetone (5 
mL, 0.2 M) and transferred dropwise to a vigorously stirring aqueous solution (0.4 M) of 
sodium azide (130 mg, 2.0 mmol) at 0 °C. The resulting solution was maintained at 0 °C 
for 15 minutes at which time it was partitioned betw en EtOAc (10 mL) and H2O (5 mL). 
CAUTION: the aqueous layer may contain hydrazoic acid (HN3) as a byproduct.
15 The 
layers were separated and the aqueous layer was extract d with EtOAc (2 x 5 mL) and 
the combined organic layers were washed with H2O (10 mL), brine (5 mL), then dried 
(Na2SO4) and concentrated in vacuo to provide acyl azide, which could be stored at rt for 
several hours, or at -20 ˚C for several days without decomposition or rearrangement. 
Although acyl azides are a widely used intermediate n organic synthesis, the authors 
caution that low molecular weight acyl azides can be potentially explosive if evaporated 
to dryness.16 On larger scale, the authors recommend partial concentration of the acyl 
azide intermediate, followed by introduction of MeOH. The acyl azide residue was 
transferred to a vial using MeOH (5 mL, including rinses). The solution was maintained 
at 25 °C for 18 h, at which time it was concentrated  in vacuo. The residue was purified 
by silica gel chromatography using a gradient of 2–80% EtOAc in hexanes to yield the 
desired product. 
General Procedure B (Curtius rearrangement for alternative carbamates): 
To a flask charged with acyl azide (1.0 equiv., prepa d from acetic acid) was added 
CHCl3 (5 mL, anhydrous, stabilized with amylenes) followed by alcohol (5.0 equiv.). 
(Note that the majority of commercially purchased chloroform is stabilized with added 




the isocyanate intermediate. It is recommended to use anhydrous chloroform stabilized 
with amylenes to avoid this complication.) The resulting solution was maintained at rt for 
24 h, at which time it was concentrated  in vacuo. The residue was purified by silica gel 
chromatography using a gradient of 2% EtOAc in hexan s –100% EtOAc to yield the 
desired product. 
methyl 4-methoxybenzylcarbamate (18a). Prepared according to 
General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.68 (s, 3 H) 3.78 (s, 3 H) 4.28 
(d, J=5.77 Hz, 2 H) 5.11 (br. s., 1 H) 6.81 - 6.91 (m, 2 H) 7.20 (d, J=8.51 Hz, 2 H); 13C 
NMR (100 MHz, CDCl3) δ ppm 44.48, 52.02, 55.17, 76.68, 77.00, 77.31, 113.92, 128.75, 
130.61, 156.95, 158.90; IR (film) 3317, 2950, 1689, 1161 cm-1; HRMS (ESI) calcd for 
C10H13NO3 (M + Na) m/z 218.07876; found 218.07652. 
methyl 4-chlorobenzylcarbamate (18b). Prepared according to 
General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.70 (s, 3 H), 4.33 (d, J=6.06 
Hz, 2 H), 5.21 (br. s., 1 H), 7.18 -7.26 (m, 2 H), 7.27 - 7.34 (m, 2 H); 13C NMR (100 
MHz, CDCl3) δ ppm 44.3, 52.2, 128.7, 128.7, 133.1, 137.1, 157.0; IR (film) 3308, 2948, 
1686, 1538 cm-1; HRMS (ESI) calcd for C9H10Cl NO2 (M + Na) m/z 222.02923; found 
222.02905. 
methyl 2-chlorobenzylcarbamate (18c). Prepared according to 
General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.69 (s, 3 H), 4.46 (d, J=6.26 




MHz, CDCl3) δ ppm 42.9, 52.2, 126.9, 128.8, 129.4, 129.7, 133.4, 135.9, 156.9; IR (film) 
3297, 3061, 2957, 1687, 1542 cm-1; HRMS (ESI) calcd for C9H10ClNO2 (M + H) m/z 
200.04728; found 200.04718. 
methyl 2-methoxybenzylcarbamate (18d). Prepared according to 
General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.67 (s, 3 H), 3.85 (s, 3 H), 
4.37 (d, J=5.28 Hz, 2 H), 5.33 (br.s., 1 H), 6.88 (d, J=8.12 Hz, 1 H), 6.93 (td, J=7.43, 
0.98 Hz, 1 H), 7.24 - 7.32 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ ppm 40.8, 51.8, 55.1, 
76.7, 77.0, 77.3, 110.1, 120.4, 126.6, 128.6, 129.2, 156.9, 157.3; IR (film) 3331, 3006, 
1701, 1603. 
methyl naphthalen-2-ylmethylcarbamate (18e). Prepared 
according to General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.73 (s, 3 H), 4.51 
(d, J=5.18 Hz, 2 H), 5.27 (br. s., 1 H), 7.40 (d, J=8.02 Hz, 1 H), 7.44 - 7.53 (m, 2 H), 7.71 
(s, 1 H), 7.78 - 7.86 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ ppm 45.1; 52.2, 125.5, 
125.8, 125.9, 126.1, 127.57, 127.64, 128.4, 132.7, 133.2, 135.9, 157.1;  IR (film) 3325, 
3005, 1690, 1534 cm-1; HRMS (ESI) calcd for C13H13NO2 (M + H) m/z 216.10191; found 
216.10193. 
 (S)-methyl 1-(4-chlorophenyl)-2-methylpropylcarbamate (18f). 
Prepared according to General Procedure A. [α]25D –64.9 (c 1.05, CHCl3); 
1H NMR (400 
MHz, CDCl3) δ ppm 0.85 (d, J=6.75 Hz, 3 H), 0.96 (d, J=6.65 Hz, 3 H), 1.90 - 2.05 (m, 1 




(m, 2 H); 13C NMR (100 MHz, CDCl3) δ ppm 19.6, 33.4, 52.1, 60.6, 128.1, 128.5, 132.7, 
140.5, 156.5; IR (film) 3329, 2963, 1690, 1534 cm-1; HRMS (ESI) calcd for 
C12H16ClNO2 (M + Na) m/z 264.07618; found 264.07586. 
 (S)-methyl 1-phenylethylcarbamate (18g). Prepared according to 
General Procedure A. [α]25D –76.8 (c 1.77, CHCl3); 
1H NMR (400 MHz, CDCl3) δ ppm 
1.49 (d, J=6.94 Hz, 3 H), 3.67 (s, 3 H), 4.88 (br. s., 1 H), 5.26 (br. s., 1 H), 7.24 - 7.30 
(m, 1 H), 7.30 - 7.39 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ ppm 22.3, 50.5, 51.9, 
125.8, 127.1, 128.4, 143.6, 156.1; IR (film) 3323, 972, 1686, 1529 cm-1; HRMS (ESI) 
calcd for C10H13NO2 (M + Na) m/z 202.08385; found 202.08390. 
methyl furan-2-ylmethylcarbamate (18h). Prepared according to 
General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.67 (s, 3 H), 4.34 (d, J=5.48 
Hz, 2 H), 5.17 (br. s., 1 H), 6.21 (d, J=2.45 Hz, 1 H), 6.30 (dd, J=3.13, 1.86 Hz, 1 H), 
7.33 (dd, J=1.76, 0.78 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ ppm 37.9, 52.1, 106.9, 
110.2, 142.0, 151.6, 156.8; IR (film) 3324, 3006, 1700, 1522 cm-1; HRMS (ESI) calcd for 
C7H9NO3 (M + Na) m/z 178.04746; found 178.04718. 
methyl benzofuran-3-ylmethylcarbamate (18i). Prepared 
according to General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.71 (s, 3 H), 4.48 
(d, J=5.58 Hz, 2 H), 5.19 (br. s., 1 H), 7.24 -7.29 (m, 1 H), 7.33 (td, J=7.70, 1.32 Hz, 1 
H), 7.47 - 7.52 (m, 1 H), 7.57 (s, 1 H), 7.63 (d, J=7.34 Hz, 1 H); 13C NMR (100 MHz, 




156.95; IR (film) 3332, 3006, 1683, 1534 cm-1; HRMS (ESI) calcd for C11H11NO3 (M + 
Na) m/z 228.06311; found 228.06298. 
methyl (5-chlorofuro[3,2-b]pyridin-3-yl)methylcarba mate 
(18j). Prepared according to General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 
3.64 (s, 3 H), 4.47 (dd, J=6.16, 0.88 Hz, 2 H), 5.72 (br. s., 1 H), 7.20 (d, J=8.51 Hz, 1 H), 
7.67 (d, J=8.61 Hz, 1 H), 7.88 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ ppm 33.6, 52.1, 
118.4, 119.4, 121.0, 146.3, 146.7, 147.0, 147.8, 157.0; IR (film) 3256, 3126, 3083, 2957, 
1703, 1614 cm-1; HRMS (ESI) calcd for C10H9ClN2O3 (M + H) m/z 241.03745; found 
241.03761. 
methyl 2-phenylpropan-2-ylcarbamate (18k). Prepared according to 
General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 1.58 (s, 6 H), 3.50 (s, 3 H), 
5.08 (br. s., 1 H), 7.11 - 7.17 (m, 1H), 7.20 - 7.27 (m, 2 H), 7.29 - 7.35 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ ppm 29.3, 51.5, 55.1, 124.7, 126.6, 128.3, 146.98, 155.06; IR 
(film) 3335, 2977, 1697, 1525 cm-1; HRMS (ESI) calcd for C11H15NO2 (M + Na) m/z 
216.09950; found 216.09955. 
methyl 4-bromo-2-chlorophenylcarbamate (18l). Prepared 
according to General Procedure A. 1H NMR (400 MHz, CDCl3) δ ppm 3.81 (s, 3 H), 7.10 
(br. s., 1 H), 7.38 (dd, J=8.90, 2.25 Hz, 1 H), 7.50 (d, J=2.25 Hz, 1 H), 8.07 (d, J=8.90 




134.0, 153.4; IR (film) 3299, 1698, 1518, 1248, 1075, 1049; HRMS (ESI) calcd for 
C8H7BrClNO2 (M + Na) m/z 285.92409; found 285.92363. 
 (2-(trimethylsilyl)ethoxy)methyl 4-methoxybenzylcarbamate 
(18o). Prepared according to General Procedure B. 1H NMR (400 MHz, CDCl3) δ ppm 
0.04 (s, 9 H), 0.94 - 1.03 (m, 2 H), 3.79 (s, 3 H), 4.13 - 4.23 (m, 2 H), 4.28 (d, J=5.77 Hz, 
2 H), 5.00 (br. s., 1 H), 6.83 - 6.88 (m, 2 H), 7.21 (d, J=8.51 Hz, 2 H); 13C NMR (100 
MHz, CDCl3) δ ppm –1.5, 17.7, 44.4, 55.2, 63.0, 113.9, 128.8, 130.8, 156.7, 158.9; IR 
(film) 3328, 2952, 2897, 1691, 1511 cm-1; HRMS (ESI) calcd for C14H23NO3Si (M + Na) 
m/z 304.13394; found 304.13188. 
benzyl 4-methoxybenzylcarbamate (18p). Prepared according to 
General Procedure B. 1H NMR (400 MHz, CDCl3) δ ppm 3.80 (s, 3 H), 4.32 (d, J=5.87 
Hz, 2 H), 5.08 - 5.24 (m, 3 H), 6.83 - 6.91 (m, 2 H), 7.22 (d, J=8.12 Hz, 2 H), 7.30 - 7.43 
(m, 5 H); 13C NMR (100 MHz, CDCl3) δ ppm 44.5, 55.2, 66.7, 114.0, 128.0, 128.4, 
128.8, 130.5, 136.5, 156.3, 158.9; IR (film) 3310, 3 34, 2941, 1684, 1546 cm-1; HRMS 
(ESI) calcd for C16H17NO3 (M + Na) m/z 294.11006; found 294.10999. 
allyl 4-methoxybenzylcarbamate (18q).17   Prepared 
according to General Procedure B. 1H NMR (400 MHz, CDCl3) δ ppm 3.81 (s, 3 H), 4.32 
(d, J=5.97 Hz, 2 H), 4.60 (d, J=5.38 Hz, 2H), 4.97 (br. s., 1 H), 5.22 (dq, J=10.47, 1.34 




7.22 (d, J=8.41 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ ppm 44.6, 55.3, 65.6, 114.1, 
117.6, 128.9, 130.5, 132.9, 156.2, 159.0; IR (film) 3305, 3017, 2955, 1684, 1649 cm-1. 
 (2-(trimethylsilyl)ethoxy)methyl (6-methoxybenzofuran-3-
yl)methylcarbamate (18r). Prepared according to General Procedure B. 1H NMR (400 
MHz, CDCl3) δ ppm 0.05 (s, 9 H), 0.90 - 1.07 (m, 2 H), 3.85 (s, 3 H), 4.12 - 4.28 (m, 2 
H), 4.44 (d, J=5.67 Hz, 2 H), 4.90 (br. s., 1 H), 6.89 (dd, J=8.51, 2.25 Hz, 1 H), 7.00 (d, 
J=2.15 Hz, 1 H), 7.43 -7.52 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ ppm –1.5, 17.7, 
35.0, 55.7, 63.3, 96.1, 111.8, 118.0, 119.9, 120.0, 141.4, 156.6, 156.7, 158.3; IR (film) 
3330, 3005, 1691, 1518 cm-1; HRMS (ESI) calcd for C16H23NO4Si (M + Na) m/z 
344.12886; found 344.12902. 
 (2-(trimethylsilyl)ethoxy)methyl benzo[d]isoxazol-3-
ylmethylcarbamate (18s). Prepared according to General Procedure B. 1H NMR (400 
MHz, CDCl3) δ ppm  0.00 (s, 9 H), 0.82 - 1.09 (m, 2 H), 4.11 - 4.27 (m, 2 H), 4.74 (d, 
J=6.16 Hz, 2 H), 5.49 (br. s., 1 H), 7.21 - 7.34 (m,1 H), 7.45 - 7.58 (m, 2 H), 7.78 (d, 
J=7.82 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ ppm –1.6, 17.6, 36.0, 63.6, 109.7, 
120.2, 121.8, 123.5, 130.0, 156.1, 156.7, 163.3; IR (film) 3326, 2953, 3895, 1692, 1529 
cm-1; HRMS (ESI) calcd for C14H20N2O3Si (M + H) m/z 293.13160; found 293.13193. 
 (2-(trimethylsilyl)ethoxy)methyl thiophen-3-ylmethylcarbamate 




0.04 (s, 9 H), 0.92 - 1.03 (m, 2 H), 4.12 - 4.23 (m, 2 H), 4.34 (d, J=5.87 Hz, 2 H), 5.13 
(br. s., 1 H), 7.01 (d, J=4.70 Hz, 1 H), 7.12 (d, J=1.76 Hz, 1 H), 7.26 (dd, J=4.99, 2.93 
Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ ppm –1.6, 17.7, 40.1, 63.0, 121.7, 126.1, 127.0, 
139.6, 156.6; IR (film) 3329, 2952, 2896, 1691, 1517 cm-1; HRMS (ESI) calcd for 
C11H19NO2SSi (M + Na) m/z 280.07980; found 280.08012. 
 (S)-(2-(trimethylsilyl)ethoxy)methyl 1-phenylethylcarbamate 
(18u).18 Prepared according to General Procedure B. [α]25D –57.1 (c 1.56, CHCl3); 
1H 
NMR (400 MHz, CDCl3) δ ppm 0.00 (s, 9 H), 0.88 - 1.03 (m, 2 H), 1.45 (d, J=6.85 Hz, 3 
H), 4.01 - 4.23 (m, 2 H), 4.81 (br. s., 1 H), 4.88 - 5.01 (m, 1 H), 7.14 - 7.41 (m, 5 H); 13C 
NMR (100 MHz, CDCl3) δ ppm –1.50, 17.74, 22.48, 50.52, 63.00, 125.90, 127.22, 
128.57, 143.72, 155.93; HRMS (ESI) calcd for C14H23NO2Si (M + Na) m/z 288.13903; 
found 288.13928. 
3-(carboxymethyl)-5-chlorofuro[3,2-b]pyridin-4-ium (11j). To a 
flask charged with MeOH (23 mL), water (7. mL), and NaOH (0.300 g, 7.5 mmol) was 
added methyl 2-(5-chlorofuro[3,2-b]pyridin-3-yl)acetate19 (0.677 g, 3.0 mmol) as a solid 
in a single portion. The solution was maintained at rt for 18 h, at which time it was 
acidified (pH = 3.0) with conc. HCl. The resulting mixture was extracted with CH2Cl2 (3 
x 10 mL). The combined organic layers were dried (Na2SO4) and concentrated in vacuo 
to provide 3-(carboxymethyl)-5-chlorofuro[3,2-b]pyridin-4-ium (0.648 g, 87% yield) as a 




J=8.61 Hz, 1 H), 8.11 (d, J=8.61 Hz,1 H), 8.29 (s, 1 H), 12.51 (s, 1 H); 13C NMR (100 
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Exploration of Bisisoxazolidines as Small Molecule Transcriptional Activation 
Domains 
5.1 Introduction 
Transcription is the process by which cells create n RNA sequence that is 
complementary to a DNA template.1 Regulation of transcription plays a critical role in 
controlling the levels of gene expression in a celland thus controlling cellular function 
and morphology. Transcription factor (TF) proteins serve to facilitate the activation or 
repression of transcription at specific genes.1 Activator TFs up-regulate gene expression 
by binding to specific sites on DNA, recruiting chromatin remodeling enzymes that 
modify DNA-histone complexes, and initiating transcription by assembling the RNA 
polymerase II holoenzyme (Figure 1).2 
Figure 5-1: Activator TFs bind to DNA (black line) and recruit chromatin 
remodeling enzymes that help unwrap the DNA and allow initiation of transcription 






The misregulation of transcription is associated with many human diseases. For 
example, over 50% of all human cancers are found to have alterations in the function of 
the TF p53.3 Similarly, NF-ĸB is found to be constitutively active and misregulated in 
inflammatory disorders and most cancers.4 The development of artificial molecules 
capable of predictably manipulating the levels of transcription has good potential for 
disease therapy or for mechanistic investigations, a d important progress has been made 
in both areas.5 
Early experiments on TFs revealed that natural TFs are modular proteins minimally 
containing a DNA-binding domain (DBD) and a regulatory domain (RD), and each 
domain functions independently of the other one.6 The DBD selectively targets specific 
DNA sequences for a given gene, localizing the RD near the gene to be regulated. The 
RD is either a transcriptional activation domain (TAD) that binds to and recruits 
components of the transcriptional machinery for activ tion, or it is a transcriptional 
repression domain that recruits components of the repression machinery.1 Domain 
swapping experiments show that TF activity is maintained when the TAD of one TF is 
linked to the DBD of a different TF.7 This result indicates that TADs and DBDs can be 
investigated independently.  Excellent advances have been made in the development of 
artificial DBDs, including good sequence selectivity with polyamides, triplex-forming 
oligonucleotides, peptide nucleic acids, and designer proteins.8 Progress in the 
development of artificial TADs has seen slower progress. 
The development of artificial TADs has been challenging due to the limited amount 
of information known about natural RDs.6,9 The largest class of natural activator RDs is 




short repeats (Figure 2).10 These natural activator RDs associate with multiple binding 
partners while facilitating the assembly of the transcriptional machinery. RD binding 
partners include components of the chromatin remodeling machinery, the proteasome, 
and the Mediator complex.11 
Figure 5-2: Natural activation domains contain repeats of polar and hydrophobic 
residues 
 
At least two different methods can be used to functio ally evaluate small molecule 
artificial TADs. Artificial TADs can be linked to a functional DBD and evaluated by 
their ability to upregulate transcription and imitate natural TFs. Alternatively, natural and 
artificial TADs can be used to squelch activation levels by binding to transcriptional 
machinery and inhibiting the activity of activator TFs. 
Previous work in the Mapp lab and the Uesugi lab has shown that small molecules are 
capable of functionally replacing TADs in artificial TFs for activation (Figure 5-3).12  
Isoxazolidine (4) was the first reported example of a small molecul TAD. In particular, a 
variety of isoxazolidines are capable of acting as TADs.  While isoxazolidines 
functionalized with only polar or only hydrophobic groups show poor activation, 
compounds containing a combination of hydrophobic and polar groups show robust 
activation (Figure 5-3).12a Functional group position and ring stereochemistry did not 
strongly influence activation efficiency.12b The only other small molecule TAD known at 
the initiation of this research was wrenchnolol (5), reported by the Uesugi lab (Figure 
5-3).13 Wrenchnolol binds selectively to a subunit of the mediator complex, Sur-2 




Uesugi group demonstrated an entirely artificial TF based on 5 and a polyamide DBD, 
transcription levels only 3.5 times basal expression were attained. 
Figure 5-3: Isoxazolidines functionalized with mostly polar or hydrophobic 
functional groups are poor TADs.  Amphipathic isoxazolidines robustly activate 
transcription  
 
Development of an artificial TAD with potential for potent activity as part of an 
artificial TF or for squelching experiments remains a challenge limiting the potential 
utility of artificial TADs. A review of TAD potencies revealed that activation levels can 
be increased synergistically when a single TAD is repeatedly displayed as part of a TF.14 
The greater than additive improvement in activity demonstrated with natural TADs led 
the Mapp lab to hypothesize that bisisoxazolidine TADs would show improved potency. 
An array of bisisoxazolidines were targeted to probe this hypothesis. Since amphipathic 
mono-isoxazolidines showed much stronger activity than isoxazolidines functionalized 
with mainly hydrophobic or mainly polar substituents, compounds containing a mix of 




would evaluate TADs by their ability to functionally upregulate transcription in cells as 
part of an artificial TF. 
Figure 5-4: Compounds targeted for evaluation as TADs.  Compounds containing 













































































5.2 Synthesis of Bisisoxazolidines for Synergystic TAD Activity 
The synthetic strategy for preparation of bisisoxazlidines utilizes an iterative 
approach to construct the ring system (Figure 5-5).  Isoxazolidines can be synthesized 
from a diastereoselective 1,3-dipolar cycloaddition of an oxime and allylic alcohol to 
build the heterocyclic scaffold.5,6,19  Diastereoselective nucleophilic addition 
functionalizes C3, and alkylation of N2 introduces another substituent.  Deprotection and 
oxidation of the alcohol side chain allows formation f another oxime, and the process is 





Figure 5-5:  Synthetic Strategy for Bisisoxazolidine Synthesis 
 
In the forward direction, the commercially available chiral epoxide (R)-glycidol 
can be protected and ring opened to form a chiral ally ic alcohol (14, Figure 5-6). 
Similarly, commercially available 3-methyl-butanal is efficiently converted to an oxime 
(15). Activation of 15 with tert-butyl hypochlorite forms a nitrile oxide that subsequently 
undergoes diastereoselective [3+2] cycloaddition with the allylic alcohol to form 
isoxazoline 16. Protection of the free secondary alcohol followed by lewis-acid assisted 
grignard addition into C=N forms isoxazolidine 17 in excellent yield and good 
diastereoselectivity. Further functionalization of the isoxazolidine is accomplished by N-
alkylation under microwave conditions with p-methoxybenzyl bromide to generate 18. 
The allyl side chain is converted to an alcohol through the three step sequence of 
dihydroxylation with OsO4, oxidative cleavage with NaIO4 to form an aldehyde, and then 
reduction with sodium borohydride. Protection of the newly formed alcohol as a methoxy 
methyl ether, then silyl deprotection of the C5 diol forms isoxazolidine 21. Oxidative 
cleavage with NaIO4 and condensation with hydroxylamine leads to isoxaz lidine 22, 





































































































Formation of the second bisisoxazolidine ring is accomplished via a second [3+2] 
cycloaddition of the nitrile oxide of 22 with allyl alcohol (Figure 5-7). While previous 
efforts in the Mapp lab to establish diastereoselectiv  conditions for the second 
cycloaddition were unsuccessful, both isoxazolidine-isoxazoline diastereomers were 
desired in order to evaluate the influence of stereoch mistry on bisisoxazolidine TAD 
efficiency. While the initial mixture of syn and anti-adduct diastereomers were difficult 
to separate by chromatography on silica gel, silyl protection of the free alcohol led to 
easily separable diastereomeric products. Stereochemi al assignment of the 
diastereomeric products is assigned based on analogy t  the crystalographically 




yielded a single diastereomers and provided 25 after microwave assisted N-allylation. 
Conversely, syn-adduct 24 provided both diastereomers, 26 and 27, after N-allylation. 

















































































An initial series of bisisoxazolidines was prepared for functional evaluation as 
TADs by covalently attaching the compounds to oxidize  dexamethasone (OxDex) via a 
short linker fragment (Figure 5-8). Standard functional group conversion and amide-bond 
formation techniques can be used to prepare appropriate compounds for evaluation in 
HeLa cell based transcription assays.16 A similar series of compounds with variable 

































































Conditions: a) HCl (aq); b) PPh3, H2O, THF, 60 °C; c) ROH, HOBT HBTu, Et3N; d) 1,3-diaminopropane;



































 Another isoxazolidine-isoxazoline TAD was prepared to probe the influence of 
para-methoxy benzyl N-substitution on the first ring compared to N-benzyl substitution 
as utilized in 4 (Figure 5-10). Alternatively, a TAD was prepared from a racemic mixture 
of the original isoxazolidine minor diastereomers (43), while a TAD from a racemic 






















































































Figure 5-11: Synthesis of Isoxazolidine TADs with Variable Stereochemistry 
OH
N O
h, i, j, k
89%40 42










Conditions: a) Allyl-MgCl, BF3•Et2O, tol/THF -78 °C; b) MsCl, Et3N, CH2Cl2; c) NaN3, DMSO, 100 °C; d) BnBr, i-
Pr2NEt, DMF, microwave; e) OsO4, NMO THF, H2O, tBuOH; f) NaIO4, H2O, CH3CN; g) NaBH4, MeOH; h) PPh3,
H2O, THF, 60 °C; i) ROH, HOBT HBTu, Et3N; j) 1,3-diaminopropane; k) OxDex, HOBt, HBTu, Et3N, DMF.
Bn Bn






















































5.3 Functional Evaluation of TADs 
The TAD conjugates were assessed in a cell based transcriptional activation assay as 
a standard dual-reporter luciferase assay.17 To test small molecule TADs in cells, an 
appropriate DNA-targeting moiety was required. The assay was established based on a 
system developed by Kodadek and co-workers in which a fusion protein consisting of the 
Gal4 DNA binding domain and the minimal ligand binding domain of the glucocorticoid 
receptor is constitutively expressed in the cells.18 The small molecule TADs under 
examination are thus tagged with an oxidized form of dexamethasone (OxDex); upon 
binding of the TAD-OxDex conjugate, the complex localizes the small molecule to 
binding sites for Gal4 that control the activity of a reporter gene, firefly luciferase. A 
measurement of luciferase activity provides direct information regarding the ability of the 
small molecule to function as a TAD. Results from the luciferase assays in HeLa cell 
culture suggested that the targeted compounds were in ff ctive as TADs, producing very 
minimal increases in the transcriptional activity. 
In the course of testing new small molecules for function as TADs, it became 
necessary to prepare a new batch of our positive control 42. Two different diastereomers 
of the isoxazolidine TAD were prepared (Figure 5-11). Surprisingly, the new sample of 
42 that I prepared showed no significant activity in the cell based assay. I carefully 
prepared a total of four batches of 42, and each one showed no significant activity. 
Another member of the lab also prepared an inactive sample of 42 while conducting 
similar activation experiments. Alternatively, Dr. Ryan Casey, another graduate student 
at the time, later prepared an active batch of 42. An explanation for this inconsistent 




effective binding of various OxDex conjugates with solated Glucocorticoid Receptor 
(GR) in a collaboration with Professor Jorge Iniguez. These experiments will help probe 
an aspect of the transcriptional activation biological assay to help establish whether there 
are differences in binding between the active and inact ve samples. Differences in binding 
affinity to the GR could influence activity through a conformational difference in binding or 
through an affect on trafficking of the liganded complex to the nucleus. 
 Further experiments have been conducted to functionally evaluate the small 
library of isoxazolidine-isoxazoline and bisisoxazolidine TAD mimics that I have 
synthesized. The isoxazolidine-isoxazoline and bisisoxazolidine azide intermediates have 
been evaluated in some initial NMR based experiments aimed at evaluating binding to 
components of the transcriptional machinery. Similarly, these compounds have been 
tested as inhibitors of transcriptional activation in squelching experiments against a 
VP16-derived activator. While none of these moleculs have shown significant functional 
activity, the Mapp lab has many more targets against which to further evaluate these 
compounds as transcriptional inhibitors. 
5.4 Conclusion 
A small library of compounds has been synthesized in an effort to identify potent 
small molecule TADs. The compounds were designed in an effort to replicate the 
repetitive display of functionality that is known to generate a greater than additive 
improvement in potency from natural activators. 
 Initial functional evaluation of this library of compounds was conducted through a 




activity. The resynthesis of a positive control for the activation assay revealed 
inconsistent activity between different batches of c mpounds for the assay. Further 
experiments have been targeted to probe whether the differently activating samples show 
different binding affinities to a key protein involed in the biological assay. 
 The targeted small molecule TAD mimics have also been evaluated as inhibitors 
of transcriptional activation through squelching exp riments. While these compounds 
showed no activity against a VP16-derived activator, the Mapp lab is interested in testing 
their function against many other natural activators. 
5.5 Experimental Section 
General: Unless otherwise noted, starting materials were obtained from 
commercial suppliers and used without further purification. CH2Cl2, THF, CH3CN and 
toluene were dried by passage through activated alumina columns and degassed by 
stirring under a dry N2 atmosphere. NMP and DMF were used as purchased without 
further purification. BF3•OEt2 and Et3N were distilled from CaH2, MeOH was distilled 
from sodium metal, and t-BuOH was distilled from MgSO4. All reactions involving air- 
or moisture-sensitive reagents were performed under a dry N2 atmosphere.  Purification 
by column chromatography was carried out with E. Merck Silica Gel 60 (230-400 mesh). 
1H and 13C NMR spectra were recorded in CDCl3 at 500 MHz and 125 MHz, 
respectively, unless otherwise specified. Reverse-phase HPLC purification was 
performed on a Varian ProStar 210 equipped with Rainin Dynamax UVD II detector 
using a C18 (8 x 100 mm) Radial-PakTM cartridge using a gradient of 0.1% TFA in H2O 




determine the concentration of all methotrexate conjugates (3-7), the characteristic UV-
vis absorptions of methotrexate at λmax = 257, 302, and 370 nm with extinction 
coefficients of 23,000, 22,000, and 7,100 M-1cm-1, respectively, was used. Once the 
concentration was determined, the sample was aliquoted, lyophilized, and stored at –78 
°C.  The in vitro transcription assays were carried out as previously described.17 The 
buffer used for transcription assays contains 5 mM MgCl2, 400 mM of each NTP, 10 µg 
of salmon sperm carrier DNA, 10 mM HEPES (pH 7.9), 50 mM KCl, 0.1 mM EDTA, 
0.25 mM DTT, and 10% glycerol.  3-Methylbutyraldehyde oxime (15),19 (S)-1-(tert-
butyldimethylsilyloxy)but-3-en-2-ol (14),20 2-(tert-Butyl-dimethyl-silanyloxy)-(1R)-1-
[(5R)-3-isobutyl-4,5-dihydro-isoxazol-5-yl]-ethanol (16),12b and 4217 were prepared 
according to published procedures. Yields refer to is lated yields of compounds 
estimated to be ≥95% pure as determined by 1H NMR. 
 
Synthesis of Compounds 
 (R)-3-isobutyl-5-((R)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-
disiladecan-5-yl)-4,5-dihydroisoxazole (17). To a solution of 16 (1.0 equiv) in THF (0.2 
M) cooled in an ice-H2O bath was added DMAP (0.10 eq) and Et3N (2.2 equiv).  
TBSOTf (2.2 equiv) was then added dropwise and the solution slowly warmed to ambient 
temperature.  The reaction was complete in 2 h as indicated by TLC analysis.  The 
mixture was again cooled in an ice-H2O bath, diluted with sat. NH4Cl (15 mL), and 
extracted with Et2O (3 x 15 mL).  The combined organic extracts were washed with brine 




yielded the title compound 17 (10.58 g, 92%) as a yellow oil after purification by 
chromatography with 5% EtOAc/hexanes as the eluant. 1H NMR (400 MHz, CDCl3) δ 
4.63-4.56 (m, 1 H), 3.71-3.64 (m, 2 H), 3.61-3.54 (m, 1 H), 2.90-2.84 (m, 2 H), 2.25-2.12 
(m, 2 H), 1.95-1.83 (m, 1 H), 0.97-0.93 (m, 6 H), 0.88 (s, 9 H), 0.87 (s, 9 H), 0.09 (s, 3 
H), 0.08 (s, 3 H), 0.06-0.04 (m, 6 H).  13C NMR (100 MHz, CDCl3) δ 157.9, 80.3, 74.1, 
64.4, 38.6, 36.7, 26.0, 25.9, 25.8, 22.6, 22.4, 18.3, 18.1, -4.4, -4.8, -5.5, -5.5. 
 (3S,5R)-3-allyl-3-isobutyl-5-((R)-2,2,3,3,8,8,9,9-octamethyl-4,7-
dioxa-3,8-disiladecan-5-yl)isoxazolidine (18). To a solution of isoxazoline 17 (1.0 eq) in 
toluene (0.1 M) cooled in a dry ice-acetone bath was added distilled BF3•OEt2 (3.0 eq) 
and the resultant mixture was stirred with continued cooling for 30 min.  Allylmagnesium 
chloride (2.0 M solution in THF, 6.0 eq) was added ropwise over 10 min.  The reaction 
mixture was allowed to stir with continued cooling until the reaction was complete by 
TLC analysis (6 h).  H2O (10 mL) was added and the mixture stirred for 20 min.  H2O (20 
mL) was added and the aqueous and organic layers were separated.  The aqueous layer 
was extracted with EtOAc (3 x 20 mL) and the combined organic extracts were washed 
with H2O (1 x 20 mL) and brine (1 x 20 mL), dried over MgSO4, filtered and 
concentrated in vacuo.  A diastereomeric ratio of 10:1 was determined by crude 1H NMR.   
This procedure yielded the title compound 18 (2.03 g, 79%) as a yellow oil after 
purification by chromatography with 5% EtOAc/hexanes as the eluant. 1H NMR (500 
MHz, CDCl3) δ 5.94−5.83 (m, 1 H), 5.11 (d, 6 Hz, 1 H), 5.09 (s, 1 H), 4.30 (t, 7 Hz, 1 H), 




J = 8.5, 12.5 Hz, 1 H), 1.89−1.81 (m, 2H), 1.48 (dd, J = 6.5, 14 Hz, 1 H), 1.39 (dd, J = 
6.5, 14 Hz, 1 H), 0.94 (d, J = 6.5 Hz, 6 H), 0.91 (s, 9 H), 0.89 (s, 9 H), 0.11 (s, 6 H), 
0.07−0.06 (m, 6 H). 
  
(3S,5R)-3-allyl-3-isobutyl-2-(4-methoxybenzyl)-5-((R)-
2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoxazolidine (19). To a 
solution of isoxazolidine 11 (210 mg, 0.61 mmol, 1.0 eq) in DMF (3.0 mL) was added 
iPr2NEt (0.31 mL, 1.8 mmol, 3.0 eq) and BnBr (0.48 mL, 3.7 mmol, 6.0 eq).  The 
reaction mixture was irradiated in a 1000 W microwave (6 x 20 s) @ 20% power with 
mixing between each interval.  Upon cooling to ambient temperature the solution was 
diluted with H2O (3 mL) and extracted with Et2O (3 x 5 mL).  The combined organic 
extracts were washed with H2O (1 x 5 mL) and brine (1 x 5 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo.  This procedur yielded the title compound 19 (14.72 
g, 93%) as a yellow oil after purification by chromatography with 5% EtOAc/hexanes as 
the eluant. 1H NMR (500 MHz, CDCl3) δ 7.34 (d, J = 8.5 Hz, 2 H), 6.87-6.84 (m, 2 H), 
6.02-5.92 (m, 1 H), 5.15-5.12 (m, 1 H), 5.11 (s, 1 H), 4.09 (dt, J = 5.0, 8.5 Hz, 1 H), 3.86-
3.74 (m, 5 H), 3.71-3.63 (m, 2 H), 3.57 (dd, J = 6.0, 10 Hz, 1 H), 2.44-2.28 (m, 2 H), 
2.19-2.09 (m, 2 H), 1.97-1.87 (m, 1 H), 1.64 (dd, J = 5.0, 14.5 Hz, 1 H), 1.38 (dd, J = 6.5, 
14.5 Hz, 1 H), 1.02 (t, J = 6.5 Hz, 6 H), 0.91 (s, 18 H), 0.07 (s, 3 H), 0.42-0.29 (m, 6 H), -







To a solution of isoxazolidine 19 (14.39 g, 24.9 mmol, 1.0 equiv) in t-BuOH (125 mL), 
THF (33.5  mL), and H2O (8.3 mL) was added NMO (3.2 g, 27.4 mmol, 1.1 equiv) 
followed by OsO4 (5 ml of a 2.5 wt% solution in t-BuOH, 1.25 mmol, 0.05 equiv). The 
reaction mixture was stirred at ambient temperature until complete by TLC analysis (24 
h).  The mixture was cooled in an ice-H2O bath, Na2SO3 was added, and the mixture 
stirred 1 h.  The mixture was diluted with H2O (100 mL) and extracted with EtOAc (3 x 
100 mL).  The combined organic extracts were dried over Na2SO4, filtered and 
concentrated in vacuo.  The crude diol was taken up in 80 mL CH3CN and 80 mL H2O 
and cooled in an ice-H2O bath.  Sodium periodate (8.0 g, 37.3 mmol, 1.5 equiv) was 
added and the reaction mixture stirred at ambient tmperature until complete by TLC 
analysis (30 min).  The reaction mixture was diluted with H2O (100 mL) and extracted 
with Et2O (3 x 100 mL).  The combined organic extracts were washed with H2O (1 x 50 
mL) and brine (1 x 50 mL), dried over Na2SO4, filtered and concentrated in vacuo.  The 
crude aldehyde thus obtained was dissolved in 150 mL MeOH and cooled in an ice-H2O 
bath prior to addition of NaBH4 (1.41 g, 37.3 mmol, 1.5 equiv).  Upon completion as 
noted by TLC analysis (1h), H2O (50 mL) was added and the reaction extracted with




and concentrated in vacuo. This procedure yielded th  ti le compound 20 (12.83 g, 89%) 
as a yellow oil after purification by chromatography with 20% EtOAc/hexanes as the 
eluant. 1H NMR (500 MHz, CDCl3) δ 7.29-7.25 (m, 2 H), 6.84-6.80 (m, 2 H), 5.45 (bs, 1 
H), 4.30-4.24 (m, 1 H), 3.94-3.87 (m, 1 H), 3.86-3.75 (m, 6 H), 3.71-3.66 (m, 1 H), 3.62-
3.54 (m, 2 H), 2.27 (dd, J = 10, 12.5 Hz, 1 H), 2.08 (dd, J = 7.5, 12.5 Hz, 1 H), 2.05-1.97 
(m, 1 H), 1.93-1.87 (m, 1 H), 1.77-1.68 (m, 1 H), 1.68-1.60 (m, 1 H), 1.38 (dd, J = 8.0, 
13.5 Hz, 1 H), 1.02 (d, J = 6.5 Hz, 3 H), 0.99 (d, J = 6.5 Hz, 3 H), 0.95 (s, 9 H), 0.87 (s, 9 




yl)isoxazolidine (S1). A flame-dried flask  was  cooled under a stream of nitrogen  and  
charged with 20 (11.86 g, 20.4 mmol, 1.0 equiv) and CH2Cl2. The resulting solution was 
cooled in an ice-water bath and DIPEA (5.3 mL, 30.6 mmol, 1.5 equiv) was added, 
followed by MOMCl (2.24 mL, 29.5 mmol, 1.45 equiv) dropwise. The reaction was 
allowed to come to rt and stired overnight. TLC analysis (20% EtOAc/hexanes) shows 
some S1 remaining. The reaction was then cooled in an ice-water bath, and DIPEA (2.7 
mL, 0.75 equiv) was added, followed by MOMCl (1.2 mL, 0.7 equiv). The reaction was 
allowed to warm to rt and stirred 24 h. The reaction was diluted with H2O (100 mL), 




M HCl and brine, dried over Na2SO4, filtered, and concentrated in vacuo.  This procedur  
yielded the title compound S1 (10.0 g, 78%) as a yellow oil after purification by 
chromatography with 15% EtOAc/hexanes as the eluant. 1H NMR (500 MHz, CDCl3) δ 
7.31 (d, J = 9.0 Hz, 2 H), 6.84 (d, J = 9.0 Hz, 2 H), 4.64 (s, 2 H), 4.15-4.09 (m, 1 H),
3.82-3.77 (m, 4 H), 3.76-3.70 (m, 3 H), 3.68 (q, J = 5.5 Hz, 1 H), 3.62 (dd, J = 5.0, 10 
Hz, 1 H), 3.55 (dd, J = 6.0, 10 Hz, 1 H), 3.38 (s, 3 H), 2.24-2.10 (m, 2 H), 1.99-1.82 (m, 
3 H), 1.64 (dd, J = 5.0, 14 Hz, 1 H), 1.34 (dd, J = 7.0, 14 Hz, 1 H), 1.03 (d, J = 7.0 Hz, 3 
H), 1.00 (d, J = 7.0 Hz, 3 H), 0.90 (s, 9 H), 0.89 (s, 9 H), 0.08 (s, 3 H), 0.02 (m, 6 H), 
0.01 (s, 3 H). 
 
(R)-1-((3S,5R)-3-isobutyl-2-(4-methoxybenzyl)-3-(2-
(methoxymethoxy)ethyl)isoxazolidin-5-yl)ethane-1,2-diol (21). A flame-dried flask  was  
cooled under a stream of nitrogen  and  charged with S1 (1.0 g, 1.6 mmol, 1.0 equiv) and 
THF (10 mL). TBAF (3.5 mL, 1 M in THF, 3.5 mmol, 2.2 equiv) was added slowly, and 
the reaction was stirred until TLC (33% EtOAc/hexanes) indicates reaction completion (2 
h). The reaction was diluted with H2O (10 mL), and extracted with EtOAc (3 x 20 mL). 
The combined organic extracts were washed with H2O (1 x 5 mL) and brine (1 x 5 mL), 
dried over Na2SO4, filtered, and concentrated in vacuo.  This procedur  yielded the title 
compound 21 (0.51 g, 80%) as a clear colorless oil after purification by chromatography 




Hz, 2 H), 6.82 (d, J = 8.5 Hz, 2 H), 4.60 (s, 2 H), 4.02-3.95 (m, 1 H),3.80-3.72 (m, 5 H), 
3.71 (s, 1 H), 3.68-3.60 (m, 1 H), 3.55-3.45 (m, 2 H), 3.44-3.38 (m, 1 H), 3.34 (s, 3 H), 
3.23 (s, br, 1 H), 2.56 (s, br, 1 H), 2.33 (dd, J = 8.5, 12.4 Hz, 1 H), 2.18 (dd, J = 5.5, 12.4 
Hz, 1 H), 1.98-1.78 (m, 3 H), 1.58 (dd, J = 4.5, 14.5 Hz, 1 H), 1.37 (dd, J = 7.0, 14.5 Hz, 









(methoxymethoxy)ethyl)isoxazolidine-5-carbaldehyde oxime (22). A flame-dried flask  
was  cooled under a stream of nitrogen  and  charged with 21 (0.508 g, 1.28 mmol, 1.0 
equiv), CH3CN (5 mL), and H2O (5 mL). Sodium periodate (0.424 g, 2 mmol, 1.5 equiv) 
was added and the reaction was stirred until TLC show  reaction completion (1 h). The 
reaction was diluted with H2O (10 mL), extracted with Et2O (3 x 20 mL). The combined 
organic extracts were washed with brine, dried over Na2SO4, and concentrated in vacuo. 
The crude aldehydes intermediate was dissolved in MeOH (10 mL), and 
hydroxylamine•HCl (0.107 g, 1.5 mmol, 1.2 equiv) and potassium carbonate (0.213 g, 
1.5 mmol, 1.2 equiv) were added. The reaction was stirred for 2 h, then the reaction was 
diluted with H2O (10 mL), extracted with EtOAc (3 x 20 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  
This procedure yielded the title compound 22 (0.468 g, 96%) as a yellow oil after 




H), 4.65 (s, 2 H), 4.19 (dd, J = 5.5, 12 Hz, 1 H), 3.83-3.80 (m, 5 H), 3.80-3.65 (m, 3 H), 
3.39 (s, 3 H), 2.52 (dd, J = 12, 16 Hz, 1 H), 2.38 (dd, J = 5.5, 16 Hz, 1 H), 2.04-1.94 (m, 
1 H), 1.94-1.84 (m, 1 H), 1.84-1.74 (m, 1 H), 1.59 (dd, J = 6, 18 Hz, 1 H), 1.33 (dd, J = 




isobutylisoxazolidin-5-yl)-4,5-dihydroisoxazol-5-yl)methanol (S2) and ((S)-3-((3S,5R)-
3-(2-(methoxymethoxy)ethyl)-2-(4-methoxybenzyl)-3-isobutylisoxazolidin-5-yl)-4,5-
dihydroisoxazol-5-yl)methanol (S3). A flame-dried flask  was  cooled under a stream of 
nitrogen  and  charged with oxime (22, 468 mg, 1.23 mmol, 1.0 equiv) and toluene (10 
mL). The solution was cooled in an ice-water bath, then allyl alcohol (0.84 mL, 12.3 
mmol, 10 equiv) was added, followed by sodium hypochl rite (4.13 mL, 744 mM, 3.1 
mmol, 2.5 equiv) dropwise over 20 min. A white precipitate forms and the reaction is 
stirred for 1 h. The reaction was diluted with H2O (10 mL), extracted with Et2O (4 x 10 
mL). The combined organic extracts were washed withbrine, dried over Na2SO4, filtered, 
and concentrated in vacuo.  This procedure yielded th  title compounds S2 (0.145 g, 
27%) and S3 (0.129 g, 24%) as clear colorless oils after purification by chromatography 
with 50% EtOAc/hexanes as the eluant and HPLC gradiation separated the diastereomers. 




4.72 (dd, J = 6.5, 8.0 Hz, 1 H), 4.62 (s, 2 H), 4.61-4.53 (m, 1 H), 3.81-3.66 (m, 7 H), 3.61 
(d, br, J = 12 Hz, 1 H), 3.49 (dd, J = 5.0, 12 Hz, 1 H), 3.37 (s, 3 H), 2.82 (dd, J = 11, 17.5 
Hz, 1 H), 2.70 (dd, J = 7.5, 17.5 Hz, 1 H), 2.53 (dd, J = 8.5, 13 Hz, 1 H), 2.49-2.39 (m, 2 
H), 1.99-181 (m, 3 H), 1.61 (dd, J = 5.0, 14.5 Hz, 1 H), 1.36 (dd, J = 7.0, 14.5 Hz, 1 H), 
0.99 (t, J = 6.0 Hz, 6 H). 
S3: 1H NMR (500 MHz, CDCl3) δ 7.22 (d, J = 8.5 Hz, 2 H), 6.83 (d, J = 8.5 Hz, 2 H), 
4.70 (t, J = 7.5 Hz, 1 H), 4.64-4.57 (m, 3 H), 3.77 (s, 3 H),3.76 (s, br, 2 H), 3.74-3.68 (m, 
2 H), 3.59 (d, br, J = 11 Hz, 1 H), 3.45 (d, br, J = 11 Hz, 1 H), 3.37 (s, 3 H), 2.84 (dd, J = 
11, 17.5 Hz, 1 H), 2.65 (dd, J = 7.5, 17.5 Hz, 1 H), 2.52 (d, J = 7.5 Hz, 2 H), 2.39 (s, br, 1 
H), 1.98-1.89 (m, 2 H), 1.89-1.81 (m, 1 H), 1.63 (dd, J = 5.0, 14.5 Hz, 1 H), 1.37 (dd, J = 




yl)(tert-butyldimethylsilyloxy)methane (23). A flame-dried flask  was  cooled under a 
stream of nitrogen  and  charged with S2 (15 mg, 0.034 mmol, 1 equiv) and CH2Cl2 (0.2 
mL). The solution was cooled in an ice-water bath and DMAP (0.2 mg, 0.001 mmol, 0.04 
equiv) and Et3N (9.4 µL, 0.069 mmol, 2.0 equiv) were added, followed by TBSCl (9.8 
mg, 0.065 mmol, 1.9 equiv). A white precipitate forms, and the reaction is stirred until 
TLC indicates completion (2 h). The reaction is filtered, diluted with water, extracted 




over Na2SO4, filtered, and concentrated in vacuo.  This procedur  yielded the title 
compound 23 (0.014 g, 74%) as a clear colorless oil after purification by chromatography 
with 15% EtOAc/hexanes as the eluant. 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 8.5 
Hz, 2 H), 6.85 (d, J = 8.5 Hz, 2 H), 4.79 (t, J = 8.0 Hz, 1 H), 4.64 (s, 2 H), 4.59-4.52 (m, 
1 H), 3.84-3.70 (m, 7 H), 3.67 (dd, J = 5.0, 11.0 Hz, 1 H), 3.61 (dd, J = 5.0, 11.0 Hz, 1 
H), 3.39 (s, 3 H), 2.85 (d, J = 9.0 Hz, 1 H), 2.55 (dd, J = 9.0, 12.5 Hz, 1 H), 2.41 (dd, J = 
6.0, 13 Hz, 1 H), 2.01-183 (m, 3 H), 1.63 (dd, J = 5.0, 14.5 Hz, 1 H), 1.39 (dd, J = 7.0, 




yl)-methyl methanesulfonate (S4). A flame-dried flask  was  cooled under a stream of 
nitrogen  and  charged with S2 (17.6 mg, 0.040 mmol, 1.0 equiv) and dichloromethane 
(1.0 mL, 0.1 M). The solution is cooled in an ice-water bath and Et3N (16 µL, 0.117 
mmol, 1.1 equiv) is added. Methylsulfonyl chloride (9 µL, 0.117 mmol, 1.1 equiv) is 
added, and the reaction is stirred until ESI-MS indicates reaction completion (1 h). The 
reaction is diluted with sat. aq. NH4Cl (5 mL), extracted with CH2Cl2 (3 x 6 mL). The 
combined organic extracts were washed with aq. 1 M HCl, brine, dried over Na2SO4, 
filtered, and concentrated in vacuo.  This procedur yielded the title compound S4 (0.014 
g, 68%) as a yellow oil after workup. 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 8.5 Hz, 




(m, 7 H), 3.40 (s, 3 H), 3.32 (dd, J = 4.0, 13.0 Hz, 1 H), 3.24 (dd, J = 5.5, 13.0 Hz, 1 H), 
2.88 (dd, J = 11.0, 17.5 Hz, 1 H), 2.69 (dd, J = 6.5, 17.5 Hz, 1 H), 2.64-2.53 (m, 2 H), 
2.03-195 (m, 1 H), 1.95-1.86 (m, 2 H), 1.64 (dd, J = 5.0, 15.0 Hz, 1 H), 1.40 (dd, J = 7.0, 
14.5 Hz, 1 H), 1.02 (d, J = 6.5 Hz, 6 H). 
 
2-((3S,5R)-5-((R)-5-(azidomethyl)-4,5-dihydroisoxazol-3-yl)-
3-isobutyl-2-(4-methoxybenzyl)isoxazolidin-3-yl)ethanol (28). A flame-dried flask was 
cooled under a stream of nitrogen  and  charged with S4 (14.0 mg, 0.027 mmol, 1 equiv), 
sodium azide (17.7 mg, 0.27 mmol, 10 equiv), and DMSO (0.27 mL, 0.1 M). The 
reaction flask was attached to a reflux condenser and heated to 100 ̊C for 3 h. The 
reaction was diluted with sat. aq. ammonium chloride (5 mL) and extracted with EtOAc 
(4 x 5 mL). The combined organic extracts were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to yield a protected azide intermediate.  The crude 
clear colorless oil was dissolved in isopropanol (0.25 mL) and conc. aq HCl (0.05 mL) 
was added. The solution was stirred until ESI-MS indicates reaction completion (6 h). 
The reaction was diluted with sat. aq. ammonium chloride (5 mL), extracted with EtOAc 
(4 x 5 mL). The combined organic extracts were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. This procedure yielded compound 28 (0.0048 g, 
58%%) as a clear colorless oil after after purification by chromatography with 2% 
MeOH/CH2Cl2 as the eluant. 
1H NMR (500 MHz, CDCl3) δ 7.24 (d, J = 8.5 Hz, 2 H), 




Hz, 1 H), 3.93-3.86 (m, 1 H), 3.86-3.75 (m, 5 H), 3.40 (dd, J = 3.5, 13.0 Hz, 1 H), 3.30 
(dd, J = 5.0, 13.0 Hz, 1 H), 2.99-2.90 (m, 1 H), 2.82-2.68 (m, 2 H), 2.55 (dd, J = 8.5, 13.5 
Hz, 1 H), 2.06-1.94 (m, 1 H), 1.88-1.72 (m, 3 H), 1.46 (dd, J = 8.5, 13.5 Hz, 1 H), 1.02 






dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxamide (11). A flame-dried flask 
was cooled under a stream of nitrogen  and  charged with 28 (4.8 mg, 0.011 mmol, 1 
equiv), triphenyl phosphine (6.0 mg, 0.023 mmol, 2.0 equiv), and THF (0.2 mL). The 
reaction was heated under a reflux condenser to 85 ̊C for 2 h. The mixture was allowed to 
cool to rt and was then transferred into a biphasic m xture of 1 M HCl (10 mL) 
and ether (10 mL). The layers were partitioned and the organic layer was extracted with 
1 M HCl (2× 10 mL). The combined aqueous layers were basified with 3 M NaOH (until 
pH 10 or greater). The aqueous mixture was then extracted with CH2Cl2 (3× 15 mL) and 
the combined organic extracts were dried over Na2SO4, filtered, and concentrated in 
vacuo. To a solution of 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 




added HOBt (6.3 mg, 0.045 mmol, 3.0 equiv based) and HBTU (17 mg, 0.045 mmol, 
3.0 equiv). This solution was agitated for 15 min. The solution of activated ester was 
added to the crude amine dissolved in NMP (0.067 mL) and the resulting mixture was 
allowed to stir for 12 h at which time the reaction was complete as judged by ESI-MS 
analysis. Excess reagents were quenched by the addition of 1M HCl (10 mL) and EtOAc 
(10 mL). The reaction vessel was washed with EtOAc (2 x 2 mL) to remove all residues. 
The resulting biphasic mixture was separated and the aqueous layer was extracted with 
EtOAc (3 x 10 mL). The combined organic fractions were dried over Na2SO4, filtered, 
and concentrated in vacuo. The resulting oil was disolved in a solution of 
20% piperidine in DMF (0.037 mL, 0.076 mmol piperidine, 5.0 equiv) and was allowed 
to stir for 30 minutes. The resulting solution was diluted with aq 0.1% TFA (0.50 mL) 
and CH3CN (0.50 mL) and partially purified by reverse-phase HPLC to remove Fmoc 
byproducts. The partially purified amine was used immediately in subsequent steps. To a 
solution of OxDex21 (17 mg, 0.045 mmol, 3.0 equiv) dissolved in NMP (0.15 mL) were 
added HOBt (6.2 mg, 0.045 mmol, 3.0 equiv) and HBTU (17 mg, 0.045 mmol, 3.0 equiv) 
and the resulting mixture was agitated for 15 min. To this solution were added the amine 
dissolved in NMP (0.15 mL), 2,6-lutidine (35 µL, 0.30 mmol, 6.7 equiv), and DIPEA 
(49 µL, 0.30 mmol, 6.7 equiv). The resulting mixture was stirred for 12 h at rt. The 
product was isolated by reverse-phase HPLC purification to provide 11 as a white solid 
(2.7 mg, 26%). The purity of compound 11 was confirmed by analytical reverse-phase 
HPLC analysis. The identity was verified by mass spectral analysis of the isolated 
compound. LRMS (ESI) calcd for [C48H69FN4O11 + H]







(methoxymethoxy)ethyl)-3,5'-biisoxazolidine (S6). A solution of compound 23 (109 mg, 
0.198 mmol, 1.0 equiv) in toluene (2.8 mL) was cooled in a dry ice-acetone bath.  
BF3•OEt2 (75 µl, 0.59 mmol, 3.0 eq) was added dropwise over 15 min and the mixture 
was stirred with continued cooling for 30 min.  Benzylmagnesium chloride (0.5 mL of a 
2.0 M solution in THF, 1.0 mmol, 5.0 eq) was added ropwise over 30 min.  The reaction 
mixture was stirred for 4 h with continued cooling at which point TLC analysis indicated 
complete consumption of starting material.  Saturated aqueous NH4Cl (5 mL) was added 
to the reaction and the resultant solution was transferred to an ice-H2O bath.  After slowly 
warming to rt the mixture was diluted with H2O (5 mL) and Et2O (5 mL) and the organic 
and aqueous layers separated.  The aqueous layer was extr cted with Et2O (3 x 5 mL).  
The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  This procedure yielded the ti le compound S6 (0.094 g, 73%) as a 
clear colorless oil after purification by chromatography with 15% EtOAc/hexanes as the 
eluant. 1H NMR (500 MHz, CDCl3) δ 7.32-7.21 (m, 5 H), 7.19-7.14 (m, 2 H), 6.89-6.84 
(m, 2 H), 6.02 (s, br, 1 H), 4.65 (s, 2 H), 4.10 (s, br, 1 H), 4.06-3.98 (m, 1 H), 3.82-3.72 
(m, 5 H), 3.70-3.62 (m, 2 H), 3.39 (s, 3 H), 3.30-3. 0 (m, 2 H), 2.85 (s, 2 H), 2.48-2.38 




4 H), 1.67 (s, br, 1 H), 1.58 (dd, J = 5.0, 14.5 Hz, 1 H), 1.44-1.38 (m, 1 H), 1.01 (d, J = 















(methoxymethoxy)ethyl)-3,5'-biisoxazolidine (25). A flame-dried flask was cooled under 
a stream of nitrogen  and  charged with S6 (94 mg, 0.145 mmol, 1 equiv), allyl bromide 
(126 µL, 1.46 mmol, 10 equiv), DIPEA (76 µL, 0.439 mmol, 3 equiv), and DMF (0.4 
mL). The solution was irradiated in a 1000 W microwave at 10% power (10 x 10 s) with 
cooling and stirring between each interval until TLC shows reaction completion. Upon 
cooling to rt, the mixture was diluted with H2O (5 ml) and extracted with Et2O (3 x 5 ml).  
The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  This procedure yielded the ti le compound 25 (0.093 g, 94%) as a 
clear colorless oil after purification by chromatography with 7% EtOAc/hexanes as the 
eluant. 1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 9.0 Hz, 2 H), 7.24-7.15 (m, 5 H), 6.86 
(d, J = 9.0 Hz, 2 H), 5.95-5.85 (m, 1 H), 5.16-5.10 (m, 1 H), 5.09-5.03 (m, 1 H), 4.66 (s, 
2 H), 4.31-4.24 (m, 1 H), 3.83-3.70 (m, 8 H), 3.62-3.50 (m, 3 H), 3.40 (s, 3 H), 3.39-3.33 
(m, 1 H), 3.22 (dd, J = 6.5, 15.5 Hz, 1 H), 2.88 (d, J = 14.0 Hz, 1 H), 2.80 (d, J =14.0 Hz, 




2.05-1.87 (m, 5 H), 1.78-1.71 (m, 1 H), 1.67-1.56 (m, 2 H), 1.51-1.44 (m, 1 H), 1.06 (d, J 




The reaction of 25 was conducted using a procedure analogous to that described above 
for the preparation of 21. This procedure yielded the title compound S7 (0.061 g, 78%) as 
a clear colorless oil after purification by chromatography with 33% EtOAc/hexanes as the 
eluant. 1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 9.0 Hz, 2 H), 7.25-7.17 (m, 5 H), 6.86 
(d, J = 9.0 Hz, 2 H), 5.96-5.86 (m, 1 H), 5.19-5.13 (m, 1 H), 5.12-5.07 (m, 1 H), 4.66 (s, 
2 H), 4.24 (t, J = 8.0 Hz, 1 H), 3.83-3.78 (m, 4 H), 3.78-3.70 (m, 4 H), 3.69-3.64 (m, 1 
H), 3.64-3.58 (m, 1 H), 3.48-3.39 (m, 5 H), 3.29 (dd, J = 6.0, 15.5 Hz, 1 H), 2.90 (d, J = 
14.5 Hz, 1 H), 2.82 (d, J =14.5 Hz, 1 H), 2.30 (dd, J = 8.0, 12.5 Hz, 1 H), 2.26-2.14 (m, 2 
H), 2.08 (dd, J = 7.5, 12.5 Hz, 1 H), 2.03-1.80 (m, 5 H), 1.62 (dd, J = 5.5, 14.5 Hz, 1 H), 







methanesulfonate (S8). The reaction of S7 was conducted using a procedure analogous to 
that described above for the preparation of S4. This procedure yielded the title compound 
S8 (0.053 g, 77%) as a yellow. 1H NMR (500 MHz, CDCl3) δ 7.22-7.12 (m, 5 H), 7.11-
7.08 (m, 2 H) 6.78 (d, J = 9.0 Hz, 2 H), 5.86-5.76 (m, 1 H), 5.12-5.05 (m, 1 H), 5.04-4.99 
(m, 1 H), 4.61 (s, 2 H), 4.18 (t, J = 8.0 Hz, 1 H), 4.13 (dd, J = 6.5, 11.5 Hz, 1 H), 4.03 
(dd, J = 3.0, 11.5 Hz, 1 H),  3.76-3.63 (m, 8 H), 3.42-3.33 (m, 4 H), 3.25-3.18 (m, 1 H), 
2.96 (s, 3 H), 2.82 (d, J = 14.0 Hz, 1 H), 2.75 (d, J =14.0 Hz, 1 H), 2.27 (dd, J = 8.0, 12.5 
Hz, 1 H), 2.16-2.04 (m, 2 H), 1.98-1.90 (m, 1 H), 1.90-1.80 (m, 2 H), 1.64-1.55 (m, 2 H), 
1.00 (d, J = 7.0 Hz, 3 H), 0.97 (d, J = 7.0 Hz, 3 H). 
 
 (3S,3'S,5R,5'R)-2-allyl-5-(azidomethyl)-3-benzyl-3'-isobutyl-
2'-(4-methoxybenzyl)-3'-(2-(methoxymethoxy)ethyl)-3,5'-biisoxazolidine (S9). The 
reaction of S8 was conducted using a procedure analogous to that described above for the 
preparation of 28. This procedure yielded the title compound S9 (0.043 g, 84%) as a clear 




eluant. 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 9.0 Hz, 2 H), 7.25-7.14 (m, 5 H), 6.85 
(d, J = 9.0 Hz, 2 H), 5.95-5.85 (m, 1 H), 5.19-5.12 (m, 1 H), 5.11-5.07 (m, 1 H), 4.66 (s, 
2 H), 4.28 (t, J = 8.0 Hz, 1 H), 3.82-3.70 (m, 7 H), 3.68- 3.62 (m,1 H), 3.46-3.39 (m, 4 
H), 3.29-3.17 (m, 3 H), 2.88 (d, J = 14.0 Hz, 1 H), 2.80 (d, J =14.0 Hz, 1 H), 2.32 (dd, J 
= 8.0, 12.5 Hz, 1 H), 2.22 (dd, J = 8.5, 12.5 Hz, 1 H), 2.07 (dd, J = 8.5, 12.5 Hz, 1 H), 
2.04-1.97 (m, 1 H), 1.96-1.86 (m, 2 H), 1.74 (dd, J = 7.5, 13.0 Hz, 1 H), 1.64 (dd, J = 5.5, 
14.0 Hz, 1 H), 1.46 (dd, J = 5.5, 14.0 Hz, 1 H),  1.06 (d, J = 6.5 Hz, 3 H), 1.03 (d, J = 6.5 
Hz, 3 H). 
 
2-((3S,3'S,5R,5'R)-2-allyl-5-(azidomethyl)-3-benzyl-3'-
isobutyl-2'-(4-methoxybenzyl)-3,5'-biisoxazolidin-3'-yl)ethanol (S10). The reaction of S9 
was conducted using a procedure analogous to that described above for the preparation of 
28. This procedure yielded the title compound S10 (0.013 g, 67%) as a clear colorless oil 
after purification by chromatography with 3% MeOH/C2Cl2 as the eluant. 1H NMR 
(500 MHz, CDCl3) δ 7.30-7.19 (m, 6 H), 7.17-7.13 (m, 1 H), 6.91-6.85 (m, 2 H), 5.96-
5.86 (m, 1 H), 5.19-5.08 (m, 2 H), 4.39-4.33 (m, 1 H), 4.24-4.14 (m, 1 H), 4.04-3.90 (m, 
2 H), 3.89-3.62 (m, 8 H), 3.47-3.40 (m, 1 H), 3.31-3. 0 (m, 3 H)4.28 (t, J = 8.0 Hz, 1 H), 
3.82-3.70 (m, 7 H), 3.68- 3.62 (m, 1 H), 3.46-3.39 (m, 4 H), 3.29-3.02 (m, 4 H), 3.00-
2.90 (m, 1 H), 2.86-2.76 (m, 1 H), 2.42-2.28 (m, 1 H), 2.23-2.09 (m, 2 H), 1.96-1.82 (m, 









carboxamide (12). The reaction of S10 was conducted using a procedure analogous to 
that described above for the preparation of 11. This procedure yielded the title compound 
12 (2.5 mg, 25%) as a white solid. The purity of compund 12 was confirmed by 
analytical reverse-phase HPLC analysis. The identity was verified by mass spectral 












cyclopenta[a]phenanthrene-17-carboxamide (13). A flame-dried flask was cooled under a 
stream of nitrogen  and  charged with S10 (19.0 mg, 0.035 mmol, 1 equiv), triphenyl 
phosphine (18 mg, 0.070 mmol, 2.0 equiv), and THF (0.35 mL). The reaction was heated 
under a reflux condenser to 85 ̊C for 2 h. The mixture was allowed to cool to rt and was 
then transferred into a biphasic mixture of 1 M HCl (10 mL) and ether (10 mL). The 
layers were partitioned and the organic layer was extracted with 1 M HCl (2× 10 mL). 
The combined aqueous layers were basified with 3 M NaOH (until pH 10 or greater). The 
aqueous mixture was then extracted with CH2 l2 (3× 15 mL) and the combined organic 
extracts were dried over Na2SO4, filtered, and concentrated in vacuo. To a solution of 8-
(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid (20 mg, 0.05 mmol, 
1.5 equiv) dissolved in NMP (0.067 mL) were added HOBt (7.0 mg, 0.05 mmol, 
1.5 equiv based) and HBTU (20 mg, 0.05 mmol, 1.5 equiv). This solution was agitated 
for 15 min. The solution of activated ester was added to the crude amine dissolved in 
NMP (0.067 mL) and the resulting mixture was allowed to stir for 12 h at which time the 
reaction was complete as judged by ESI-MS analysis. Excess reagents were quenched by 
the addition of 1M HCl (10 mL) and EtOAc (10 mL). The reaction vessel was washed 
with EtOAc (2 x 2 mL) to remove all residues. The resulting biphasic mixture was 
separated and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
organic fractions were dried over Na2SO4, filtered, and concentrated in vacuo. The 
resulting oil was dissolved in a solution of 20% piper dine in DMF (0.037 mL, 




solution was diluted with aq 0.1% TFA (0.50 mL) and CH3CN (0.50 mL) and partially 
purified by reverse-phase HPLC to remove Fmoc byproducts. The partially purified 
amine was used immediately in subsequent steps. The amine product was then dissolved 
in t-BuOH (0.3 mL), THF (0.1  mL), and H2O (30 µL), then NMO (1.1 mg, 8.9 µmol, 1.1 
equiv) was added followed by OsO4 (3 µl of a 2.5 wt% solution in t-BuOH, 0.9 µmol, 0.1 
equiv). The reaction mixture was stirred at ambient t mperature until complete by ESI-
MS analysis (1 h).  The mixture was cooled in an ice-H2O bath, Na2SO3 was added, and 
the mixture stirred 1 h.  The mixture was diluted with H2O (5 mL) and extracted with 
CH2Cl2 (3 x 5 mL).  The combined organic extracts were dri d over Na2SO4, filtered and 
concentrated in vacuo to yield a trihydroxyamine. To a solution of OxDex22 (17 mg, 
0.045 mmol, 3.0 equiv) dissolved in NMP (0.15 mL) were added HOBt (6.2 mg, 
0.045 mmol, 3.0 equiv) and HBTU (17 mg, 0.045 mmol, 3.0 equiv) and the resulting 
mixture was agitated for 15 min. To this solution were added the trihydroxyamine 
dissolved in NMP (0.15 mL), 2,6-lutidine (35 µL, 0.30 mmol, 6.7 equiv), and DIPEA 
(49 µL, 0.30 mmol, 6.7 equiv). The resulting mixture was stirred for 12 h at rt. The 
product was isolated by reverse-phase HPLC purification to provide 13 as a white solid 
(0.8 mg, 9%). The purity of compound 13 was confirmed by analytical reverse-phase 
HPLC analysis. The identity was verified by mass spectral analysis of the isolated 
compound. LRMS (ESI) calcd for [C58H83FN4O13 + H]







dihydroisoxazole (24). The reaction of S3 was conducted using a procedure analogous to 
that described above for the preparation of 23. This procedure yielded the title compound 
24 (0.062 g, 41%) as a clear colorless oil after purification by chromatography with 15% 
EtOAc/hexanes as the eluant. 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.5 Hz, 2 H), 
6.85 (d, J = 8.5 Hz, 2 H), 4.71 (t, J = 7.5 Hz, 1 H), 4.64 (s, 2 H), 4.62-4.55 (m, 1 H),
3.83-3.77 (m, 5 H), 3.77-3.70 (m, 2 H), 3.63-3.55 (m, 2 H), 3.39 (s, 3 H), 2.84 (dd, J = 
11.0, 17.5 Hz, 1 H), 2.72 (dd, J = 7.0, 17.5 Hz, 1 H), 2.64-2.57 (m, 1 H), 2.52 (dd, J = 
8.5, 12.5Hz, 1 H), 1.98-183 (m, 3 H), 1.65 (dd, J = 5.0, 14.0 Hz, 1 H), 1.40 (dd, J = 7.0, 




dihydroisoxazole (31). The reaction of S3 was conducted using a two step procedure 
analogous to that described above for the preparation of S4 and 28. This procedure 
yielded the title compound 31 (0.043 g, 72%) as a clear colorless oil after purification by 
chromatography with 25% EtOAc/hexanes as the eluant. 1H NMR (400 MHz, CDCl3) δ 




(m, 3 H), 3.85-3.67 (m, 7 H), 3.39 (s, 3 H), 3.31 (dd, J = 4.0, 13.0 Hz, 1 H), 3.23 (dd, J = 
5.0, 13.0 Hz, 1 H), 2.87 (dd, J = 11.0, 17.5 Hz, 1 H), 2.69 (dd, J = 6.5, 17.5 Hz, 1 H), 
2.61-2.52 (m, 2 H), 2.04-1.84 (m, 3 H), 1.64 (dd, J = 5.0, 14.5 Hz, 1 H), 1.40 (dd, J = 6.0, 
14.5 Hz, 1 H), 1.02 (t, J = 6.0 Hz, 6 H). 13C NMR (100 MHz, CDCl3) δ 161.0, 158.6, 
130.6, 129.6, 113.6, 96.5, 78.6, 71,0, 67.7, 64.6, 55.3, 55.2, 53.5, 53.1, 44.3, 42.0, 37.5, 
34.0, 25.2, 24.4, 24.3. 
 
2-((3S,5R)-5-((S)-5-(azidomethyl)-4,5-dihydroisoxazol-3-yl)-
3-isobutyl-2-(4-methoxybenzyl)isoxazolidin-3-yl)ethanol (32). The reaction of 31 was 
conducted using a procedure analogous to that describ d above for the preparation of 28. 
This procedure yielded the title compound 32 (0.015 g, 77%) as a clear colorless oil after 
purification by chromatography with 2% MeOH/CH2Cl2 as the eluant. 1H NMR (500 
MHz, CDCl3) δ 7.24 (d, J = 8.5 Hz, 2 H), 6.87 (d, J = 8.5 Hz, 2 H), 4.79 (t, J = 8.0 Hz, 1 
H), 4.76-4.68 (m, 1 H), 3.97 (d, J = 14.0 Hz, 1 H), 3.92-3.86 (m, 1 H), 3.86-3.76 (m,5 
H), 3.39 (dd, J = 4.0, 13.0 Hz, 1 H), 3.30 (dd, J = 5.0, 13.0 Hz, 1 H), 2.94 (dd, J = 11.0, 
17.0 Hz, 1 H), 2.77 (dd, J = 7.0, 17.5 Hz, 1 H), 2.71 (dd, J = 7.5, 17.5 Hz, 1 H), 2.55 (dd, 
J = 7.5, 18.0 Hz, 1 H), 1.98 (s, br, 1 H), 1.86-1.70 (m, 3 H), 1.47 (dd, J = 7.5, 14.0 Hz, 1 






methoxybenzyl)-3-(2-methoxyethyl)isoxazolidin-5-yl)4,5-dihydroisoxazole (33). A 
flame-dried flask  was  cooled under a stream of nitrogen  and  charged with 32 (7 mg, 
0.017 mmol, 1 equiv) and THF (0.17 mL, 0.1 M). Sodium hydride (1.2 mg, 60% 
dispersion in mineral oil, 0.05 mmol, 3 equiv) was added and the mixture was allowed to 
stir for 10 min before addition of iodomethane (3 µL, 0.05 mmol, 3 equiv). After stirring 
1 h, TLC analysis shows 32 remaining, so sodium hydride (2.4 mg, 6 equiv) and 
iodomethane (6 µL) were added. The mixture was stirred until TLC analysis indicated 
reaction completion, then the reaction was quenched with H2O (5 mL), extracted with 
EtOAc (3 x 5 mL). The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo.  This procedur  yielded the title compound 
33 (0.006 g, 87%) as a clear colorless oil after purification by chromatography with 25% 
EtOAc/hexanes as the eluant. 1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.5 Hz, 2 H), 
6.86 (d, J = 8.5 Hz, 2 H), 4.77-4.71 (m, 1 H), 4.69-4.61 (m, 1 H), 3.85-3.72 (m, 5 H), 
3.65-3.51 (m, 2 H), 3.38 (s, 3 H), 3.32 (dd, J = 4.5, 13.0 Hz, 1 H), 3.24 (dd, J = 5.0, 13.0 
Hz, 1 H), 2.88 (dd, J = 11.0, 17.5 Hz, 1 H), 2.69 (dd, J = 7.0, 17.5 Hz, 1 H), 2.63-2.51 
(m, 2 H), 2.01-1.82 (m, 3 H), 1.62 (dd, J = 5.0, 14.5 Hz, 1 H), 1.39 (dd, J = 6.0, 14.5 Hz, 










carboxamide (7). The reaction of 32 was conducted using a procedure analogous to that 
described above for the preparation of 11. This procedure yielded the title compound 
7 (1.4 mg, 15%) as a white solid. The purity of compund 7 was confirmed by analytical 
reverse-phase HPLC analysis. The identity was verified by mass spectral analysis of the 
isolated compound. LRMS (ESI) calcd for [C48H69FN4O11 + H]










carboxamide (8). The reaction of 33 was conducted using a procedure analogous to that 
described above for the preparation of 11. This procedure yielded the title compound 
8 (1.9 mg, 20%) as a white solid. The purity of compund 8 was confirmed by analytical 
reverse-phase HPLC analysis. The identity was verified by mass spectral analysis of the 
isolated compound. LRMS (ESI) calcd for [C49H71FN4O11 + H]







cyclopenta[a]phenanthrene-17-carboxamide (9). The reaction of 31 was conducted using 
a procedure analogous to that described above for the preparation of 11. This procedure 
yielded the title compound 9 (1.2 mg, 11%) as a white solid. The purity of 
compound 9 was confirmed by analytical reverse-phase HPLC analysis. The identity was 
verified by mass spectral analysis of the isolated compound. LRMS (ESI) calcd for 
[C50H73FN4O12 + H]







methoxybenzyl)-3'-(2-(methoxymethoxy)ethyl)-3,5'-biisoxazolidine (26) and 
(3R,3'S,5S,5'R)-2-allyl-3-benzyl-5-((tert-butyldimethylsilyloxy)methyl)-3'-isobutyl-2'-(4-
methoxybenzyl)-3'-(2-(methoxymethoxy)ethyl)-3,5'-biisoxazolidine (27). The reaction of 
24 was conducted using a two step procedure analogous to that described above for the 
preparation of S6 and 25. This procedure yielded the title compounds 26 (0.405 g, 54%) 
and 27 (0.057 g, 8%) as a clear colorless oils after purification by chromatography with 
7% EtOAc/hexanes as the eluant. 26: 1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 9.0 Hz, 
2 H), 7.23-7.17 (m, 3 H), 7.07-7.02 (m, 2 H), 6.90 (d, J = 9.0 Hz, 2 H), 6.00-5.91 (m, 1 
H), 5.19 (d, J = 17.5 Hz, 1 H), 5.07 (d, J = 10.0 Hz, 1 H), 4.60 (s, 2 H), 4.15-4.08 (m, 1 
H), 4.01-3.95 (m, 1 H), 3.83-3.64 (m, 10 H), 3.43 (dd, J = 6.0, 10.0 Hz, 1 H), 3.34 (s, 3 
H), 3.26-3.18 (m, 1 H), 2.98 (d, J = 12.5 Hz, 1 H), 2.74-2.64 (m, 2 H), 2.19 (dd, J = 8.5, 
13.0 Hz, 1 H), 1.98-1.84 (m, 4 H), 1.56-1.44 (m, 2 H), 1.31 (dd, J = 6.0, 13.0 Hz, 1 H), 
1.04 (d, J = 3.0 Hz, 3 H), 1.03 (d, J = 3.0 Hz, 3 H), 0.89 (s, 9 H), 0.06 (d, J = 1.5 Hz, 6 
H). 27: 1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 9.0 Hz, 2 H), 7.23-7.17 (m, 3 H), 7.10-
7.07 (m, 2 H), 6.87 (d, J = 9.0 Hz, 2 H), 5.92-5.83 (m, 1 H), 5.17-5.12 (m, 1 H), 5.07-
5.03 (m, 1 H), 4.67-4.54 (m, 3 H), 4.22 (t, J = 8.0 Hz, 1 H), 3.88-3.78 (m, 6 H), 3.78-3.68 
(m, 5 H), 3.46-3.30 (m, 5 H), 3.24 (dd, J = 7.0, 10.0 Hz, 1 H), 2.18 (dd, J = 6.5, 15.5 Hz, 
1 H), 2.89 (dd, J = 5.5, 10.0 Hz, 1 H), 2.84 (d, J = 14.0 Hz, 1 H), 2.76 (d, J = 14 Hz, 1 




(m, 2 H), 1.74 (dd, J = 4.5, 13.5 Hz, 1 H), 1.67-1.59 (m, 1 H), 1.47 (dd, J = 5.0, 14.0 Hz, 
1 H), 1.05 (d, J = 6.5 Hz, 3 H), 1.02 (d, J = 6.5 Hz, 3 H), 0.82 (s, 9 H), -0.06 (s, 3 H), -
0.08 (s, 3 H). 
 
(3S,5R)-3-allyl-2-benzyl-3-isobutyl-5-((R)-2,2,3,3,8,8,9,9-
octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoxazolidine (34). The reaction of 18 was 
conducted using a procedure analogous to that describ d above for the preparation of 19. 
This procedure yielded the title compound 34 (1.84 g, 81%) as a yellow oil after 
purification by chromatography with  EtOAc/hexanes as the eluant. 1H NMR (300 MHz, 
CDCl3) δ 7.40 (d, J = 7.5 Hz, 2 H), 7.31-7.18 (m, 3 H), 6.03-5.87 (m, 1 H), 5.13 (d, J = 
4.2 Hz, 1 H), 5.08 (s, 1 H), 4.11-4.01 (m, 1 H), 3.91-3.75 (m, 2 H), 3.69-3.50 (m, 3 H), 
2.39-2.32 (m, 2 H), 2.12 (dd, J = 3.6, 8.4 Hz, 2 H), 1.97-1.83 (m, 1 H), 1.62 (dd, J = 5.1, 
14.4 Hz, 1 H), 1.55 (s, 3 H), 1.35 (dd, J = 6.6, 14.1 Hz, 1 H), 0.99 (dd, J = 5.4, 6.6 Hz, 6 
H), 0.88-0.86 (m, 18 H), 0.03- -0.02 (m, 9 H), -0.06 (s, 3 H).  
 
2-((3S,5R)-2-benzyl-3-isobutyl-5-((R)-2,2,3,3,8,8,9,9-octamethyl-
4,7-dioxa-3,8-disiladecan-5-yl)isoxazolidin-3-yl)ethanol (35).  The reaction of 34 was 
conducted using a procedure analogous to that describ d above for the preparation of 20. 
This procedure yielded the title compound 35 (0.730 g, 73%) as a yellow oil after 




MHz, CDCl3) δ 7.36 (d, J = 7.5 Hz, 2 H), 7.31-7.26 (m, 2 H), 7.24-7.19 (m, 1 H), 5.35 (s, 
br, 1 H), 4.32-4.25 (m, 1 H), 3.96-3.85 (m, 3 H), 3.82-3.75 (m, 1 H), 3.69 (dt, J = 4.0, 6.0 
Hz, 1 H), 3.57 (dt, J = 6.0, 10.0 Hz, 2 H), 2.29 (dd, J= 10.0, 12.5 Hz, 1 H), 2.10 (dd, J= 
7.5, 12.5 Hz, 1 H), 2.07-1.98 (m, 1 H), 1.94-1.87 (m, 1 H), 1.79-1.70 (m, 1 H), 1.70-1.63 
(m, 1 H), 1.39 (dd, J= 8.0, 13.5 Hz, 1 H), 1.03 (d, J = 6.5 Hz, 3 H), 1.00 (d, J = 6.5 Hz, 3 
H), 0.95 (s, 9 H), 0.87 (s, 9 H), 0.14 (s, 3 H), 0.08 (s, 3 H), -0.02 (s, 6 H). 
 
 (3S,5R)-2-benzyl-3-isobutyl-3-(2-(methoxymethoxy)ethyl)-5-
((R)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)isoxazolidine (S11). The 
reaction of 35 was conducted using a procedure analogous to that described above for the 
preparation of 21. This procedure yielded the title compound S11 (0.493 g, 83%) as a 
yellow oil after purification by chromatography with 5%  EtOAc/hexanes as the eluant. 
1H NMR (500 MHz, CDCl3) δ 7.40-7.37 (m, 2 H), 7.30-7.25 (m, 2 H), 7.22-7.18 (m, 1 
H), 4.64 (s, 2 H), 4.11 (dt, J = 5.0, 8.5 Hz, 1 H), 3.86 (d, J = 14.0 Hz, 1 H), 3.79-3.70 (m, 
3 H), 3.68-3.63 (m, 1 H), 3.59 (dd, J = 5.0, 10.5 Hz, 1 H), 3.53 (dd, J = 6.0, 12.5 Hz, 1 
H), 3.38 (s, 3 H), 2.22-2.10 (m, 3 H), 1.99-1.82 (m, 3 H), 1.63 (dd, J = 5.0, 14.0 Hz, 1 H), 
1.54 (s, 2 H), 1.34 (dd, J = 6.5, 14.0 Hz, 1.02 (d, J = 6.5 Hz, 3 H), 0.99 (d, J = 6.5 Hz, 3 






(methoxymethoxy)ethyl)isoxazolidin-5-yl)ethane-1,2-diol (36). The reaction of S11 was 
conducted using a procedure analogous to that describ d above for the preparation of 21. 
This procedure yielded the title compound 36 (0.051 g, 82%) as a yellow oil after 
purification by chromatography with 66%  EtOAc/hexanes as the eluant. 1H NMR (500 
MHz, CDCl3) δ 7.36-7.30 (m, 4 H), 7.28-7.23 (m, 1 H),  4.64 (s, 2 H), 4.05-3.99 (m, 1 
H), 3.87 (d, J = 14.5 Hz, 1 H), 3.84-3.76 (m, 2 H), 3.72-3.65 (m,1 H), 3.59-3.52 (m, 2 
H), 3.49-3.43 (m, 1 H), 3.39 (s, 3 H), 3.09 (s, br, 1 H), 2.39 (dd, J = 9.0, 12.5 Hz, 1 H), 
2.24 (dd, J = 6.0, 12.5 Hz, 1 H), 2.16 (s, br, 1 H), 2.02-1.94 (m, 1 H), 1.93-1.85 (m, 2 H), 
1.63 (dd, J = 5.0, 14.0 Hz, 1 H), 1.42 (dd, J = 7.5, 14.0 Hz, 1 H), 1.01 (t, J = 6.5 Hz, 6 H). 
 
((R)-3-((3S,5R)-2-benzyl-3-isobutyl-3-(2-
(methoxymethoxy)ethyl)isoxazolidin-5-yl)-4,5-dihydroisoxazol-5-yl)methanol (38). The 
reaction of 36 was conducted using a procedure analogous to that described above for the 
preparation of 22 and S2. This procedure yielded the title compound 38 (0.014 g, 20%) as 
a clear colorless oil after purification by chromatography with 50%  EtOAc/hexanes as 
the eluant and HPLC seperation of diastereomers. 1H NMR (500 MHz, CDCl3) δ 7.38-
7.29 (m, 4 H), 7.27-7.23 (m, 1 H), 4.76-4.71 (m, 1 H), 4.66-4.60 (m, 3 H), 3.87-3.82 (m, 




J = 11.0, 17.5 Hz, 1 H), 2.66 (dd, J = 7.5, 17.5 Hz, 1 H), 2.56 (d, J = 8.0 Hz, 2 H), 2.02-
1.84 (m, 3 H), 1.77 (s, br, 1 H), 1.67 (dd, J = 5.0, 14.5 Hz, 1 H), 1.41 (dd, J = 7.0, 14.5 







carboxamide (6). The reaction of 38 was conducted using a procedure analogous to that 
described above for the preparation of S4, 28, and 11. This procedure yielded the title 
compound 6 (1.3 mg, 11%) as a white solid. The purity of compund 6 was confirmed by 
analytical reverse-phase HPLC analysis. The identity was verified by mass spectral 









previously.17 It was isolated after HPLC separation of diastereom rs. 1H NMR (400 
MHz, CDCl3) δ 7.29-7.26 (m, 4 H), 7.24-7.19 (m, 1 H), 4.54 (s, br, 1 H), 4.39-4.31 (m, 1 
H), 3.94 (d, J = 13.6 Hz, 1 H), 3.85-3.74 (m, 2 H), 3.69 (d, J = 13.6 Hz, 1 H), 3.42 (dd, J 
= 6.4, 12.8 Hz, 1 H), 3.22 (dd, J = 4.8, 12.8 Hz, 1 H), 2.35 (dd, J = 8.8, 12.8 Hz, 1 H), 






dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxamide (43). The reaction of 41 
was conducted using a procedure analogous to that described above for the preparation of 
11. This procedure yielded the title compound 41 (0.3 mg). The purity of 
compound 43 was confirmed by analytical reverse-phase HPLC analysis. The identity 
was verified by mass spectral analysis of the isolated compound. LRMS (ESI) calcd for 
[C44H64FN3O9 + H]
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Exploratory Studies on the Reactivity of Electrophiles with Enediol Diboronates 
6.1 Introduction 
Tandem reactions in organic synthesis often allow fr the rapid preparation of 
complex molecules in an efficient manner. Previous work in the Wolfe lab has explored 
tandem Wittig rearrangement/aldol reactions for the synthesis of glycolate aldols (Figure 
6-1).1 This reaction provided a new approach to the construction of α-alkyl-α,β-
dihydroxy esters (2) through a tandem one-pot sequence of two different C−C bond-
forming reactions.1a Further investigation of the reaction identified a chiral auxiliary that 
provided excellent stereoselectivity, and after cleavage, provides products in good yield 
and excellent enantiopurity.1b An improved synthesis of a key intermediate for the natural 
product alternaric acid was reported as a result of this development. Expansion to imine 
electrophiles provided selective access to both syn-α-alkyl-α-hydroxy-β-amino esters (3) 
and anti-α-alkyl-α-hydroxy-β-amino esters (4) (Figure 6-2).1c Interestingly, utilization of 
imines provided access to the syn-products, while use of N-Boc-2-
(phenylsulfonyl)amines electrophiles led to formation of anti-products. 





Figure 6-2: Asymmetric Tandem Wittig Rearrangement/Mannich Reactions 
 
6.2 Importance of Aldol Addition with Anti Selectivity 
Anti-α-alkyl-α,β-dihydroxy esters and anti-α,β-dihydroxy carbonyl compounds are 
important synthetic building blocks and can be found in biologically important 
compounds and natural products.2-4 For example, Rapamycin2 (5) is a natural product and 
immunosuppressant drug used to prevent rejection in organ transplantation, AI-77B3 (6) 
is a natural product with antiulcerogenic and antihistaminergic activity, and 3’S-
hydroxyneoharringtonine4 (7) is a natural product with antileukemia activity. While 
reactions that selectively generate nti-aldol products are known, none of these reports 
included products containing unprotected tertiary alcohols, like those potentially formed 





Figure 6-3: Biologically Important Compounds that Contain 1,2-anti-aldol 
Fragments 
 
6.3 Selection for Anti-Selective Aldol Reactions via Oxonium Electrophiles 
The selectivity change in the tandem Wittig rearrangement/Mannich reactions 
suggested that the selective synthesis of anti-α-alkyl-α,β-dihydroxy esters should be 
possible. Consideration of the tandem Wittig Rearrangement/Mannich reactions indicated 
that the nature of the electrophile played a key role in determining diastereoselectivity. 
While N-benzyl- and N-Boc-imine electrophiles participate in a boat-like transition state 
leading to syn-products (10), it was hypothesized in these reactions that use of N-Boc-2-
(phenylsulfonyl)amines led to formation of anti-products (12) through an N-Boc iminium 
mediated open transition state (11, Figure 6-4).1c Thus, I hypothesized that a similar 
strategy could be used for targeting the anti-α-alkyl-α,β-dihydroxy esters. The Sinha 
group has recently reported aldol-type reactions of ketone boron enolates with acetals 
both intermolecularly6 and intramolecularly,7 confirming the feasibility of this strategy. It 




(phenylsulfonyl)amines in the reaction by generating electrophilic alkyl oxonium ion  
intermediates in situ that should preferentially participate in an open transition state and 
form the anti-type products. Execution of this strategy for the formation of anti-α-alkyl-
α,β-dihydroxy esters showed improved selectivity for the anti-products, but the overall 
diastereoselectivity only shifted to 3:1 syn-to-anti under the best conditions explored to 
date (Figure 6-5). To unequivocally identify the major diastereomer as the syn-diol ester 
product (16), an authentic sample of the syn-diol ester product was synthesized for 
comparison (Figure 6-6). Use of 2-phenyl-1,3-dioxane (17) as electrophile showed no 
improvement in selectivity (Figure 6-5). It’s not clear why anti-aldol selectivity for the 
reactions involving oxonium ion intermediates is not comparable to the reactions 
involving iminium ion intermediates. It is possible that transition state 11 has improved 
organization and stability due to an interaction betwe n the N-Boc carbonyl and boron on 
the enolate, which results in higher stereocontrol for the iminium ion reactions than can 
be achieved in the oxonium ion cases. 





Figure 6-5: Tandem Wittig Rearrangement/Aldol Reaction 
 
Figure 6-6: Authentic Synthesis of Syn-Diol Ester Product 
 
6.4 Selection for Anti-Selective Aldol Reactions via Metal Enolates 
 Work with the dialkyl acetal electrophiles indicated that diastereoselectivity was 
influenced by the nature of the electrophile, but efforts to develop electrophiles strongly 
favoring the desired anti-aldol type products have not yet been successful. We therefore 
decided to more closely investigate aspects of the enolate nucleophile. While the 
previously developed tandem Wittig/aldol procedure p oceeds through a diboron enolate 
intermediate (14) in route to syn-aldol type products, we thought it would be possible to 
favor production of anti-aldol type products by changing the reactivity of the enolate by 
switching to other metal enolates.  Literature precedent indicates that aldol selectivity can 
be strongly influenced by the metal bound to the int rmediate enolates.8 In particular, the 
Kazmaier lab has shown that glycolate titanium enolates can preferentially form anti-
aldol products (22, Figure 6-7). However, none of these reports included products 
containing unprotected tertiary alcohols (2, Figure 6-1), like those formed by the tandem 




Figure 6-7: Selectivity for anti-aldol Products Controlled by Metal Enolate 
 
The glycolate aldol reaction was investigated on its own with the intent of 
expanding to the tandem Wittig/aldol reaction system once conditions strongly favoring 
anti-aldol selectivity were identified. Starting from α-hydroxy ester 23, addition of 
lithium diisopropyl amide generates a lithium enolate, then addition of Et2AlCl followed 
by benzaldehyde yields products with a minor preference for the anti-aldol 
stereochemistry (24) as judged by crude 1H-NMR analysis. Interestingly, it was found 
that the relative stoichiometry of base and Lewis acid mediated selectivity for the anti-
aldol product (24, Table 6-1). However, further screening of other metals (AlMe3, 
Me2AlOTf, TiCl(OiPr)3, Bu2BOTf, Sc(OTf)3, LiClO4) showed no improvement in 
reaction selectivity. 





6.5 Selection for Anti-Selective Aldol Reactions via Aldehyde Activation 
 Work from the Heathcock9 and Oppolzer10 labs has shown that reactions of 
enolates with Lewis acid coordinated aldehydes can provide products with good to 
excellent anti-selectivity. Although these conditions have not been reported in aldol 
reactions involving tetrasubstituted enolates or glycolates, application of this 
stereochemical model to our tandem Wittig/aldol process suggests that a similar strategy 
should work in our chemistry (Figure 6-8).  The reported reactions are proposed to 
proceed through open transition states (25 and 27) with minimization of gauche 
interactions leading to good selectivity for the anti-aldol products (26). Both TiCl4 and 
Et2AlCl have been shown to promote anti-aldol selectivity, so our preliminary 
experiments tested these Lewis acids (Figure 6-9).9-11 Conducting the Wittig 
rearrangement followed by reaction with precoordinated Lewis acids provided no 
evidence of the desired aldol products. Varying the order in which the components were 
mixed, either adding 14 to the activated aldehydes or adding the activated ldehydes to 
14, did not influence the result. It seems like the added steric bulk of the tetrasubstituted 
enolate is preventing the desired aldol reactivity, or exchange of boron and titanium may 
be occurring, reducing the enolate’s reactivity. Reaction of a lithium enolate with Et2AlCl 
activated benzaldehyde provided the aldol products with selectivity comparable to that 




Figure 6-8: Stereochemical Model for Selectivity with Aldehyde Activation 
 
Figure 6-9: Exploring Enolate Addition to Activated Aldehydes 
 
6.6 Investigating New Electrophiles for Tandem Wittig Rearrangment Reactions 
Development of new tandem Wittig rearrangement/electrophilic alkyl reactions was 
sought as a way to gain access to new and useful products. Application of epoxide 
electrophiles was investigated as a route to 1,3-diols, but only Wittig rearrangement 
products were isolated from these reactions (Figure 6-10). Similarly, Michael acceptors 
were tested as electrophiles for the enolate intermediates (28), but no evidence of a 
tandem reaction was observed. Examples of epoxide ring opening and michael addition 
reactions are known with other metal enolates including Zn,12 Al,13 and Li,14,15 so further 
exploration of these reactions from glycolate interm diates with other metals (such as 




Figure 6-10: Testing Epoxides and Michael Acceptors in Tandem Reactions  
 
 Alternatively, pyridinium salts have been used as electrophiles for the formation 
of substituted piperidines.16 Use of pyridinium salt 31 gave promising preliminary results 
for the construction of substituted piperidine 33 (Figure 6-11). Subjecting the 1,2-Wittig 
rearrangement enolate intermediate (28) to 31 generated intermediate 32, which 
underwent an intramolecular condensation to form 33 in low yield. The α-hydroxy ester 
(36), which results from Wittig rearrangement without electrophilic trapping, is the other 
main product isolated from this reaction. Initial modifications of solvent, temperature, 
concentration, and order of addition have yet to prvide improved results.  Surprisingly, 
intermediates from the 2,3-Wittig rearrangement have not shown reactivity with 31 
(Figure 6-12). 
Figure 6-11: Tandem 1,2-Wittig Rearrangement/Pyridinium Addition Reaction 
 





Extension of this tandem reaction to other pyridinium salts has not yet been 
successful. N-alkyl pyridinium salts17 are isolable and are known electrophiles for 
nucleophilic addition, but tandem reaction conditions have only afforded α-hydroxy ester 
(36) along with substrate decomposition (Figure 6-13). 
Figure 6-13: N-Methyl Pyridinium Electrophiles Fail to Provide Tandem Products 
 
 To improve the tandem Wittig rearrangement/Pyridinium addition reactions, 
improved conditions need to be identified that promote full conversion of the Wittig 
rearrangement intermediate to the tandem reaction product. It is anticipated that 
improving enolate stability while promoting nucleophilic addition to a pyridinium salt 
will provide the desired products in improved yields. Screening amine bases may 
improve results, as improved reactivity was achieved in the Wittig rearrangement/aldol 
reactions by switching from Et3N to iPr2NEt for the O-allyl glycolate ester substrate (1a). 
Exploration of solvent mixtures may help achieve improved results, as the pyridinium 
salts have low solubility in CH2Cl2, which is currently the best solvent for inducing the 
Wittig rearrangement. Further exploration of various pyridinium salts my improve 
conversion with adjustment of electrophelicity. 
6.7 Conclusions 
A range of conditions were explored for expanding the potential utility of tandem 




diastereoselectivity for syn-aldol type products, but a reversal of selectivity to afford the 
anti-stereoisomer was not achieved. Application of other α-hydroxy ester metal enolates 
shifted aldol selectivity in favor of the anti-aldol products, though the best conditions 
using aluminum enolates only preferred the anti-aldol products by 2.7:1. Attempts to 
promote anti-selectivity via open transition state aldol reactions through aldehy  
activation with precoordinated Lewis acids were unsuccessful. 
Extension of the Wittig rearrangement intermediates to new electrophiles with 
application towards 1,3-diols (epoxides) or tertiary lcohols (activated alkenes) did not 
show any evidence of successful reactivity. Pyridinium salt electrophiles have shown 
preliminary success with the benzyl rearrangement substrate, but low reaction conversion 
and an initially limited substrate scope indicate that more optimization is needed. 
6.8 Experimental Section 
General:  All reactions were carried out under a nitrogen atmosphere in oven or 
flame dried glassware. Dibutylboron triflate (1.0 M solution in methylene chloride), tert-
butyl acrylate, methyl iodide, sodium hydride, trifluoromethanesulfonic acid, and DMF 
were purchased from Aldrich Chemical Co. and used without further purification. All 
aldehydes, benzaldehyde dimethyl acetal, and 2-ethyl oxirane were obtained  from 
commercial sources (Aldrich Chemical Co. or Acros Chemical Co.) and were purified by 
distillation from Ca2SO4. Triethylamine and diisopropylethylamine were obtained from 
Aldrich Chemical Co. and were purified by distillation from CaH. Phosphate buffer 
solution (pH 7) was obtained from Aldrich Chemical Co. Methylene chloride, toluene, 





(benzyloxy)acetate (1b),1b Methyl 2-(benzyloxy)acetate (13),1a (±)-(2R*,3S*)-Methyl-2-
benzyl-2,3-dihydroxypent-4-enoate (19),1a (±)-Methyl-2-hydroxy-3-phenylpropanoate 
(23),1a and 4-methoxy-1-methyl-pyridinium iodide (35),17 were prepared according to 
published procedures. Yields refer to isolated yields of compounds estimated to be ≥95% 
pure as determined by 1H NMR. 
 
Synthesis of Substrates 
 2-Phenyl-1, 3-dioxane (17). A flame-dried flask was cooled under a stream of 
nitrogen and charged with benzaldehyde (2.04 mL, 20.0 mmol, 1.0 equiv.), 1,3-
propanediol (2.3 mL, 32.0 mmol, 1.6 equiv.), p-toluenesulfonic acid monohydrate (2 
mg), and toluene (20 mL). The resulting solution was brought to reflux under a Dean-
Stark trap until the starting material was consumed as judge by TLC analysis (ca. 24 h). 
The reaction was then cooled to rt, poured into a sat. aq. solution of NaHCO3. The 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic extracts 
were washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The crude product was purified by flash chromatography on silica gel using 10% 
EtOAc/hexanes as the eluent to afford the title comp und (3.21 g, 98%) as a white solid. 





Selection for anti-selective aldol reactions via oxonium electrophiles 
 
(±)-(2R*,3S*)-methyl 2-benzyl-2-hydroxy-3-methoxy-3-phenylpropanoate (16). A 
flame-dried flask  was  cooled under a stream of nitrogen  and  charged with a 1 M 
solution of dibutylboron triflate in dichloromethane (0.5 mL, 0.5 mmol, 3.2 equiv). The 
pale yellow solution was cooled to 0 °C, and triethylamine (0.625 mmol, 4.0 equiv) was 
added dropwise to afford a colorless solution. Methyl 2-(benzyloxy)acetate (13) (28.2 
mg, 0.16 mmol, 1.0 equiv) in CH2Cl2 (0.25 mL) was then added dropwise, and the 
reaction mixture was warmed rt, stirred for 1.5 h, and then cooled to -78 °C. A second 
portion of Bu2BOTf (0.5 mL, 0.5 mmol, 3.2 equiv) was added, then benzaldehyde 
dimethyl acetal in CH2Cl2 was added dropwise. The reaction was stired at -78 °C for 3 h, 
the warmed to 0 °C in an ice/water and stirred another 1 h. The reaction vessel was then 
opened to air, and pH 7 buffer (1 mL/mmol substrate), and methanol (2 mL/mmol 
substrate) were added. The resulting mixture was cooled to 0  °C, 30% aqueous H2O2 (2 
mL/mmol substrate) was added slowly, and the reaction mixture was warmed to rt and 
stirred for 1 h. The mixture was diluted with ether (10 mL/mmol substrate) and water (5 
mL/mmol substrate), then was transferred to a separatory funnel. The layers were 
separated, and the organic layer was washed with a saturated aqueous solution of FeSO4 
(4 x 5 mL/mmol substrate) until a red-orange aqueous phase no longer persisted in order 




solution should be added via glass pipette SLOWLY DROPWISE.  The organic layer 
was then washed with brine, dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was purified by flash chromatography on silica 
gel to yield the title compound 16 (25.8 mg, 55%, 3:1 dr) as a colorless oil. The pure 
material was judged to be of 3:1 dr by 1H NMR analysis.  Major ( syn) diastereomer 
(16): 1H NMR (500 MHz, CDCl3) δ 7.49−7.45 (m, 2 H), 7.43−7.36 (m, 3 H), 7.24−7.16 
(m, 3 H), 7.12−7.08 (m, 2 H), 4.50 (s, 1 H), 3.71 (s, 3 H), 3.23−3.20 (m, 4 H), 2.97 (d, J
= 13.5 Hz, 1 H), 2.48 (d, J = 13.5 Hz, 1 H). Minor ( anti) diastereomer: 1H NMR (500 
MHz, CDCl3) δ 7.49−7.45 (m, 2 H), 7.43−7.36 (m, 3 H), 7.24−7.16 (m, 3 H), 7.12−7.08 
(m, 2 H), 4.50 (s, 1 H), 3.55 (s, 3 H), 3.47 (d, J = 13.5 Hz, 1 H), 3.33 (s, 3 H), 3.12 (d, J = 
13.5 Hz, 1 H), 3.06 (s, br, 1 H). 
 
(±)-(2R*,3S*)-methyl 2-benzyl-2-hydroxy-3-(3-hydroxypropoxy)-3-
phenylpropanoate (18). The reaction of 13 (28.2 mg, 0.16 mmol) was conducted using a 
procedure analogous to that described above for the preparation of 16. This procedure 
afforded the title compound 18 (35 mg, 65%, 1.5:1 dr) as a colorless oil. The pure 
material was judged to be of 1.5:1 dr by 1H NMR analysis.  Major ( syn) diastereomer 
(18): 1H NMR (400 MHz, CDCl3) δ 7.48−7.32 (m, 5 H), 7.25−7.16 (m, 4 H), 7.14−7.10 
(m, 1 H), 4.55 (s, 1 H), 3.76−3.69 (m, 5 H), 3.56−3.47 (m, 2 H), 3.22 (s, br, 1 H), 3.02 (d, 
J = 13.5 Hz, 1 H), 2.56 (d, J = 13.5 Hz, 1 H), 2.29 (s, br, 1 H), 1.82−1.74 (m, 2 H). 




7.25−7.16 (m, 4 H), 7.14−7.10 (m, 1 H), 4.59 (s, 1 H), 3.83−3.69 (m, 5 H), 3.46−3.39 (m, 
2 H), 3.38 (d, J = 13.5 Hz, 1 H), 3.14 (s, br, 1 H), 3.10 (d, J = 13.5 Hz, 1 H), 2.29 (s, br, 1 
H), 1.92−1.82 (m, 2 H). 
 
Authentic synthesis of syn-diol ester product 
 
(±)-(2R*,3S*)-methyl 2-benzyl-2-hydroxy-3-methoxy-3-phenylpropanoate (16). A 
flame-dried flask  was  cooled under a stream of nitrogen  and  charged with (±)-
(2R*,3S*)-Methyl-2-benzyl-2,3-dihydroxypent-4-enoate (19) (50 mg, 0.175 mmol, 1.0 
equiv) and DMF (2 mL). The resulting solution was cooled in an ice/water bath and 
sodium hydride (60% dispersion in mineral oil, 7 mg, 0.175 mmol, 1.0 equiv) was added. 
After gas evolution ceased, methyl iodide (11 µL, 0.175 mmol, 1.0 equiv) was added. 
The reaction was stirred at 0 °C for 1 h, then warmed to rt and stirred for 1 h. The 
reaction mixture was then quenched with 1 M HCl (5 mL), diluted with EtOAc (5 mL), 
and the layers were separated. The aqueous layer was extracted with EtOAc (3 x 5 mL), 
and the combined organic layers were washed with brne, dried over Na2SO4, filtered, 
and concentrated in vacuo. The crude product was purified by flash chromatography on 
silica gel using 10% EtOAc/hexanes as the eluent to afford the title compound (17.4 mg, 





Selection for anti-selective aldol reactions via metal enolates  
 
A flame-dried flask  was  cooled under a stream of nitrogen  and  charged with 
diisopropyl amine (148 µL, 1.05 mmol, 5.25 equiv) and THF (1.0 mL). The resulting 
solution was cooled in an ice/water bath and n-butyl lithium (2.00 M in hexanes, 0.5 mL, 
1.0 mmol, 5.0 equiv) was added dropwise. The resulting stock LDA solution was stirred 
15 minutes before use. A separate flame-dried flask was cooled under a stream of 
nitrogen and charged with (±)-Methyl-2-hydroxy-3-phenylpropanoate (23) (36 mg, 0.2 
mmol, 1.0 equiv) and toluene (0.5 mL). The flask was cooled to 0 °C in an ice/water 
bath. Stock LDA (x equiv) was added dropwise, and the reaction was allowed to stir for 
10 minutes. Diethyl aluminum chloride (1 M in hexanes, x equiv) was added dropwise to 
the yellow solution and white LiCl precipitated. The reaction mixture was stirred for 20 
minutes, then benzaldehyde (61 µL, 0.60 mmol, 3.0 equiv) was added. The reaction was
allowed to warm to rt and stirred 3 h.  The reaction mixture was then quenched with 1 M 
HCl (5 mL), diluted with EtOAc (5 mL), and the layers were separated. The aqueous 
layer was extracted with EtOAc (3 x 5 mL), and the combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The reaction 
dr was determined by crude 1H-NMR analysis. Spectroscopic properties for (19) were 
consistent with those reported in the literature.1a Major ( anti) diastereomer (24): 1H 




7.11−7.04 (m, 2 H), 4.88 (s, 1 H), 3.69 (s, 3 H), 3.38 (d, J = 13.5 Hz, 1 H), 3.18 (d, J = 
13.5 Hz, 1 H), 2.04 (s, br, 1 H), 1.89 (s, br, 1 H).
 
Exploring Enolate Addition to Activated Aldehydes 
 
A flame-dried flask  was  cooled under a stream of nitrogen  and  charged with a 1 M 
solution of dibutylboron triflate in dichloromethane (0.5 mL, 0.5 mmol, 3.2 equiv). The 
pale yellow solution was cooled to 0 °C, and triethylamine (0.625 mmol, 4.0 equiv) was 
added dropwise to afford a colorless solution. Methyl 2-(benzyloxy)acetate (13) (28.2 
mg, 0.16 mmol, 1.0 equiv) in CH2Cl2 (0.25 mL) was then added dropwise, and the 
reaction mixture was warmed rt, stirred for 1.5 h, and then cooled to -0 °C. A second 
flame-dried flask  was  cooled under a stream of nitrogen, cooled to -78 °C, and  charged 
with aldehyde (2.0 equiv) and TiCl4 (1 M in CH2Cl2, 4.0 equiv). Cannula transfer of 14 to 
the aldehydes or the aldehydes to 14 was conducted. The reaction was stired at -78 °C for 
3 h, the warmed to 0 °C in an ice/water and stirred another 1 h. The reaction vessel was 
then opened to air, and pH 7 buffer (1 mL/mmol substrate), and methanol (2 mL/mmol 
substrate) were added. The resulting mixture was cooled to 0 °C, 30% aqueous H2O2 (2 
mL/mmol substrate) was added slowly, and the reaction mixture was warmed to rt and 
stirred for 1 h. The reaction was worked up as described for 16 above. Crude 1H-NMR 





A flame-dried flask  was  cooled under a stream of nitrogen  and  charged with 
diisopropyl amine (148 µL, 1.05 mmol, 5.25 equiv) and THF (1.0 mL). The resulting 
solution was cooled in an ice/water bath and n-butyl lithium (2.00 M in hexanes, 0.5 mL, 
1.0 mmol, 5.0 equiv) was added dropwise. The resulting stock LDA solution was stirred 
15 minutes before use. A separate flame-dried flask was cooled under a stream of 
nitrogen and charged with (±)-Methyl-2-hydroxy-3-phenylpropanoate (23) (36 mg, 0.2 
mmol, 1.0 equiv) and toluene (0.5 mL). The flask was cooled to 0 °C in an ice/water 
bath. Stock LDA (2.0 equiv) was added dropwise, and the reaction was allowed to stir for 
10 minutes, then the reaction solution was cannula transferred to a 0 °C flask containing 
benzaldehyde (1.0 equiv) and Et2AlCl (1 M in hexanes, 1.0 equiv). The reaction was 
allowed to warm to rt and stirred 3 h.  The reaction mixture was then quenched with 1 M 
HCl (5 mL), diluted with EtOAc (5 mL), and the layers were separated. The aqueous 
layer was extracted with EtOAc (3 x 5 mL), and the combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The reaction 





Investigating new electrophiles for tandem wittig rearrangement reactions 
 
(±)-(1R*,8aR*)-((1R*,2S*)-2-phenylcyclohexyl) 1-benzyl-3,7-dioxo-3,7,8,8a-
tetrahydro-1H-oxazolo[3,4-a]pyridine-1-carboxylate (33). A flame-dried flask  was  
cooled under a stream of nitrogen  and  charged with a 1 M solution of dibutylboron 
triflate in dichloromethane (0.64 mL, 0.64 mmol, 3.2 equiv). The pale yellow solution 
was cooled to 0 °C, and triethylamine (112 µL, 0.80 mmol, 4.0 equiv) was added 
dropwise to afford a colorless solution. (±)-(1R*,2S*)-2-Phenylcyclohexyl-2’-
(benzyloxy)acetate (1b) (65 mg, 0.20 mmol, 1.0 equiv) in CH2Cl2 (0.40 mL) was then 
added dropwise, and the reaction was stirred for 1.5 h. The solution was cannulated into a 
solution (-40 °C) of pyridinium salt 31 which was formed from 4-methyoxypyridine (61 
µL, 0.60 mmol, 3.0 equiv) and benzyl chloroformate (86 µL, 0.60 mmol, 3.0 equiv) in 
toluene (1 mL) at -23 °C for 40 min. After 2 h, the reaction mixture was then quenched 
with 1 M HCl (5 mL), diluted with EtOAc (5 mL), and the layers were separated. The 
aqueous layer was extracted with EtOAc (3 x 5 mL), and the combined organic layers 
were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude product was purified by flash chromatography on silica gel to yield the title 
compound 33 (24.2 mg, 27%). 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.0 Hz, 1 H), 




5.17 (dt, J = 4.0, 11.0 Hz, 1 H), 3.03 (d, J = 14.5 Hz, 1 H), 2.97 (d, J = 14.5 Hz, 1 H), 
2.89 (dd, J = 4.0, 15.5 Hz, 1 H), 2.73 (dt, J = 3.5, 11.5 Hz, 1 H), 2.55 (t, J = 15.5 Hz, 1 
H), 2.20 (dd, J = 4.5, 15.5 Hz, 1 H), 2.04−1.87 (m, 2 H), 1.84−1.77 (m, 1 H), 1.60−1.33 
(m, 5 H). 
 
(±)-(1R*,2S*)-2-phenylcyclohexyl 2-hydroxypent-4-enoate (34). The reaction with (±)-
(1R*,2S*)-2-Phenylcyclohexyl-2’-(allyloxy)acetate (1a) was conducted using a 
procedure analogous to that described above for the preparation of 33. The crude product 
was purified by flash chromatography on silica gel using 25% EtOAc/hexanes as the 
eluent to afford the title compound (34) (28 mg, 56%). The pure material was judged to 
be of 1:1 dr by 1H NMR analysis.  1H NMR (500 MHz, CDCl3) δ 7.30−7.24 (m, 2.5 H), 
7.21−7.16 (m, 2.5 H), 5.63−5.54 (m, 0.5 H), 5.17−5.01 (m, 2.5 H), 4.89−4.85 (m, 0.5 H), 
4.78−4.73 (m, 0.5 H), 2.73−2.65 (m, 1 H), 2.54 (s, br, 1 H), 2.42−2.35 (m, 0.5 H), 
2.30−2.23 (m, 0.5 H), 2.20−2.09 (m, 1 H), 2.04−1.92 (m, 1.5 H), 1.91−1.85 (m, 1 H), 





N-Methyl pyridinium electrophiles fail to provide tandem products 
 
(±)-(1R*,2S*)-2-phenylcyclohexyl 2-hydroxy-3-phenylpropanoate (36). The reaction 
with 4-methoxy-1-methyl-pyridinium iodide (35) was conducted using a procedure 
analogous to that described above for the preparation of 33. The crude product was 
purified by flash chromatography on silica gel using 15% EtOAc/hexanes as the eluent to 
afford the title compound (36) (23 mg, 35%). 1H NMR (400 MHz, CDCl3) δ 7.29−7.24 
(m, 5 H), 7.17−7.15 (m, 5 H), 5.05−4.97 (m, 1 H), 4.06−4.00 (m, 1 H), 2.94 (dd, J = 4.5, 
14.0 Hz, 1 H), 2.77−2.65 (m, 2 H), 2.49 (d, J = 4.5 Hz, 1 H), 2.12−2.06 (m, 1 H), 
1.99−1.92 (m, 1 H), 1.92−1.85 (m, 1 H), 1.84−1.77 (m, 1 H), 1.65−1.56 (m, 1 H), 
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